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Introduction: The impact of diabetes as a major cause of chronic kidney disease (CKD) is 
established however the risk associated with impaired glucose regulation (IGR) is not well 
characterised. It is not clear whether individuals with IGR are at risk of developing CKD or 
whether the risk is confined to individuals who progress to overt diabetes.  
Objective: To determine the risk of CKD in young adults aged 18 to 40 years with IGR 
compared to those with normoglycaemia.   
Methods: This study consists of three main parts: 1) systematic review, 2) analysis to 
determine incidence and period prevalence of IGR, and 3) analysis to determine risk of CKD 
in IGR. A systematic review was undertaken to estimate the risk of CKD associated with 
IGR. MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
EMBASE, PubMed, Database of Abstracts of Reviews of Effects (DARE), Cochrane 
Database of Systematic Reviews (CDSR) and Trip Database were searched for cohort and 
case control studies comparing risk of CKD in individuals with and without IGR. A 
retrospective cohort study was undertaken using a large dataset of patient records to describe 
the incidence and prevalence of IGR and to investigate the relationship between IGR and 
CKD. Patients diagnosed with IGR (2000 - 2015) registered at a practice from across the UK 
contributing data to The Health Improvement Network (THIN) database were included in the 
analyses. Read coded diagnoses and clinical measurements were used to ascertain incident 
CKD and selected covariates. Incidence rate of IGR per 100,000 person-years and period 
prevalence were reported by age group, sex, ethnicity, area of deprivation and calendar year. 
Poisson regression model were used to obtain adjusted incident rate ratio of CKD. 
Furthermore, incidence rate of CKD was calculated by CKD category (stage 1 – 2 /3 – 5) in 
individuals with IGR. Cox proportional hazards model was fitted to estimate the risk of CKD 
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following IGR diagnosis. The five year survival probability of remaining free of CKD was 
estimated using Kaplan-Meier survivor function.  
Results: The systematic review found no evidence associating risk of CKD in young adults 
aged 18 to 40 years with IGR. Sufficient studies were not available for a meta-analysis hence 
quantification of CKD risk was not possible. The THIN database analysis shows that 
incidence of recorded IGR increased 8.4 times between 2000 and year 2014. Recorded 
incidence was higher in those aged 26 to 40 years than those aged 18 to 25 years, in women 
than men, in more deprived than less deprived areas and in Black and South Asian than 
White ethnic groups. Prevalence was significantly higher for those aged 26 to 40 years than 
those aged 18 to 25 years. Prevalence increased consistently across age groups for the period 
2000 - 2014. Prevalence in females was consistently higher than males throughout the 14 
year period. During 2000 – 2014, prevalence of diagnosed IGR increased among both males 
and females. Incidence of CKD was 4 times higher in IGR than normoglycaemia, after 
adjusting for confounders risk of CKD was reduced to 2.6 times. The incidence of CKD stage 
(3 – 5) was approximately 4 times higher than the incidence of CKD stage (1 – 2) in the IGR 
cohort. The predictors of CKD in IGR model shows that patients with hypertension were 
approximately 3 times more at risk of CKD and for each additional year of age at IGR 
diagnosis, CKD risk increased by 7%. The overall proportion of variation explained by the 
model was 24% (R2 0.24). The Kaplan-Meier (K-M) estimates show that 2% of IGR patients 
were diagnosed with CKD by 2 years increasing to 4% after 5 years follow-up.  
Conclusion: Results of the systematic review demonstrate that the risk of CKD in young 
adults with IGR remains to be elucidated, as no evidence was found associating risk of CKD 
in young adults with IGR. The THIN database analyses provide evidence of an increased risk 
of CKD amongst young adults with IGR. It also showed that IGR patients are at higher risk 
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of CKD stage (3 – 5) compared to CKD stage (1 – 2). Among the modifiable risk factors, 
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BACKGROUND, PREVALENCE, AETIOLOGY OF 
CHRONIC KIDNEY DISEASE (CKD) AND IMPAIRED 
GLUCOSE REGULATION (IGR) 
 
1.1 Introduction to chapter 
Chronic kidney disease (CKD) is defined as a gradual loss of kidney function for more than 
three months with or without kidney damage (1). It is a continuum of kidney conditions 
encompassing mild kidney damage to the most serious form of end stage renal disease 
(ESRD). CKD is now recognised as a major public health threat resulting in an increase in 
mortality, morbidity and poor quality of life (2). It is common, progressive, usually 
asymptomatic (3) and can co-exist with other conditions (3). 
Impaired glucose regulation (IGR) is an intermediate state between normal glucose 
homeostasis and diabetic hyperglycaemia. Individuals with IGR have glucose levels higher 
than normal but not high enough for a diagnosis of diabetes (4).  
 
IGR has been shown to be linked with increased risk of cardiovascular outcomes. Although 
the risk of CKD in patients with diabetes is relatively well established, the risk of young 
adults aged 18 to 40 years with IGR developing CKD is not well characterised. There is some 
evidence that the incidence of CKD is elevated in individuals with IGR, but this is confined 
to specific populations (5-7). Furthermore, progression of IGR to type 2 diabetes (T2DM) 
and subsequent CKD development is not well understood. Research is clearly warranted to 




1.2 Heterogeneous nature of CKD 
 
CKD is a general term frequently used to describe numerous renal disorders and processes, 
some of which are better defined than others. This variation is explained to a certain extent by 
the cause, severity and rate of progression of the disease. The term was coined to simplify 
recognition and classification of the disease. Treatment and management of these unique 
conditions will significantly differ in many important aspects. Subsequently, Kidney Disease 
Improving Global Kidney Outcomes (KDIGO), an international independent non-profit 
organisation whose mission is to improve the care and outcomes of CKD patients provided 
important guidelines on CKD classification and staging in recognition to these important 
differences (8). This is further discussed in the next section.  
1.3    Definitions, staging and measurement of CKD 
1.3.1 Definition and staging of CKD 
 
Chronic kidney disease has been defined as an estimated glomerular filtration rate (eGFR) of 
<60ml/min/1.73m2 (standard body size) for at least 3 months or pathological abnormalities in 
the composition of blood, urine or abnormalities in imaging test for ≥3 months with or 
without reduced kidney function (1). Furthermore, the National Institute for Health and Care 
Excellence (NICE) recommend that an eGFR of (≤60ml/min/1.73m2) along with a serum 
creatinine reduction of >20% should be regarded as clinically significant (9). The National 
Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) in 2002 
introduced clinical practical guidelines on the evaluation, classification and risk stratification 
of CKD (10). This was endorsed by KDIGO in 2004 (11). However, in 2009 KDIGO 
initiated and sponsored a Controversies Conference to examine the current definition and 
classification of CKD. It was acknowledged that the (K/DOQI) definition and staging was 
deficient because it was largely based on cross-sectional data and association of adverse 
clinical outcomes with levels of eGFR, albuminuria and proteinuria were poorly reported. 
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Furthermore, multiple meta-analyses of cohort studies have reported eGFR levels to be 
independently associated with cardiovascular mortality, ESRD and acute kidney injury (AKI) 
(12-14). The conference report recommended that both GFR and albuminuria should be used 
to define and classify CKD for a better estimation of CKD prognosis in patients (15). The 
thresholds of GFR categories remained largely the same but CKD category 3 was sub-divided 
into categories 3a (<60 ml/min/1.73m2) and 3b (<45ml/min/1.73m2) which represent mildly 
to moderately decreased and moderately to severely decreased kidney function. The updated 
guideline retained the original definition of GFR (<60ml/min/1.73m2) but added albumin to 
creatinine ratio (ACR) of (≥30mg/mmol) as criteria for CKD (Table 1).   
Table 1: Classification of chronic kidney disease using GFR and ACR categories:  
GFR and ACR categories and risk of adverse 
outcomes 
ACR categories (mg/mmol), description and range 
<30 






A1 A2 A3 
≥90 
Normal to high 
G1   
60-89 
Mild reduction related to 
normal range for a young 
adult 
G2   
45-59 
Mild-moderate reduction 
G3a    
30-44 
Moderate – severe reduction 
G3b    
15-29 
Severe reduction 
G4    
<15 
Kidney failure 
G5    
 
 
Adapted from Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for 
the evaluation and management of chronic kidney disease, Kidney International (Suppl.3): 1-150 
  
 















1.3.2 Renal function assessment 
1.3.2.1 Glomerular filtration rate (GFR) 
 
The glomerular filtration rate is the volume of blood filtered through by the kidney’s 
glomeruli per unit time, measured in (ml/min). It is a measure of how well the kidneys are 
filtering waste products and maintaining fluid balance. GFR is the commonly accepted 
overall standard measure of renal function. It is usually detected by measurement of both 
exogenous and endogenous filtration markers (16). Exogenous measurements include Inulin, 
iohexol, 51Cr-EDTA, 125I-iothalamate and 99mTc-diethylenetriaminepentaacetic acid (DTPA). 
These are considered as gold standard in yielding reliable results. These tests however are 
expensive and time consuming and can only be performed in specialised laboratories. 
Endogenous markers (creatinine and cystatin C) are much more commonly used to estimate 
GFR. They are cheaper and more simple but less reliable (17). Level of GFR fluctuates with 
age, sex, body size and haemodynamic factors (18). Calculating GFR is usually complex and 
expensive, making it unsuitable for routine assessment of kidney function. Instead, estimated 
glomerular filtration rate (eGFR) calculated using a prediction equation is reported by 
laboratories as a practical test of kidney function (9). The most widely used equation is the 
abbreviated Modification of Diet in Renal Disease (MDRD); it is calculated from serum 
creatinine, sex, age and race (19). On the other hand, Cockcroft-Gault was developed to 
estimate creatinine clearance. The equation is based on serum creatinine, age, gender and 
weight (20). Prediction equations such as MDRD and Cockcroft-Gault are frequently used to 
ascertain eGFR based on creatinine and cystatin C.  
1.3.2.2 Serum creatinine 
 
Serum creatinine level is the most widely used parameter to assess renal function in clinical 
practice. During muscle metabolism creatinine is produced as a by-product and for the 
majority of people remains stable as muscle mass varies little from day to day. Creatinine is a 
5 
 
low molecular weight cation which is distributed throughout the body and freely filtered by 
the renal glomerulus (21). The serum creatinine level depends on the glomerular filtration 
rate (GFR), during renal dysfunction the creatinine filtration is reduced and serum creatinine 
rises. This has been found to be a useful and accurate enough marker to evaluate renal 
function (22). Unfortunately, serum creatinine is also known to be a poor marker of GFR and 
insensitive to even mild to moderate decrease in GFR (23). Furthermore, it does not take into 
account variations in demographics, ethnicity, body mass, diet and medications which all 
affect creatinine concentration and therefore GFR (24).  
1.3.2.3 Cystatin C 
Cystatin C is a small protein produced by all nucleated cells at a steady rate. It is freely 
filtered by the glomerulus and almost completely reabsorbed by the renal tubular cells. Also 
its production does not appear to be influenced by gender, body mass and diet (25). Multiple 
studies have confirmed cystatin C as a superior marker in estimating GFR than serum 
creatinine (26-28). Additionally, cystatin C has been shown to be particularly sensitive in 
patients with mild to moderate changes in GFR (29). Furthermore, the accuracy of GFR 
estimating equations (MDRD and Chronic Kidney Disease Epidemiology Collaboration 
CKD-EPI) incorporating cystatin C and adjusting for ethnicity, proteinuria and diabetes is 
being investigated in a novel health technology assessment (HTA) funded prospective 
longitudinal study in a multi-ethnic population with stage 3 CKD across six UK centres (30). 
These equations are further discussed below. 
1.3.2.4 Proteinuria and Albuminuria 
Proteinuria is the most common and sensitive marker of progressive renal disease (31). 
Furthermore, albuminuria has been shown to be a predictor of renal impairment in the general 
population independent of age, gender and cardiovascular risk factors (32). Numerous studies 
in different population have evaluated the role of proteinuria and albuminuria in the 
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progression of renal disease. In a multi-centre randomised controlled trial to determine 
whether the risk of developing end stage renal disease was associated with multiple risk 
factors including proteinuria, a total of 12,866 men without kidney disease at baseline but at 
risk of heart disease were recruited between 1973 and 1975 and followed-up through 1999. 
Proteinuria was measured by urine dipstick and categorised as negative/trace, 1+ and ≥2+. 
The adjusted hazard ratio (HR) for developing ESRD in men with 1+ proteinuria was 2.30 
(95% confidence interval [CI], 1.28 to 4.13) and 14.21 (95% CI, 9.16 to 22.05) in men with 
2+ proteinuria (33). Additionally, in a study of 917 non-diabetic hypertensive patients free 
from renal disease at baseline and followed-up for 11.8 years, micro-albuminuria was found 
to be associated with an increased risk of developing chronic renal insufficiency with a 
relative risk (RR) of 7.61 (95% CI, 3.91 to 8.16) (34).  
1.3.3 What are the available equations for estimating GFR? 
1.3.3.1 Modification of Diet in Renal Disease (MDRD) 
The MDRD equation was developed in 1999 from a study population of 1628 non-diabetic 
predominantly Caucasian men and women, aged 18 to 70 years with CKD. The equation was 
based on 6 variables namely: age, sex, serum creatinine, urea, albumin and ethnicity (35). A 
simplified version of the MDRD equation was introduced in 2000, the abbreviated 4-
variables (age, sex, serum creatinine and ethnicity) was demonstrated to have greater 
precision and accuracy in predicting GFR (Figure 1) (36).   




eGFR (mL × min–1 × [1.73 m2] –1) = 175 × (SCr standardized [mg × dL–1]) –1.154 × (age [years]) – 0.203                                                                                                         
 
Gender correction:  
                            





1.3.3.2 Cockroft – Gault (C-G) formula 
The C-G formula was originally developed to predict creatinine clearance from serum 
creatinine, age and weight. The formula (Figure 2) was subsequently re-expressed to estimate 
GFR (20).  





1.3.3.3 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
The chronic disease collaboration (CKD-EPI) was published in 2009 and development of the 
equation included participants with or without kidney disease from various clinical settings 
with diverse clinical characteristics and a wide range of GFR measurements. The equation 
uses the same variables (serum creatinine level, age, sex, and race) as the MDRD model. The 
(CKD-EPI) model (Figure 3) has been shown to have greater precision in estimating GFR 
than the MDRD equation especially in patients with higher GFR values (37).  
Figure 3: The CKD-EPI equation 
1.4 Advances in estimating GFR 
Predictive equations (MDRD and C-G) provide a rapid method of estimating GFR and 
assessing renal function in patients with kidney disease. These formulas however are limited 
                                               
                                            [140 – AGE] × WEIGHT (KG) 
 
                                                          PCr × 72 × 0.85 
Gender correction:  
Female: 0.85 
Male: 1.00 
         
GFR = 141 × min (SCr/k, 1)α × max (SCr/k, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] 
 
    Where:    
     SCr is serum creatinine in mg/dL 
     k is 0.7 for females and 0.9 for males 
     α is -0.329 for females and -0.411 for males 
     min indicates the minimum of SCr/k or 1, and 




by a lack of validation in the full range of GFR and ethnic diversity to which they are applied. 
Both equations greatly overestimate the strength of association between GFR and serum 
creatinine. These equations were reasonably accurate in estimating GFR in patients with 
moderate to advanced CKD but were poor in estimating GFR in healthy population. This 
could mean that underestimation of GFR could potentially lead to individuals labelled as 
false positive (38). Variability in laboratories calibrating serum creatinine and subsequent 
estimation of GFR from serum creatinine based equations can potentially introduce errors in 
estimating GFR. To overcome these limitations, the National Kidney Disease Education 
Program (NKDEP) introduced usage of calibrated serum creatinine assays based on isotope 
dilution mass spectrometry method which on average leads to lower level of serum creatinine 
but higher values for eGFR (36). The accuracy of eGFR estimation is likely to further 
improve by the introduction of more accurate prediction models such as the Chronic Kidney 
Disease Epidemiology (CKD-EPI) (39) or alternative prediction markers such as cystatin-C 
in CKD staging (40) and application of novel biomarker such as kidney injury molecule- 1 
and clusterin (41).  
1.5 Prevalence of CKD: United Kingdom and International Perspectives 
1.5.1 UK prevalence of CKD 
 
A number of studies have estimated the prevalence of CKD in the UK. The Health Survey for 
England showed that the overall prevalence of CKD stage 3-5 based on eGFR 
(<60ml/min/1.73m2) was 6% in men and 7% in women. Serum creatinine levels were used to 
estimate eGFR, using the MDRD equation. The survey showed wide variation by age, with 
1% in men and 2% in women aged 16 to 54 years at stage 3-5. Prevalence rose significantly 
to 31% of men and 36% women aged 75 and over. The presence of albuminuria was found in 
9% of men and 8% of women. In most cases micro-albuminuria was most prevalent with 8% 
in both men and women (42). 
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The NEw Opportunities for Early Renal Intervention by Computerised Assessment 
(NEOERICA) project, a large UK primary care study (practice population: 162,113) showed 
an age standardised prevalence of CKD stage 3-5 of 8.5% (10.6% females and 5.8% males). 
The prevalence of CKD and age shows a striking relationship, with approximately 70% of 
patients diagnosed with CKD aged (≥65 years) (43). CKD was determined by serum 
creatinine measured over a period of 1 year and eGFR calculated by MDRD equation. 
Additionally, the Quality and Outcomes Framework (QOF) data for England showed that the 
prevalence of diagnosed CKD (eGFR<60ml/min/1.73m2) in patients aged (≥18 years) was 
4.3%. The QOF data shows significant variation in CKD prevalence between health 
authorities, ranging from 1.4% to 9.6% in 2010/11 (9). Furthermore, the QOF register 
provided separate CKD stage 3-5 estimates defined by an eGFR (<60ml/min/1.73m2) in 
individuals aged (≥18 years) for England, Scotland, Wales and Northern Ireland (Table 2). 
Table 2: CKD prevalence in the UK 
Country CKD prevalence (%) 
England (44) 4.3  
Scotland(45) 3.23  
Wales (46) 3.6  
Northern Ireland(47) 5.0  
 
1.5.2 Global prevalence of CKD 
Worldwide, approximately 10% of the adult population is affected by some form of CKD and 
millions die prematurely each year due to CKD related complications (48). In the United 
States (US), the National Health and Nutrition Examination Survey (NHANES) cross 
sectional surveys showed prevalence of CKD stage 1-4 between 10% ((NHANES III (1988-
1994)) and 13.1% ((NHANES IV (1999-2004)). The largest increase was in stage 2 (2.7% to 
3.3%) and stage 3 (5.4% to 7.7%) with a superior female representation in both studies (49). 
A cross-sectional study conducted in Beijing (China) found that the prevalence of CKD 
defined by (eGFR<60ml/min/1.73m2) and stratified by age was: 10% aged 18 to 39 years, 
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14.2% aged 40 to 59 years, 20.8% aged 60 to 69 years and 30.5% aged (>70 years) (50). 
Additionally, a cross sectional study aimed at determining the prevalence of reduced kidney 
function in an Australian population by the presence of proteinuria, haematuria and GFR 
(<60ml/min/1.73m2), showed that in 11.2% of cases reduced GFR was detected, proteinuria 
in 2.4% and haematuria in 4.6% of cases (51). Furthermore, in a Norwegian study, Hallan 
and colleagues (52) using data from the second Health Survey of Nord-Trøndelag County 
(HUNT II) estimated an overall CKD prevalence of 4.7% in adults aged (≥20 years).  
1.6 Natural history of CKD 
CKD is a progressive disease which is independently associated with poor health outcomes. 
The disease remains typically asymptomatic during the earlier stages until the condition 
progresses to a more advanced state. Kidney function may deteriorate and get worse over 
months or years depending on the severity of the associated aetiologies. However, the 
mechanism underpinning rate of progression of CKD is largely unknown. The Framingham 
Heart Study Offspring Cohort (1991-1995) examined the development of CKD (eGFR <59 
ml/min/1.73m2 in women and <64 ml/min/1.73m2 in men) after patients were given an oral 
glucose tolerance test and followed up for an average 7 years. The subsequent mean GFR at 
follow up were: normo-glycaemia (87 ml/min/1.73m2), IGR (85 ml/min/1.73m2), newly 
diagnosed diabetes (82 ml/min/1.73m2) and known diabetes (78 ml/min/1.73m2) (5).  
The NHANES survey demonstrated a strong association between increased rates of CKD risk 
factors such as diabetes mellitus, cardiovascular disease, hypertension, age, obesity and 
severity of renal dysfunction (53). In a recent meta-analysis exploring the contribution of low 
eGFR and albuminuria in both a general and high risk CKD population developing ESRD 
and CKD outcomes, lower eGFR and higher albuminuria were both risk predictors of ESRD, 
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acute kidney disease and progressive CKD independent of each other and of cardiovascular 
disease (14). 
1.7 Cardiovascular risk in CKD 
As CKD progresses, specific risk factors associated with renal disease and accelerated 
development of cardiovascular events come into play. People with CKD are at increased risk 
of morbidity and mortality as a consequence of cardiovascular disease. After adjusting for 
traditional cardiovascular risk factors such as hypertension, dyslipidaemia and diabetes, the 
risk of cardiovascular disease increased by approximately 2 to 4 times in individuals with 
impaired renal function and raised albuminuria (54). 
A review by Baigent and colleagues (55) also revealed that patients with CKD stage 4-5 have 
a cardiovascular disease related mortality 2-4 times higher compared to the general 
population, whilst the risk is 100 fold higher in patients with ESRD. Studies in various 
populations have demonstrated that reduced eGFR and proteinuria are independently 
associated with an increased risk of cardiovascular disease.  
In a large US community based study that used data from a renal registry, age standardised 
death, cardiovascular events and hospitalisation was analysed for various levels of GFR. 
Cardiovascular events were defined as hospitalisation for coronary heart disease, heart 
failure, stroke, and peripheral arterial disease. Across all studied events, a clear association 
between age standardised rate of events and GFR progression was apparent. As GFR declined 
(≥60 ml/min/1.73m2), the rate of death, cardiovascular events and hospitalisation increased in 




Figure 4: Age-Standardised Rates of Death, Cardiovascular events, and Hospitalisation by decline 
in GFR 
         
1
 A cardiovascular event was defined as hospitalization for coronary heart disease, heart failure, ischemic stroke, and peripheral arterial 
disease. 
2
  Error bars represent 95 percent confidence intervals. The rate of events is listed above each bar.  
3
  Reproduced with permission from (Go, A.S., Chertow, G.W., Fan, D., McCulloch, C.E., Hsu, C (2004) Chronic Kidney Disease and the 
Risks of Death, Cardiovascular Events and Hospitalization. The NEW ENGLAND JOURNAL OF MEDICINE, 351(13): 1296-305. 






1.8 Type 2 Diabetes – A risk factor for CKD 
 
Diabetes is a major risk factor for the development of CKD. Long term complications of 
diabetes often lead to either diabetic nephropathy or vascular damage which may result in 
kidney failure requiring dialysis or kidney transplantation. The health burden of CKD is 
likely to rise because the prevalence of type 2 diabetes (T2DM) has been rapidly increasing 
worldwide (57). A recent prospective study using data from 368 general practices (GP) 
contributing to the QRESEARCH database was conducted in England and Wales. A random 
cohort of patients aged 35 to 74 years registered with a GP practice between 1st January 2002 
and 31st December 2008 and without evidence of CKD at baseline was identified. Patients 
had approximately 7 years of follow-up data available. The adjusted hazard of developing 
CKD stage (3b, 4 and 5) in people with T2DM was approximately 5 times in women (HR: 
4.50; CI, 4.14 to 4.89) and 6 times in men (HR: 6.07; CI, 5.61 to 6.57) (58). 
 
In England the estimated prevalence of CKD as a direct result of diabetes vary across 
population and the definition used. To establish the impact of ethnicity on the prevalence of 
diabetes mellitus and development of CKD, a cross-sectional study of diabetic patients (93% 
coded as T2DM) was carried out. The prevalence of CKD stage 3-5 was 18% in this 
population. The White population had a higher prevalence of stage 3 CKD than Asians (OR: 
0.79; CI, 0.71 to 0.87) and Black (OR: 0.49; CI, 0.43 to 0.57). Results of this study should be 
interpreted with caution, as the result may not be generalisable. This study was conducted 
mostly in deprived areas of East London and approximately half of the population was 
classified as non-White (59).  
The highest CKD prevalence estimate was in a study involving 17 general practices in Kent, 
Greater Manchester and West Surrey. Data on patient’s demographics, laboratory results, 
diagnosis and prescriptions were extracted from routine electronic patient records. The study 
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revealed that 31% of patients with diabetes had CKD stage 3-5 compared to 6.9% without 
diabetes. Patients with diabetes were identified with a Read code suggesting a diagnosis of 
diabetes, the researchers however, did not categorise patients as type 1 or type 2 diabetes 
(60). The difference in prevalence may also be attributed to increased creatinine measurement 
as part of routine follow-up of diabetic patients.  
1.9 Origin and background of impaired glucose regulation (IGR) 
The term IGT was first introduced by the National Diabetes Data Group in 1979 (61). This 
was endorsed a year later by the World Health Organisation (WHO), replacing the terms 
“borderline diabetes” and various categories of glucose intolerance. The newly proposed 
definition suggests that individuals with IGR are at high risk of developing overt diabetes and 
are at significantly increased risk of death and morbidity due to cardiovascular disease, 
although it was also recognised that a proportion will revert back to normal glucose tolerance 
(62). IGR therefore represents an intermediate state between normal glucose homeostasis and 
diabetic hyperglycaemia. Individuals who are classified as IGR have a blood sugar level 
raised beyond normal level but it is not high enough to suggest overt diabetes (63). 
1.10 Similarities and differences between IGT and Impaired Fasting Glucose (IFG) 
 
The American Diabetes Association (ADA) Introduced IFG and/ or IGT as a disease process 
intermediate between normal glucose homeostasis and diabetic hyperglycaemia (64). The 
main difference between IFG and IGT can be explained by the marked difference in plasma 
glucose concentration at baseline and after a standard 75-g ingestion of oral glucose. People 
with IGT at baseline have similar fasting plasma glucose to those with normoglycaemia 
during a standard 2 hour oral glucose tolerance test (OGTT). Following glucose ingestion the 
plasma glucose concentration rapidly rises and fails to decline after 2 hours. On the other 
hand, patients with IFG have a higher fasting plasma glucose concentration at baseline 
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compared to those with normoglycaemia or IGT but the physiological response to oral 
glucose administration is normal (4).  
1.11 Diagnosis of IGR 
For the purpose of this review, IGR was classified as a (fasting plasma glucose (FPG) <7 
mmol/l (<126 mg/dl) or a two hour Oral Glucose Tolerance Test (OGTT) of ≥7.8mmol/l and 
<11.1 mmol/l (140-200mg/dl), or a glycated haemoglobin (HbA1c) of 6.0 - 6.4% (42 - 47 
mmol/mol) (65, 66). This condition is diagnosed using a FPG and an OGTT test. The OGTT 
measures a person’s blood glucose level before and after a 2 hour glucose load. Prior to the 
test clinicians advise patients not to eat or drink for up to 8-12 hours. After the test it should 
be possible to determine if the person has IGR based on the amount of glucose in the blood 
before and after the glucose load. If a person has IGR the amount of glucose in their blood 
will be between (6.1 - 6.9 mmol/l) before the test and (7.8 - 11 mmol/l) two hours after the 
test (65, 67). The International Expert Committee (IEC) advocates the use of HbA1c assay in 
the diagnosis of diabetes. The report recommends an HbA1c threshold of ≥6.5% (≥48 
mmol/mol) with a repeat test as confirmation of diabetes in asymptomatic individuals. 
Patients with a value between 6.0% - 6.4% (42 - 47 mmol/mol) HbA1c should be considered 
at high risk of progressing to overt diabetes (67).  
The American Diabetes Association (ADA) supports the use of HbA1c as a satisfactory 
measurement to define patients at risk of progressing to diabetes and maintained IGR 
threshold as a suitable and viable measure to determine whether patients are at increased risk 
of developing diabetes (68). ADA further revised the cut-off value of HbA1c from 6.0% - 
6.4% proposed by IEC to 5.7% - 6.4%, arguing this lower threshold has better combined 
sensitivity and specificity (68). In the UK, an expert advisory body convened by the 
Department of Health recommended that patients with an HbA1c of 6.0% to 6.4% (42 - 47 
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mmol/mol) should be considered at increased risk of developing diabetes and retested 
annually. The term high risk group was used as an equivalent to describe individuals with 
impaired glucose regulation which encompasses IGT and IFG (69) 
1.12 UK burden of IGR 
1.12.1   UK prevalence of IGR 
 
The prevalence of IGR is poorly characterised in the UK, a number of studies were conducted 
in specific population with relatively small sample size and lack of standardisation and 
accuracy of glucose measurement to identity patients with IGR, could potentially mean that 
prevalence rates of IGR may not be standardised across studies (70, 71) Two London based 
studies in adults over the age of 40 years, reported IGR prevalences of (4.2% in men and 
3.4% in women) and 4.1% in a study population of 1919 and 1040 respectively (72, 73). 
Furthermore,  a study of 1482 adults aged 59 to 70 years conducted in Hertfordshire, reported 
a dramatic increase in prevalence rate (19% in men and 31% in women) (74). In contrast, a 
study conducted in 193 young adults aged 18 to 40 years reported a prevalence rate of 9.3% 
at high risk of developing diabetes and 6.2% diagnosed with IGR (75).   
Impaired glucose regulation is part of the umbrella term “pre-diabetes” and is the most 
widely used definition of describing blood glucose level higher than normal but below the 
threshold for diabetes. The term prediabetes has received little support from some expert 
groups namely: WHO, International Diabetes Federation (IDF) and National Institute of 
Clinical Excellence (NICE), because of the stigma attached to the word diabetes and many 
people will not progress to diabetes as the term prediabetes appears to suggest. Nevertheless, 
many research articles still refer to impaired glucose metabolism as pre-diabetes. The 
prevalence of pre-diabetes in England was recently analysed from a population based cross-
sectional study. Data from the years 2003, 2006, 2009 and 2011 were extracted from Health 
Survey for England (HSE) for adults aged 16 and above and provided a blood sample. Pre-
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diabetes was defined using the HbA1c cut-off value of 5.7% - 6.4%. Individuals were 
excluded if they were previously diagnosed with diabetes or currently on diabetic 
medications. Weighted blood samples were used in the analysis. This is because HSE 
provides different levels of weights for analysing different variables and weighted samples 
allow generalisability of the adult population of England. The weighted sample size for 2003 
was 7892, for 2006 it was 6385, for 2009 it was 2172 and 2011 the sample size was 3690. 
The proportion of individuals aged 16 and older with pre-diabetes, also known as non-
diabetic hyperglycaemia increased from 11.6% in 2003 to 35.3% in 2011. In contrast, only 
the second most deprived quintile (quintile 4) appears to be significantly associated with pre-
diabetes. The odds ratio (OR) and confidence interval (CI) for the risk of pre-diabetes in 2003 
and 2011 were: 1.62 (1.26 to 2.07) and 1.45 (1.21 to 1.88) (76). 
Additionally, a report published by the National Cardiovascular Intelligence Network on 
behalf of Public Health England (77), to determine the prevalence of non-diabetic 
hyperglycaemia also known as pre-diabetes or impaired glucose regulation in adults aged 
(≥16 years), used a combined dataset (54,644 records) from 2009 to 2013 from HSE. Non-
diabetic hyperglycaemia was defined as an HbA1c value between 6.0 – 6.4% (42 - 47 
mmol/mol) excluding those diagnosed with diabetes at baseline. Prevalence of non-diabetic 
hyperglycaemia was categorised by age group, in the age group 16 to 39 years, the 
prevalence of non-diabetic hyperglycaemia was 2.6%. 
1.12.2 Incidence of IGR  
In order to estimate the incidence of IGT/IFG in primary care, a descriptive study was carried 
out using the General Practice Research Database (GPRD), a large longitudinal database 
which provides anonymised data that can be used for research purposes. GPRD represents 
approximately 6% of the UK general population in terms of age, sex and geographical 
distribution. Patients were identified as IGT/IFG if they had a recorded measurement of 
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glucose in blood, urine, random blood samples or codes (READ or OXMIS) suggesting 
IGT/IFG. The date of the first recorded measurement or codes was taken as the index date. 
Patients diagnosed with diabetes or on diabetes medications before the index date were 
excluded. Potential IGT/IFG cases were confirmed if patients had no subsequent diabetes for 
at least 1 month after the index date. From a study population of approximately 2.8 million 
patients registered with a GP practice between 1st January 2000 and April 2005 with a 
minimum of 6 month follow-up, a total of 9096 patients were identified with at least one code 
suggesting IGT/IFG and were included in the final analysis. Participants were stratified in age 
band: 21.9% aged 20 to 39 years, 28.4% aged 40 to 39 years, 40.1% aged 60 to 79 years and 
9.6% aged (≥80 years). The annual incidence rate of IGT/IFG increased from 17 cases per 
100,000 person-years in 2000 to 31 cases per 100,000 person-years in 2004 (78).  
1.13 Global burden of IGR 
 
According to the International Diabetes Federation (IDF), an estimated 344 million or 7.9% 
of adults worldwide have IGR, and this number is projected to increase to an estimated 472 
million or 8.4% of the population by 2030. Approximately 130 million of this population are 
aged 40 to 59 years and if left untreated are at higher risk of progressing to T2DM. IGR in 
this age group will continue to rise and is projected to reach 180 million by 2030. 
Furthermore, nearly one-third of all those with an IGR diagnosis in 2010 were in the age 
group 20 to 39 years (79).  
1.14 Variation by ethnic group 
 
The prevalence of impaired glucose regulation (IGT/IFG) was determined in a multi-ethnic 
cohort of 193 obese young adults aged 18 to 40 years across Leicestershire and 
Northamptonshire. The prevalence of impaired glucose metabolism was 32.5% in Black and 
minority ethnic (BME) populations compared to 14.5% in a White population (75). To 
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describe ethnic differences in the prevalence of IGR, a study of 1894 patients who attended a 
glucose tolerance test was conducted in Foleshill (Coventry, UK), reporting the following 
prevalence rates: Caucasians (5.7% male and 6.8% female) and Asians (9.8% male and 
11.2% female) (80). Furthermore, a cross sectional study set in Leicestershire, UK, data of 
3707 patients aged 40 to 74 years were analysed for the joint prevalence of diabetes, impaired 
glucose regulation (IGR), cardiovascular disease and CKD. Impaired glucose regulation was 
defined as either impaired fasting glucose or impaired glucose tolerance. Impaired glucose 
tolerance (IGT) was defined according to WHO criteria (2011) by a 2 hour post glucose 
challenge between 7.8 and 11.0 mmol/l and impaired fasting glucose (IFG) was defined as 
fasting blood glucose between 6.1 and 6.9 mmol/l (81). Patients were stratified by age and 
ethnicity. The largest cohort was from White European (76.4%) compared to South Asian 
(23.6%). The prevalence of IGR in White European males was 12.5 compared to 9.2% in 
South Asian males. Similarly, the prevalence in White European females was 10.8% 
compared to 9.3% in South Asian females (82).  
1.15 Associations with other illnesses 
1.15.1 Risk of macrovascular disease in IGR 
 
Not many studies have comprehensively looked at cardiovascular risk factors in people with 
IGR. Studies have closely linked IGR with similar cardiovascular and metabolic risk profiles 
as T2DM (83). The risk of cardiovascular disease (CVD), ischaemic heart disease (IHD) and 
stroke were analysed in a large Koreans (384,795) population aged ≥20 years with IGR, 
followed-up for approximately 10 years. IGR was defined according to the 2003 ADA 
criteria of 110 - 125 mg/dL or 6.1 - 6.9 mmol/L, excluding those with coronary heart disease, 
cerebrovascular accident or malignancy at baseline. After adjusting for age, there was a 30% 
increased risk of CVD in patients with IGR (HR, 1.30; 95% CI, 1.24 to 1.35). In a recent 
meta-analysis, Huang and colleagues (84) examined 53 prospective cohort studies with a total 
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population of more than 1.6 million participants aged ≥18 years with prediabetes compared to 
those with normoglycaemia and risk of cardiovascular (CVD) outcomes, coronary heart 
disease (CHD) and stroke over a mean follow-up period of 9.5 years. Prediabetes was 
classified according to the World Health Organisation (WHO) guideline (FPG: 110 - 125 
mg/dL or 6.1 – 6.9 mmol/L) or OGTT ≥7.8mmol/l and <11.1 mmol/l or the American 
Diabetes Association (ADA) lower cut-offs (FPG: 100 – 125mg/dl or 5.6 – 6.9 mmol/l) and 
glycated haemoglobin (HbA1c) of 5.7 - 6.4% (39 - 47 mmol/mol) according to ADA or 6.0 – 
6.4% (42 – 47 mmol/mol) according to the National Institute for Health and Care Excellence 
(NICE) criteria. This review demonstrated a 13% increased risk of CVD outcomes (RR, 1.13; 
95% CI, 1.26 to 1.30), risk of CHD and stroke increased by 10% (RR, 1.10; 95% CI, 1.18 to 
1.20) and 6% (RR, 1.06; 95% CI, 1.17 to 1.20) respectively.  
In The Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Europe 
(DECODE) study group of 10 prospective European cohort studies with 15,388 men and 
7126 women aged 39 to 89 years, the risk of CVD, coronary heart disease (CHD), stroke and 
all-cause mortality in patients with IGR and normoglycaemia where analysed, adjusted for 
age, study centre, systolic blood pressure, body mass index (BMI), serum cholesterol level, 
smoking status and sex. The aged standardised mortality in men with normal glucose 
tolerance (NGT) increased from 7% (CVD), 4.2% (CHD), 1.2% (Stroke), and all-cause 
mortality 19.3% to 8.3% (CVD), 4.9% (CHD), 1.4% (Stroke) and all-cause mortality 22.8% 
in men with IGR. In the smaller cohort of women with normal glucose tolerance (NGT) the 
mortality rate increased from 3.2% (CVD), 1.1% (CHD) and 6.9% all-cause mortality to 
3.7% (CVD), 1.2% (CHD) and 9.6% all-cause mortality in women with IGR, however there 
was a slight decrease in mortality from stroke, the rate decreased from 1.1% (NGT) to 1.0% 
(IGR) (85).  In a systematic review and meta-analysis of prospective observational studies 
performed to estimate the relative risk (RR) of developing CVD among participants with 
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IGT/IFG, 18 publications were identified, of which eight publications had information on the 
estimated RR associated with IGT. Six out of eight publications adjusted for age, smoking 
status, blood pressure and lipid profiles. The fixed-effects summary estimate of RR after 
adjustment for potential confounders was 1.20 (95% CI, 1.06 to 1.35), showing a statistically 
significant association (86). In addition, a meta-regression of 20 studies assessing the 
relationship between glucose threshold and cardiovascular risk when adjusted for risks 
factors such as hypertension and lipids showed a statistically significant association, however 
the results also showed that IGR remains an independent risk factor in the development of 
CVD (87).  
1.15.2 Risk of microangiopathic complications associated with IGR  
IGR has been shown to be independently associated with an increased risk of 
microangiopathic complications which include retinopathy, neuropathy and nephropathy 
(88). 
 Retinopathy  
Multiple studies on retinopathy have reported a higher risk of retinal injury/reduced visual 
acuity in patients with IGR. In a population based study, Nagi and colleagues (89) examined 
the risk of retinopathy by glycaemic status in 1219 Pima Indians aged ≥15 years. Glycaemic 
status was categorised as normal glucose tolerance, IGR and diabetes. Plasma glucose was 
measured using the World Health Organisation (WHO) criteria and retinopathy was 
examined by fundus photography. The prevalence of retinopathy in patients with IGR was 
12% compared to 3% in those with normal glucose tolerance. Additionally, a subset of 
patients with IGR from The Diabetes Prevention Programme (DPP) was followed (mean 
follow-up: 5.6 years) for the development of diabetic retinopathy. Patients were excluded if 
they had a history of diabetes or were on glucose lowering treatment at baseline. IGR was 
defined by the following criteria [FPG between 5.3 – 6.9 mmol/l and OGTT between 7.8 – 
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11.0 mmol/l]. Retinopathy was defined using the Early Treatment Diabetic Retinopathy 
Study (ETDRS) level 20 criteria. Retinopathy was detected in 7.9% of the IGR patients (90).  
 Neuropathy 
Lee and colleagues (91) examined data of patients who participated in the Prospective 
Metabolism and Islet Cell Evaluation (PROMISE) study, an observational study aimed to 
investigate the association of glycaemic status and risk of peripheral neuropathy/nerve 
dysfunction. Glycaemic status was categorised as normal glucose tolerance, IGR and diabetes 
and determined according to the 1999 WHO diagnostic criteria. IGR was defined as fasting 
plasma glucose of 6.1–6.9 mmol/L and a 2 hour OGTT of 7.8 – 11.0 mmol/L. Data of 496 
patients were assessed for the presence of neuropathy and nerve dysfunction at the 3-year 
follow-up examination. The prevalence of peripheral neuropathy was 49% in patients with 
IGR compared to 29% in those with normal glucose tolerance.  
 Nephropathy 
Metcalf and colleagues (92), studied urinary albumin concentration in 5467 Maori,  
Pacific Islander, and European workers aged ≥40 years who participated in a health screening 
survey of 46 companies across New Zealand. Microalbuminuria was defined as a urine 
albumin concentration of 29-299mg/L. IGR was determined according to WHO criteria of 
2 hour plasma glucose concentrations of 7.8-11.1mmol/L. A higher prevalence of 
microalbuminuria was found in individuals with IGR (16.1%) compared to those with 
normoglycaemia (4%).   
1.16 Natural history of IGR 
Imbalance in glucose homeostasis usually precedes the development of diabetes mellitus. 
This state is usually referred to as impaired glucose regulation which encompasses IGT and 
IFG. Patients with IGR have been shown to be at increased risk of developing T2DM and at 
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increased risk of micro and macro-vascular complications independent of patients 
progressing to diabetes (65). 
IGR is a dynamic and reversible condition. Patients with IGR may follow more than one 
pattern, some may revert to normal glucose tolerance while some may progress to diabetes 
mellitus and some may stay in the IGR range (93). The natural history of IGR has been 
reported in a number of studies. In a ten year prospective study of 241 individuals with IGR, 
15% developed T2DM, 53% reverted to normal glucose tolerance and 22% remained glucose 
intolerant (94). Similarly, a 4 year prospective study conducted in 128 South African Indians 
with IGR at baseline, found that after 4 years, 50.4% progressed to diabetes, 24.8% persisted 
with IGR and 24.8% reverted to normoglycaemia (95). In a cohort study conducted in 1342 
non-diabetic residents of Hoorn (Netherlands) from October 1989 to February 1992 to 
determine the cumulative incidence of diabetes in different categories of dysglycaemia, 
glucose measurements were determined according to the diagnostic criteria of WHO (1985 
and 1999) and ADA (1997). The 6 year cumulative incidence of diabetes in people with IGR 
and NGT (normal glucose tolerance) at baseline and according to WHO (1985) diagnostic 
criteria was: 32.4% (111 individuals) and 3.7% (1231 individuals) respectively (96).  
In a systematic review and meta-analysis of prospective studies published from 1979 through 
to 2004, annualised incidence rates of progression to diabetes and reversion to 
normoglycaemia in patients with various categories of glucose intolerance was performed. 
The annualised incidence of diabetes in patients with IGR was between 1.8 to 16.8%, patients 
with isolated impaired glucose tolerance (IIGT) varied from 4.4 to 6.4% and patients with a 
combination of IGT/IFG was between 10 to 15%. The meta-analysed overall risk and 
annualised relative risk of studies with people diagnosed with IGR reverting to 
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normoglycaemia after 1 year were 0.33 times as likely compared to normoglycaemic 
individuals (97).  
Caution should be used in the interpretation of these prevalence rates, IGR has a 
heterogeneous pathogenesis which may be influenced by the individual or study population 
as well as standardisation and accuracy of the glucose measurement (71). Furthermore, 
overestimation of clinical diagnosis, which is almost always based on one positive result 
rather than repeated measurements has made it difficult to interpret the natural history of IGR 
in individuals or population (64). 
1.17 Who is at risk of developing impaired glucose regulation? 
IGR evolves gradually over time, there are several risk factors associated with a higher risk of 
developing IGR. These risk factors are essentially the same as risk factors similar with the 
development of T2DM: 
 Overweight and obese 
Diaz-Redondo and colleagues (98) examined data of 2,022 participants included in the 
Primary Health Care on the Evolution of Patient with Prediabetes (PREDAPS) prospective 
cohort study. The study cohort consisted of subjects aged 29 to 75 years with prediabetes at 
baseline compared to those without a glucose abnormality, followed for a minimum of 5 
years. Prediabetes was defined by the following criteria [FPG between 100 and 125 mg/dl, 
and/or a glycated haemoglobin HbA1c range between 5.7% - 6.4% (39 – 47 mmol/mol)]. 
Data were collected by 125 general practitioners (GPs) during routine clinical consultations 
across Spain. Data of blood pressure, height, weight and waist circumference, hypertension, 
cholesterol, smoking habit and alcohol consumption were obtained during these 
consultations. Participants with general obesity (BMI ≥30 kg/m2) were approximately twice 
as likely to have prediabetes in both men (OR: 2.51) and women (OR: 2.26) compared to 
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those without obesity after adjusting for age, educational level, marital status, region of 
residence, and family history of diabetes. 
 Hypertension 
Morales and colleagues (99) examined data of patients who participated in the San Antonio 
Heart study to determine the incidence of T2DM and IGR in hypertensive patients compared 
to those without hypertension. Data of 1,471 Mexican Americans and non-Hispanic Whites 
aged 25 to 64 years free from diabetes and IGR at baseline and follow-up for 8 years were 
examined. Patients with missing data, and those on antihypertensive drugs were excluded 
from the study. Patients with hypertension were more likely to develop IGR (25.2%) than 
normotensive patients (10.0%). After adjusting for age, sex, ethnicity, BMI, subscapular-to-
triceps skin-fold ratio, fasting glucose and fasting insulin, risk of IGR in hypertensive patients 
was attenuated but remained statistically significant (OR: 1.87; 95% CI, 1.08 to 3.22).  
1.18 Risk of CKD amongst young adults with IGR 
 
In a cross sectional study among Australian adults aged (≥25 years), the prevalence of 
albuminuria, an early marker for the development of CKD, was 5.1% with normal glucose 
tolerance, 11% with IGR, 17.8% newly diagnosed and 36.2% known T2DM (100). Similarly, 
data from the National Health and Nutrition Examination Survey (NHANES) from 1999 
through to 2006, the prevalence of CKD was found to be 39.6% in self-reported diagnosed 
diabetes, 41.7% in previously undiagnosed diabetes (FPG ≥126 mg/dl), 17.7% in pre-diabetes 
(IGR ≥100 and <126 mg/dl) and 10.6% in those without glycaemic abnormality (101). These 
cross sectional data are however subject to some limitations. As it is unclear whether CKD 
precedes impaired glucose metabolism or vice versa (Figure 5) and eGFR values were taken 














1.19 IGR trajectory and the development of CKD in young adults aged 18 to 40 years 
Two epidemiological studies in Native American populations found evidence linking renal 
function to IGR. One found similar rates of decline in GFR over four years in persons with 
IGR (14% decline) and with newly diagnosed diabetes (18% decline) (102). The other found 
15% of the 934 non-diabetic participants had micro-albuminuria (103). In contrast, data 
derived from the Framingham Heart Study offspring cohort (1991-1995) examining the 
development of CKD (eGFR <59 ml/min/1.73m2 in women and <64 ml/min/1.73m2 in men) 
after patients were given an oral glucose tolerance test and followed up for an average 7 
years, the subsequent mean GFR at follow up were: normo-glycaemia (87 ml/min/1.73m2), 
IGR (85 ml/min/1.73m2), newly diagnosed diabetes (82 ml/min/1.73m2) and know diabetes 
(78 ml/min/1.73m2) (5).  
1.20 Use of electronic health/patient record databases for research 
Large health care databases are increasingly being used to facilitate medical research in the 
UK and around the world. Recent UK government policy proposes that by 2020 patient 
records should be virtually paperless (104). Countries such as Canada, the United States, 


























record repositories which are increasingly being used for medical research (105-109). The 
UK took an early lead in developing high quality patient records repositories, particularly 
primary care databases which have been assessed both for their validity and quality through 
numerous studies (110). To further harness the capability of a diversity of existing databases 
the UK government announced their support to the creation of large data warehouses (also 
known as big data) which is part of the government ‘eight great technologies’ strategy (111). 
Research institutes such as the Farr Institute of Health Informatics Research (112) and the 
Alan Turing Institute (113) received significant investments to support the big data strategy 
and drive high quality research linking routinely collected electronic health data to other 
national databases (114).  
There are several large and many smaller primary care databases currently in use in the UK, 
the three most prominent systems widely used for epidemiological research are: the Health 
Improvement Network database (THIN) (115), Clinical Practice Research Datalink (CPRD) 
(116) and QResearch (117). These databases flourished because of the almost complete 
adoption of computerised patient records in general practices across the UK since the 1990’s. 
This was further enhanced by the Government incentivisation scheme the Quality and 
Outcomes Framework (QOF) (118), requiring General Practitioners (GPs) to record more 
information in electronic patients records and therefore improved the quality of record 
keeping. These databases are powerful tools for researchers if used appropriately.    
1.21 Summary 
 
It is widely accepted that the risk of CKD is elevated in patients with diabetes mellitus. It is 
far less certain whether this risk is also present in patients with IGR. As many studies have 
used a single determination of glycaemic status at baseline, it is not clear whether the risk of 
developing a CKD event is confined to people with IGR who progress to overt diabetes or 
whether the risk is still increased among people with IGR even if they never develop 
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diabetes. Also many studies do not particularly include young adults aged 18 to 40 years in 
their analyses.  
Due to these limitations it is inappropriate to extrapolate rates and relative risks to this 
narrower age group of individuals and in particular to primary care where the majority of 
decisions for early prevention are made. It is therefore important to have a reliable estimate of 
the incidence of CKD in this cohort of individuals.  
1.22 Research aims and objectives 
 Aim: 
The overall aim of this study is to elucidate whether the presence of IGR is associated with an 
increased risk of CKD by comparing the risk of CKD in individuals with IGR to those 
without IGR. 
 Objectives:  
 Determine the incidence and period prevalence of IGR in young adults aged 
18 to 40 years 
 Determine the incidence of CKD in young adults aged 18 to 40 years with and 
without IGR and after adjustment for confounders 
 Determine the incidence of CKD by category (stages 1 – 2 /3 – 5) in young 
adults aged 18 to 40 years with IGR 
 Determine CKD predictors in IGR to identify likely risk factors and determine 
their value in determining incident CKD in young adults aged 18 to 40 years 





PRIMARY CARE DATA FROM THE HEALTH 
IMPROVEMENT NETWORK (THIN) DATABASE 
2.1 Background 
In the United Kingdom (UK) almost the entire population is registered with a general 
practitioner (119), with some individuals registered on a practice list contributing several 
decades of data which are captured in computerised medical records. A large volume of 
electronic patient records have been collected since the 1990’s (120). Some practices 
contribute anonymised electronic patient records to large research databases. The Health 
Improvement Network (THIN) database is one of several large UK databases arising from 
general practice electronic patient records which are being used for health services research 
(121).  
Other large databases which provide patient data from across the UK include Clinical 
Practice Research Datalink (CPRD) (116), QRESEARCH (117) and ResearchOne (122) 
databases. CPRD (formerly known as General Practice Research Database (GPRD)) is 
managed by the Medicines and Healthcare products Regulatory Agency (MHRA) and as of 
July 2013 contained anonymous data of over 13 million patients (4.4 million active) from 674 
practices. The database represents approximately 6.9% of the UK population (116). 
QRESEARCH database on the other hand contained 13 million pseudonymised patient 
records from 754 practices in May 2014, representing approximately 7% of the UK 
population (117). Additionally, ResearchOne holds data of 6.3 million patients with 4.9 
million active from approximately 413 practices (122). Furthermore, in 2014 THIN database 
contained approximately 12 million patients record from over 600 practices contributing to 
the database, covering approximately 6% of the UK population (123). Participating practices 
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voluntarily contribute data to these databases. Patient records are uploaded to research 
databases on a regular basis. THIN data for example are collected on a monthly basis. For 
practices using Vision (THIN and CPRD) or EMIS (QRESEARCH) software, the electronic 
records are pseudonymised, in that the name, address, date of birth, post code, NHS number 
and non-structured data such as scanned hospital letters are removed from patient records 
before they are collected. Some free text is de-personalised by the data custodian (e.g. 
anonymisation of free texts by THIN) and re-inserted back into the research database before 
it is made available for research purposes. Records of patients are then aggregated into 
databases containing millions of patient records from across the UK. Patient records are 
organised in individual files by a clinical software company providing a longitudinal track 
record for each patient allowing for studies examining incidence of disease or of prediction 
model design. Access to these records is subject to approval from the respective scientific 
review board. Patients are given the option to have their de-personalised medical records 
collected for scientific research purposes, therefore patients consent are not required when 
working with anonymised patients records in the THIN database.   
Recent addition to primary care research databases involves linkage to other databases such 
as the Hospital Episode Statistics (HES) database, the National Cancer Data repository and 
Office for National Statistics (ONS) mortality data (117, 124, 125). For a subset of practices 
contributing to the THIN database, patient level data can now be linked to the HES database 
(126).    
2.2 The Health Improvement Network (THIN) Database 
The Health Improvement Network (THIN) is a large primary care database containing 
longitudinal anonymised medical records of patients. In September 2014 the database 
contained data from 611 practices across England, Wales, Scotland and Northern Ireland. As 
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of September 2014, the database holds a total of 13 million patients of whom 3.6 million are 
actively registered with a general practice equivalent to more than 85 million person years of 
computerised data covering approximately 6% of the UK population (123). THIN database is 
jointly managed by IMS Health Real World Evidence Solutions (http://www.epic-
uk.org/index.html) and In Practice System (InPs). THIN was developed in 2002 by the 
Epidemiology and Pharmacology Information Care (EPIC), a non-profit company. Three 
years later CSD Medical Research UK acquired EPIC, which in 2015 became part of IMS 
Health Real World Evidence Solutions (127). 
Vision software is an electronic medical records computer system used to record the details 
of each GP consultation and any other information entered by the practice outside face-to-
face consultations (e.g. lab results, hospital letters) (128). All general practices affiliated with 
the THIN database use Vision software.  
Upon joining THIN, a practice undergoes a full data collection procedure allowing current 
and retrospective data to be collected and sent to IMS Health, the data provider. Following 
this, subsequent data are automatically downloaded from the practice on a monthly basis 
ensuring minimal disruption to the practice (123, 129). From this data, THIN generates four 
standardised (patient, medical, therapy and additional health data) and one linked (postcode 
related variable) file per practice. These data are then passed on largely unaltered to provide 
fully coded records. Some additional information is added in THIN at this point, for example 
on the likely validity of the patient registration and de-registration dates. This is important 
when calculating follow-up period (123). These data are processed to provide fully coded 
records of patient demographics, laboratory data, prescription, medical diagnoses, additional 
health data (e.g. smoking status, physical examination), ethnicity, socio-economic status 
(based on postcode of residence) and environmental indices (air quality) (Table 3) (130). The 
32 
 
coded data are interpreted using look-up tables and dictionaries. Diagnoses are coded using 
the version 2 (5-byte) Read-codes (131) hierarchical classification, which include codes 
related to diagnoses, laboratory and radiology tests, observation and process of care (e.g. 
referral). Drug prescriptions issued by the GP are recorded in the database by Gemscript 
coding system, managed by RESIP UK, a sister company of InPs (132). Drugs are stored 
using their generic names and can be linked to the British National Formulary (BNF) (Figure 
6) (133).  
Figure 6: Interpretation of coded data 
 
THIN links laboratory tests and clinical measurements electronically to a coding system. 
Vision software allows additional information to be recorded by the practice, alongside the 
coded data. This is known as free-text, and may contain additional information such as 
additional observations, symptoms, plans for further investigations or information from 
scanned hospital letters. These data are uploaded from practices but are only provided to 
researchers after anonymisation. Currently over 30% of free texts records have been 
anonymised, but additional individual records can be anonymised on request at additional 
cost to the researcher (123).  
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Read code classification Drug code linked to BNF chapter 
1. Diagnoses 
2. Symptoms 
3. Process of care 
 
Any prescription issued by the GP 
AHD codes 
1. Lab & radiology tests 






Table 3: Information in the Health Improvement Network (THIN) database 
Files Information contained 
Patient Demographics including:  
 Date patient registered at practice 
 Date patient left practice 
 Death date 
 Year of birth 
 Gender 
 Household identifier number 
THIN data does not include the following: name; exact address or postcode; exact date of birth; NHS number 
Medical  Diagnosis: 
 All conditions and symptoms coded by the GP/Nurse 
 Information on referrals to secondary care, including the speciality of the secondary care service 
 The GP/nurse may summarise details of prescriptions from ongoing outpatient specialist care or over-the-
counter drugs 
 Secondary care information and other related information received by the practice can be entered 
including: 
 Details on hospital admissions 
 Discharge medication and diagnosis 
 Outpatient consultation diagnosis 
 Investigation and treatment outcomes 
 Ethnicity of patient 
Therapy Prescription: 
 GP and in some cases nurses may issue prescriptions to patients using Vision, all prescribing is logged into 
the system automatically.  
 Acute treatments and medicines for a chronic condition can be temporally linked with a symptom or 




 THIN Data contains information on lifestyle and health factors such as smoking and alcohol intake. 
 Tests and laboratory results  




The majority of patients are linked to postcode-based socioeconomic, ethnicity and environmental indicators. The 




Additional anonymised practice commentary, linked to records in the Medical file, may be available as free texts 
Source:  http://csdmruk.cegedim.com/our-data/data-content.shtml [accessed 21/01/2016] 
 
2.2.1 Acceptable Mortality Recording (AMR) 
AMR denotes the earliest period when mortality data were optimally recorded by practices 
which was consistent with ONS (134). Prior to changing to Vision software many practices 
were recording mortality rate using the Value Added Information Medical Product (Vamp) 
software. Immediately after changing to Vision mortality recording was inaccurate (immortal 
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periods) and raises a few data quality issues as practice mortality rate is determined from 
mortality data and it also affects the denominator, which affects all calculated incidence and 
prevalence rates. Patients who have died cannot get diagnosed with diseases. Discrepancies 
occurred because practices may have excluded patients during the changeover if patients had 
died before they were transferred to the new system. Therefore, the mortality rate was 
reduced when transferred and gradually increased once mortality rate was recorded in Vision. 
Furthermore, some practices split and only live patients were transferred to the new practice. 
In these cases data conversion occurred only on live patients (123). One study examined 
mortality recording in the THIN practices compared to a similar UK national death rate 
statistics. A marker date was derived, the Acceptable Mortality Recording (AMR) denoting 
the date when practices were recording mortality rate consistently and at a similar rate to the 
UK national statistics according to the age and gender structure of the practices (134). This is 
a marker for data quality in the THIN database. For this thesis it was mandatory to have an 
AMR prior to the index date (patients without CKD at diagnosis of IGR to ensure that 
practices were not under reporting important outcome and not including patients who have 
died). It is important to a have consistent record of AMR because mortality recording directly 
affects follow-up time (person-time of follow-up before developing CKD) and minimises the 
risk of immortal period (when death on further diagnoses occurred but were not recorded) 
2.2.2 Electronic transfer of laboratory results 
Laboratory test results are generally coded and stored in the patient clinical data record. Over 
75% of practices contributing to THIN are electronically linked to pathology laboratory 
allowing all tests results to be automatically coded and entered onto the system (130). Some 
practices still use paper based recording, these practices manually code their results. 
Electronic transfer and recording of tests results would have a direct impact on the 
completeness of data for example, estimated glomerular filtration rate (eGFR) recording (an 
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important marker of CKD) would have improved since the introduction of electronic links 
with pathology laboratory (123).  
2.2.3 Vision installation date 
Prior to implementing the Vision management software many general practices were using 
the Value Added Information Medical Products (VAMP) clinical system to record clinical 
events. Data recorded using VAMP were reasonably complete regarding clinical illnesses and 
prescribing (135). The Vision-date indicates when a practice converted to InPs Vision 
software for the first time. This is the date from which patients records are likely to be 
complete. When gaps in data recording are identified it is usually problematic to ascertain 
whether there was a data issue (123). Therefore, it is advisable to use the Vision-date as one 
parameter in deciding the practice start date which is important when follow-up time is 
measured, for example calculating incidence rate of CKD for this study. 
2.3 Data integrity and ethical approval 
THIN database obtained ethical approval for data collection from the South East Multicentre 
Research Ethics Committee (reference number: 07/H1102/103). Research undertaken using 
the database is therefore approved provided it has undergone independent scientific review. 
Researchers requiring access to THIN have to submit a study protocol justifying access and 
gain approval from one of THIN’s Scientific Advisory Committees. Such committees review 
study protocols and provide input whether it is an amendment or rejection of the study. The 
protocol for this study was reviewed and approved (study reference: 14-038) by a THIN 
Scientific Review Committee (SCR) in 2014. 
THIN runs a set of validation checks (e.g. record of year of birth, registration status and death 
date) to ensure data integrity for each patient. A flagging system is used to indicate whether 
the data has passed these validation checks and patients have an acceptable record. For 
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example a transfer out date is provided in THIN as a separate field, indicating whether a 
patient has left the practice or died. A field providing information on death has also been 
created in THIN, this field allows researchers to search for information available on death 
from patients anonymous death certificates or from anonymised free texts comments (123).   
2.4 Data quality and limitations 
2.4.1 THIN representativeness 
Data in THIN has been shown to be broadly generalisable of the UK population in relation to 
demographics and disease distribution. A study by Blak and colleagues (136) assessed the 
representativeness of the THIN data in terms of demographics, prevalence of some of the 
major chronic conditions, deprivation and death rates with UK national statistics and the 
2006/2007 Quality and Outcomes Framework (QOF) prevalence data. The age and sex 
distribution in the THIN population were similar to the overall UK population, although there 
are marginally fewer people aged (<25 years) identified in THIN and the male population 
matches less well than the female population. Prevalence of the major QOF conditions (e.g. 
CKD, Diabetes and Hypertension) was shown to be similar to the national estimates. For 
example THIN crude prevalence of CKD was 2.5% compared to 2.3% nationally. The QOF 
prevalence in THIN for some of the study variables compared to the QOF national estimates 




Table 4: Prevalence of QOF related chronic conditions in THIN compared with UK QOF data for 2006/2007 
Chronic conditions THIN QOF % UK QOF % 
CKD 2.5 (2.5-2.5) 2.3 
Diabetes 3.5 (3.5-3.5) 3.7 
Hypertension 12.7 (12.6-12.7) 12.6 
Atrial Fibrillation 1.4 (1.4-1.4) 1.3 
Heart Failure 0.9 (0.9-0.9) 0.8 
Stroke/TIA 1.9 (1.9-1.9) 1.7 
TIA, transient ischaemic attack; 95% confidence interval given in parentheses 
Adapted from: Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: 
demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19(4):251-5. 
 
Patients captured in the THIN database appear to be living in more affluent areas (23.5%) 
compared to the national average (20%). In 2006 death rates in THIN were compared to the 
national rate, the age-gender and deprivation adjusted death rate in THIN was 9.08 per 1000 
population compared to 9.4 per 1000 population nationally. It should be noted that 
adjustment for deprivation when estimating death rates in THIN resulted in closer estimates 
to the national death rates (136).  
2.4.2 THIN validity in predicting CKD 
General practices contributing to the THIN database receive regular validation reports 
quantifying the completeness and accuracy of data recording. These feedback reports from 
THIN are designed to improve the quality of recording and reduce data omission (123). In a 
cross-sectional study Denburg and colleagues (137) examined recording of biochemistry 
results at general practice level using the THIN database. The aim was to accurately identify 
patients with moderate to advanced CKD determined by stage 3-5 using serum creatinine 
record and a list of 45 Read codes (indicative of moderate to advanced CKD) in the absence 
of complete laboratory results. Renal function stage 3-5 was measured by an 
eGFR<60ml/min/1.72m2 on at least two occasions separated by a period of more than 3 
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months. The study demonstrated that THIN database is a reliable resource providing accurate 
data that can be used to identify patients with moderate to advanced CKD in large population. 
The list of 45 Read codes was shown to accurately identify CKD with excellent specificity 
(98.2% correctly Read coded without the disease) and high positive predictive value (PPV) 
(88.9% with a Read code indicating CKD 3-5 have the disease) but with low sensitivity 
(48.8% correctly Read coded diagnosis of CKD 3-5).  
2.4.3 Accuracy and completeness of primary care data in the UK 
The validity of routinely collected primary care data has been demonstrated in three 
systematic reviews (138-140). These reviews investigated a range of methods used to validate 
diagnoses recorded in one of the major UK primary care databases. The validation methods 
used a range of approaches including: questionnaires to patient’s general practitioners, 
additional data from the general practice medical records and comparing prevalence rates 
from external sources such as the (Morbidity Statistics from General Practice (MSGP4) or the 
Doctors Independent Network (DIN) databases. With respect to some of the variables of 
interest (Diabetes, cardiovascular disease) to this thesis, one review (138) analysed papers 
reporting validation of clinical diagnoses derived from the General Practice Research 
Database (GPRD) found that these were well recorded (positive predictive value PPV > 
90%), however atrial fibrillation another variable of interest is not so well recorded (PPV 
<80%). None of the reviews reported evidence of validity of CKD diagnoses, the outcome of 
interest of this thesis.  
Herrett and colleagues (139) reviewed 212 publications to identify methods used to validate 
diagnoses in the General Practice Research Database (GPRD). A total of 357 validation 
methods accounting for 183 diagnoses were identified. These validation methods were 
classified as either internal (diagnostic codes, review of anonymised free texts and sensitivity 
analysis) or external (Questionnaire to GP, request to GP to provide anonymised medical 
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records and comparison of incidence/prevalence with external UK - based data source). Study 
findings were extracted from individual paper and categorised into disease groups. The 
median proportion of cases identified in the disease group of interest were:  88% of cases 
with endocrine, nutritional and metabolic syndrome (e.g. impaired glucose tolerance/impaired 
fasting glucose or diabetes) and 85% of cases with a circulatory system disorder (e.g. stroke). 
It should be noted that although a large number of cases were confirmed most studies in this 
review only considered positive predict values (PPVs).  
Anandarajah and colleagues (141) collected  routinely collected data from 12 UK practices 
and  found that nearly 5% of the registered population had a record of reduced kidney 
function determined by an estimated glomerular filtration rate (eGFR) of <60ml/min/1.73m2 
corresponding to CKD stage 3-5. However, only 3.6% of this population had a Read code 
allowing identification of CKD. This would suggest that a Read code of CKD alone may not 
be sufficient to adequately identify patients with CKD in general practice database. A Read 
code of an estimated glomerular filtration rate (eGFR) or record of a measurement should 
also be included in addition to a Read code of CKD.    
2.4.4 Quality and Outcomes Framework (QOF) impact on the recording of clinical 
information in primary care 
The Quality and Outcomes Framework (QOF) was introduced in 2004 as part of the General 
Medical Services (GMS) contract. The objective of QOF is to provide incentive and reward 
practices for the provision of quality care and reduce variation in performance across 
practices (118). A set of achievement measures known as indicators were developed to 
ascertain practices level of achievement. These achievement indicators were initially 
organised into four domains (clinical, organisational, patient experience and additional 
services). In 2010 the QOF business rules was taken over by the Health and Social Care 
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Information Centre (HSCIC) from the NHS Employers and the NHS Connecting for Health 
(142).  
In 2013 practices participating in the QOF scheme were required to document patients with 
chronic conditions annually. Practices were required to maintain a register of indicators for 
which QOF points were awarded and payment calculated. For example points were allocated 
for maintaining a register of adults with CKD stage 3-5, patients receiving treatment for 
proteinuria and annual testing of patients for protein-creatinine-ratio (PCR) (142). This 
register contains details of most patients with CKD in the UK (143). These are important 
clinical indicators with respect to the diagnoses of interest for this study. The introduction of 
QOF may have driven practices to improve coding of clinical information in primary care 
databases.  
 
2.5 Advantages and limitations of THIN to this study 
2.5.1 Strengths associated with the study 
One of the key advantages of the THIN database is its size. The database holds over 3 million 
active patient records from over 600 practices throughout the UK. The database includes men 
and women of all ages, with varying health status, including conditions such as CKD. This 
allows study findings to be widely applicable and generalisable to the UK population. 
Additionally, estimation of incidence rates of CKD is permitted because of the large number 
of patients contributing to the THIN database, which may be otherwise impossible to study 
because of the potentially lower incidence of CKD in the 18 to 40 age group (123). 
Furthermore, as data on exposure (IGR) were collected prospectively THIN database is less 
likely to be subject to recall bias.  
The THIN database contains longitudinal data for some patients dating as far back as 1985, 
making it possible to have long term patient follow-up, allowing person time to be calculated 
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and occurrence of new cases documented. Another advantage of THIN is the non-
interventional way data are collected, allowing researchers to have a wide scope in terms of 
study design. Furthermore, the database is continually updated allowing immediate selection 
of both cases and controls from the same source population. THIN also permits identification 
of exposures and outcomes in various ways, for example, in addition to a Read code, 
laboratory results are also available to confirm diagnosis (123). A number of studies have 
validated the THIN data, including records on diagnoses, symptoms and prescriptions (144, 
145).     
2.5.2 Limitations 
THIN database is susceptible to some limitations. Computerised data collected for the THIN 
database are collected during routine clinical consultation and if patients do not consult, then 
no data can be collected. Although information collected by General Practitioners (GPs) is 
expected to be complete some information may be less complete in terms of important study 
variables compared to a study designed specifically for research. These data are collected for 
clinical purposes and not for research and GPs do not collect all information on all patients 
(123). Another limitation of the THIN database is the lack of data available for some patients 
on important confounders such as smoking, height and weight particularly in the early years 
of practices recording data. Additionally, recording of information is biased because GPs 
selectively record information in patients where they think it is clinically relevant, for e.g. 
weight is more often recorded if the patient is overweight (123). These are important 
variables in relation to this study. However, since the introduction of QOF in 2004, recording 
of these have been improving.  
Furthermore, before computerisation of practice records and laboratory linking, historic 
laboratory results were entered manually by practice personnel and in some cases only 
abnormal results were entered for inclusion into the THIN database (123). Since patients and 
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practices can enter and exit THIN database at any time, some patients may have short follow-
up periods, reducing the likelihood of these patients developing the outcome of interest 
(CKD). To mitigate this limitation, this study opted for an open cohort study design, allowing 
patients lost to follow up to be replaced over the study period (2000 - 2015). Some patients 
may join another THIN practice and contribute historical data twice. However, for those 
patients follow-up will cease at their original practice and a transferred out date allocated. 






A SYSTEMATIC REVIEW EXPLORING THE EFFECTS 
OF IMPAIRED GLUCOSE REGULATION (IGR) ON 
INCIDENCE OF CHRONIC KIDNEY DISEASE (CKD) IN 
YOUNG ADULTS 
3.1 Introduction to chapter 
This chapter reports a systematic review of cohort and case-control studies to elucidate 
whether the presence of impaired glucose regulation (IGR) is associated with an increased 
risk of chronic kidney disease (CKD) by comparing the risk of CKD in individuals with IGR 
to those without IGR.  
3.2 Background 
Chronic kidney disease is a long term condition attributed to the kidneys inability to 
effectively remove waste product and excess water from the body. CKD is characterised by 
the presence of kidney damage and/or a gradual loss of kidney function (eGFR) over time 
(146). Diabetes is a major risk factor for the development of CKD. Long term complications 
of diabetes often lead to either diabetic nephropathy or vascular damage which may result in 
kidney failure requiring dialysis or kidney transplantation. A prospective cohort study 
conducted in England and Wales found the hazard of developing CKD in patients aged 35 to 
74 years was 5 times higher in women and 6 times higher in men with diabetes than non-
diabetics (58).  
Pre-diabetes indicates both IFG and IGT collectively known as (impaired glucose regulation 
[IGR]). Individuals with IGR have a blood glucose raised beyond normal level but not high 
enough to suggest a diagnosis of diabetes (63). It is not clear whether risk of developing CKD 
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is elevated in patients with IGR or whether any increased risk only occurs after patients 
develop diabetes. Furthermore, the risk of young adults aged 18 to 40 years with IGR 
developing CKD is not well characterised. There is some evidence that the incidence of CKD 
is elevated in individuals with IGR, but this is confined to specific populations. Watanabe and 
colleagues (7) examined the association between metabolic syndrome and the incidence of 
CKD in a large prospective cohort study of Japanese adults aged ≥20 years without CKD, 
antihypertensive drug, diabetes or CVD at baseline. The incidence of CKD adjusted for age 
and sex was approximately twice higher [HR: 1.94 (95% CI, 1.06 to 3.54)] in individuals 
with IGR compared to those with normoglycaemia. Cross-sectional studies show that 
albuminuria an early marker of CKD was approximately 3 times more common in IGR than 
those with normoglycaemia (100). Furthermore, cross-sectional data shows some association 
between increasing blood glucose and decline in kidney function (147-149). Cross sectional 
studies are however subject to some limitations, as it is unclear whether CKD precedes 
impaired glucose metabolism or vice versa. 
3.3 Study aims and hypotheses 
To conduct a systematic review and if possible a meta-analysis of cohort and case-control 
studies to examine whether the presence of IGR in young adults aged 18 to 40 years is 
associated with an increased risk of CKD by comparing the risk of CKD in individuals with 
IGR to those without IGR, and also to evaluate whether any increased risk occurs only after 







Figure 7: Progression of IGR to T2DM or reversal to normoglycaemia and development of chronic kidney disease 
 
3.4 Methods 
Established guidelines for reviews were used to inform the search strategy, selection of 
studies, assessment of risks of bias and reporting of results (150, 151). The review protocol 
was published (152) (Appendix 1). The full review has been peer-reviewed and published 
(Appendix 2).  
3.4.1 Eligibility criteria 
 Types of participants and comparison group 
This review includes studies where some participants are aged 18 to 40 years and results 
reported separately in this age group without a diagnosis of type 1 and type 2 diabetes but 
with IGR, “Pre-diabetes” or “Pre-diabetic state”. IGT/IFG can be referred to as pre-diabetes; 
(153) or metabolic syndrome where IGR is part of the metabolic syndrome. The comparison 
group was either participant with normoglycaemia or diabetic participants. For the purpose of 
this review, IGR was classified as a (FPG <7 mmol/l (<126 mg/dl) or an OGTT ≥7.8mmol/l 
and <11.1 mmol/l (140-200mg/dl), or glycated haemoglobin (HbA1c) of 5.7 - 6.4% (39-47 
mmol/mol) and IFG was defined as FPG of 5.6 – 6.9 mmol/l (100 – 125mg/dl) (154) 
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 Participants and outcomes – cohort studies 
This review includes any cohort studies where some participants are aged 18 to 40 years and 
results reported separately in this age group with (1) IGT/IFG (exposed group) but without a 
diagnosis of type 1 or type 2 diabetes compared to participants without glycaemic 
abnormality (comparator) (2) IGT/IFG but without a diagnosis of type 1 diabetes compared 
to participants with T2DM. Participants were free from CKD at baseline. A broad range of 
measures were used to ascertain CKD (outcome). This included eGFR stages 3A, 3B, 4 and 
5; albuminuria; albumin creatinine ratio (ACR ≥2.5mg/mmol or ≥30mg/g), protein creatinine 
ratio (PCR ≥45mg/mmol or ≥300mg/g), serum creatinine (SCr 1.0mg/dL or ≥50 μmol/L), 
proteinuria (≥1+) and creatinine clearance (CrCl ≥60ml/min). Studies reporting mean 
changes in continuous variables (e.g. eGFR) were included and findings summarised 
separately. Studies reporting a single measure instead of two measures of eGFR or only by 
any of the above measures were included. Measures of association (HR, OR, IRR and RR) 
and their 95% confidence interval were extracted and reported or calculated using data 
derived from the publications. 
 Participants and outcomes – (case – control) studies 
This review also includes any case-control studies where some cases are aged 18 to 40 years 
with an incident diagnosis of CKD (the outcome of interest) by any of the above definitions 
and controls without a diagnosis of CKD and results are reported separately in this age group. 
The frequency of previous IGT/IFG (exposure to IGT/IFG) was compared to either the 
frequency of normoglycaemia (unexposed) or to the frequency of diabetes (an alternative 
exposure). There was no restriction on the length of participant follow-up. 
3.4.2 Information sources and searches 
The following electronic databases were systematically searched with no language restriction 
from inception to January 2015: MEDLINE, Cumulative Index to Nursing and Allied Health 
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Literature (CINAHL), EMBASE, PubMed, Database of Abstracts of Reviews of Effects 
(DARE), Cochrane Database of Systematic Reviews (CDSR) and Trip Database. 
Furthermore, ongoing studies, scientific literature and abstract proceedings were identified by 
searching the following databases: ClinicalTrials.gov, Cochrane Renal Group specialised 
register, Renal Registry Database, British Renal Society, Renal Association, American 
Society of Nephrology, World Congress of Nephrology, Diabetes UK Conference, Primary 
Care Diabetes Society Conference and Zetoc. A comprehensive search of the Conference 
Proceedings Citation Index (CPCI) was also carried out. Search of these databases spanned 
from January 2011 to January 2014 as it is likely that studies would have been completed and 
published. Grey literature databases, such as Grey Literature Report, OpenGrey, PubliCat and 
ScienceDaily.com were examined. Google Scholar was also explored; a scoping search 
revealed that the most pertinent articles were found in the first ten pages of the searches. 
Open access theses and dissertations were retrieved from the ProQuest Dissertation Thesis 
Database and thesis.com. The Science Citation Index (SCI) were used to scan and track study 
titles. The search strategy is shown in Appendix 3. A sensitivity search of the above 
databases was also carried out excluding diabetes as a required search term from the initial 
search strategy to ensure that all the relevant studies comparing IGR (exposed group) to 
participants without glycaemic abnormality (comparator) are identified (Appendix 4).  
3.4.3 Study selection 
Two reviewers independently reviewed all titles and abstract of the search results in two 
phases. First the retrieved titles and abstracts were reviewed to identify relevant studies. Then 
the full texts of retrieved studies were read to determine eligibility. Any discrepancies or 
difference in opinion were resolved by consensus or by involving a third reviewer. An 
inclusion criteria checklist (Appendix 5) was developed based on studies eligibility criteria 
piloted on 5 papers. 
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3.4.4 Data collection process 
A data extraction form has been designed based on Hayden and colleagues framework (155); 
this is described in more detail in Appendix 6. This form was iteratively developed and 
piloted on known papers. The form has been designed to focus on population, comparator, 
outcome and study design. Data extraction was conducted by one reviewer and checked by 
another for studies identified through the screening phase. Errors in data extraction were 
discussed and amended as appropriate. For missing data, authors were contacted for 
clarification. A Microsoft Excel sheet was used to manage data extraction.  
3.4.5 Quality assessment 
Study quality was assessed according to a modified tool based on the Ottawa-Newcastle scale 
(NOS) (156). Risk of bias was assessed on the following domain: (1) sampling, (2) outcome 
measurement, (3) attrition, (4) analytical method and (5) confounders (Appendix 7). A 
composite score was not provided, instead a risk of bias of ‘yes’ indicating adequate data 
were provided, ‘no’ if data were provided but did not meet the criteria for that domain and 
‘unclear’ potentially at high risk of bias (157).  
3.4.6 Publication bias 
If eligible studies are identified, the Begg’s(158) and Egger’s (159) regression tests 
will be carried out to detect publication bias. At least 10 studies will be needed to 
sufficiently detect publication bias (160). Studies will be grouped according to 
effects measures and reporting risk of CKD determined by any of the following 
measures (Estimated Glomerular Filtration Rate (eGFR), albumin creatinine ratio (ACR), 
proteinuria ≥1, serum creatinine (SCr) and creatinine clearance (CrCl) levels). 
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3.5 Data synthesis 
If eligible studies are identified for future update of this systematic review the following data 
analysis criteria may apply. Studies will be grouped according to similar effect measures and 
CKD markers. Adjusted and unadjusted risk estimates of CKD will be combined and pooled 
estimates determined. A random effect model will be used to ensure studies providing 
different effect sizes are represented in the summary estimate. Heterogeneity will be assessed 
using the Chi-squared (χ2) test with a p-value (<0.05) considered statistically significant. 
Chi-squared (χ2) test is poor in detecting heterogeneity, especially with small number of 
studies (161). Therefore the (I2) statistics with 95% confidence interval (CI) will be used to 
assess the percentage variance between studies. The magnitude of heterogeneity will also be 
quantified using τ2 (tau-squared) to estimate the in between study variance. Studies where 
effect measures cannot be combined, results of these studies will be reported narratively. 
Furthermore, studies reporting changes in eGFR during progression of renal disease, the 
standardised mean difference will be reported among subjects with IGT/IFG compared to 
normoglycaemia.  
3.6 Results 
3.6.1 Search results 
The initial database searches identified a total of 5568 studies. After duplicates were removed 
5478 records remained. After scanning titles, 90 citations potentially met the inclusion 
criteria. These were reviewed in detail (full text) and 19 cohort and no case-control studies 
were selected for further review for potential inclusion. A summary of the overall quality of 
the 19 studies which were assessed for potential inclusion and the confounding factors 
adjusted in the multivariate analyses are provided in Table 5 and  
Table 6. A PRISMA study flow diagram of included and excluded studies is provided along 
with reasons for exclusion (Figure 8). The sensitivity database searches identified a total of 
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14,585 studies. After duplicates were removed 13,982 studies remained. After scanning titles, 
114 potentially relevant articles were identified. These were reviewed in detail and 26 articles 
were identified, nineteen were the originally identified articles and 7 additional articles were 
identified, six cohort and 1 case control. A summary of the overall quality of the 7 studies 
which were assessed for potential inclusion and the confounding factors adjusted in the 
multivariate analyses are provided in Table 5. Review of the 7 studies identified that only one 
study reported separate data for persons with IGR aged 18 to 40 years and risk of CKD 
compared to T2DM. The remaining 6 studies reported risk of CKD in IGR compared to 
normoglycaemia or T2DM at all ages. A study flow diagram of the included and excluded 
studies is presented in Appendix 8 following the sensitivity search excluding diabetes from 



















Records identified through database search: 
(n= 5568) 
CINAHL = 603 
EMBASE = 3082 
MEDLINE = 1560 
PubMed = 323 
 
Full text articles excluded (n=71) 
Reasons: 
Cross sectional studies = 29 
Aged (>40 years) = 2 
Case-review = 1 
Conference abstract = 2 
Exposure only diabetics = 7 
No IGT/IFG patients included = 13 
No renal outcome = 4 
Review paper = 6 
Outcomes is diabetes = 2 
No separate analysis for IGT/IFG = 4 
Incidence of diabetes not CKD = 1 
 
 
Full text articles assessed 
for eligibility (n= 90) 
Additional records identified through 
other sources (n=12) 
Records excluded after title and 
abstract screening (n=5388) 
Articles further reviewed 























Reason: No separate data reported for 
persons with IGT/IFG aged 18 to 40 years 
  

































Adjustment for confounders 
Nelson et al (1996)(102) YES YES YES YES YES YES YES Unclear YES None 
Fox et al (2005)(5) YES YES YES YES YES Unclear YES NO YES Age, sex, baseline GFR, SBP, 
hypertension treatment, smoking, 
BMI, total & HDL cholesterol, MI, 
congestive heart failure 
Meigs et al (2002)(162) YES YES YES YES YES Unclear YES NO YES Age, SBP, BMI, smoking, ACE 
inhibitor, total cholesterol, HDL, 
triglyceride, hypertensive drugs. 
Nelson et al (1999)(163) YES YES YES YES YES Unclear YES NO YES None 
Nelson et al (1989)(164) YES YES YES YES YES YES YES NO YES Age, sex, BP 
Yokoyama et al 
(2009)(165)  
YES YES YES YES NO Unclear YES NO YES None 
Tozawa et al (2007)(166)  YES YES YES YES YES NO YES NO YES Age, sex, current cigarette smoking, 
alcohol drinking habit 
Nelson et al (1993)(167) YES YES YES YES YES Unclear YES NO YES None 
Rashidi et al (2007)(168) YES YES YES YES YES Unclear YES NO YES None 
Kitiyakara et al (2007)(169) YES YES YES YES YES NO YES NO YES Age, sex and smoking status 
Sun et al (2010)(6) YES YES YES YES YES YES YES NO YES Age, sex, check-up centers and 
current smoking 
Yang et al (2012)(170) YES YES YES YES YES NO YES NO YES Age, sex, BMI, serum level, total 
cholesterol, BP, triglyceride, HDL, 
waist circumference 
Kovacs et al (2013)(171) YES YES YES YES YES Unclear YES NO YES No adjustments 
Watanabe et al (2010)(7) YES YES YES YES YES NO YES NO YES Sex and age 
Ryu et al (2009)(172) YES YES YES YES Unclear NO YES NO YES Age, baseline GFR, 
glutamyltranspeptide, uric acid, 
triglyceride, HDL cholesterol, BP, 
obesity 
Tohidi et al (2012)(173) YES YES YES YES YES Unclear YES NO YES BMI, total cholesterol, SBP 
Jee et al (2005)(174)  YES YES YES YES YES NO YES NO YES None 
Carson et al (2015) (175) YES YES YES YES YES YES YES NO YES Age, race, sex, education 
Nand et al (2015) (176) YES YES YES YES Unclear Unclear NO NO YES None 
Halbesma et al ( 2008) 
(177) 
YES YES YES YES YES Unclear YES NO YES Urea excretion, cholesterol, waist 
circumference, BP, glucose 
Schottker et al (2013)(178) YES YES YES YES YES YES YES NO YES BMI, BP, cholesterol, 
antihypertensive drug, statins, 
smoking, history of CVD 
Bonnet et al (2006) (179) YES YES YES YES YES Unclear YES NO YES Age, ACE inhibitors, smoking, 
fibrinogen level 
Lucove et al (2008) (180) YES YES YES YES YES Unclear YES NO YES age, sex, study centre, education, and 
smoking 
Ninomiya et al (2006) 
(181) 
YES YES YES YES YES Unclear YES NO YES Age, sex, baseline GFR, proteinuria, 
serum albumin, cholesterol, 




Table 6: Quality assessment of included studies: IGT/IFG compared to T2DM 
         4GFR, glomerular filtration rate; SBP, systolic blood pressure; BMI, body mass index; HDL, high density lipoprotein; MI, myocardial infarction; BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose 
                                                          
 


























Adjustment for confounders 
Kim et al (2010)(182) YES YES YES YES YES Unclear YES NO YES Age and sex 
Iseki et al (2004)(183) YES YES YES YES YES Unclear YES NO YES Age, sex, baseline GFR, 
SBP,DBP,BMI, total cholesterol, 
triglyceride, serum creatinine, 
hematuria and proteinuria  
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3.6.2 Study characteristics 
The characteristics of the 25 cohort and one case-control studies are summarised in Appendix 9 
and Appendix 10. Briefly, one case-control and 25 cohort studies meeting the inclusion criteria 
were identified following the sensitivity search. One reported separate data in persons aged 18 to 
40 years with IGR compared to T2DM and this was identified in the original search:  
 Incidence of CKD in persons aged (18 to 40 years) with IGR compared to T2DM 
Kim and colleagues, (2010) (182), reported risk of CKD in young adults aged 18 to 40 years 
with IGR compared to T2DM. This cohort study followed 2,666 Pima Indian youth aged (≤20 
years) with IGR and type 2 diabetes (T2DM) during a follow-up period of 25.2 year for the 
development of macro-albuminuria, defined as an albumin creatinine ratio (ACR) of ≥300mg/g. 
The incidence of macro-albuminuria was 1.3 (new cases of macro-albuminuria per 1000 person-
years) with a total of 28 cases in 21,830 (person-years) of follow-up in subjects with IGR or 
0.13% developing macro-albuminuria each year compared to 2.4% in patients with T2DM.  
3.7 Discussion 
This systematic review aimed at exploring the risk of CKD in persons aged 18 to 40 years with 
IGR compared to those with normoglycaemia or T2DM. Nineteen cohort studies were identified 
for potential inclusion where some participants were aged 18 to 40 years with IGT or IFG 
compared to normoglycaemia or T2DM. No case-control studies were identified reporting 
incident cases of CKD person aged 18 to 40 years exposed to IGT/IFG compared to 
normoglycaemia or T2DM. Only one study reported risk estimates of CKD (macro-albuminuria 
≥300mg/g) development exclusively in young adult aged 18 to 40 years with IGR compared to a 
similar population with T2DM. With IGR the annual incidence rate of CKD was 0.13% 
compared to 2.4% with T2DM. The remaining 18 studies did not report separate result in 
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persons aged 18 to 40 years with IGT/IFG and risk of CKD but results were reported for the 
population as a whole, consequently pooled estimates of CKD and a meta-analysis could not be 
performed because risk estimates of CKD in persons with IGT/IFG compared to 
normoglycaemia/T2DM were not stratified by age and reported separately. Therefore, 
quantification of risk was not possible in this age group.  
In a systematic review of 9 population-based cohort studies, Echouffo-Tcheugui and colleagues 
(184) examined the effect of prediabetes defined as (IGT or IFG) and risk of CKD in a total 
population of 185,452 participants aged (≥18 years) with 835,146 person-years of follow-up.  
Incident diagnosis of CKD (the outcome of interest) was determined by any of the following 
definitions (micro-albuminuria, albuminuria, or proteinuria) and/or a decreased in estimated 
glomerular filtration rate (eGFR <60ml/min/1.73m2). A random effects meta-analysis was used 
to calculate pooled risk ratios of incident CKD. The summary effect estimate showed an 11% 
(95% CI, 1.02 to 1.21) increased risk of CKD in individuals with prediabetes. The researchers 
concluded that the long term association of prediabetes and CKD may be stronger than that 
found in the study because of short and intermediate follow-up period of studies included in this 
systematic review. Additionally, the effect of prediabetes and future risk of CKD were not 
assessed by age group, therefore the true extent of CKD risk associated with prediabetes 
stratified by age group remains to be clarified.  
3.8 Strength and limitations 
3.8.1 Strengths 
This review was not limited to the English language or geographical area and a broad range of 
markers were used to ascertain CKD. Furthermore, a comprehensive literature search was 
conducted on a topic where to the best of our knowledge, no systematic review evaluated the risk 
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of CKD in young adults aged 18 to 40 years with IGT/IFG compared to normoglycaemia or 
T2DM. Additionally, only cohort and case-control studies with incident CKD were reviewed for 
potential inclusion, cross-sectional studies were excluded because they do not distinguish 
between IGR diagnosed after CKD and IGR diagnosed before CKD. 
3.8.2 Limitations 
Only one study provided risk estimates of CKD in persons aged 18 to 40 years with IGR. 
Sufficient studies were not available to conduct a meta-analysis therefore a more generalisable 
and precise estimate of CKD could not be presented. Furthermore, results of this study should be 
interpreted with caution because of the small sample size and the study population (Pima 
Indians). Additionally, quantification of CKD risk was problematic because of this narrow age 
group, as risk of CKD in IGR in separate age groups was not available in existing literature. 
Researchers will be contacted requesting data to perform a sub-group analysis in the 18 to 40 age 
group.  
3.9 Conclusion 
Results of this systematic review demonstrate that evidence for the risk of CKD in young adults 
aged 18 to 40 years with IGR is lacking. Further research is needed to estimate the incidence of 
CKD in this cohort of individuals. To bridge this gap in evidence large epidemiological 
databases may be examined to quantify the risk of CKD in young adult aged 18 to 40 years with 
IGR compared to those with normoglycaemia. Data from these databases may potentially inform 
a prognostic study which may be useful in understanding the course and factors associated with 
CKD development. Finally, results may emphasise the importance of identifying individuals 
with IGR earlier and implement interventions to prevent or delay the development of CKD.  
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CHAPTER FOUR: METHODS 
INCIDENCE AND PREVALENCE 
 
4.1 Introduction 
This chapter sets out to describe the method used to determine the risk of chronic kidney disease 
(CKD) in young adults aged 18 to 40 years with impaired glucose regulation (IGR). The chapter 
begins by exploring the incidence and period prevalence of IGR in young adults followed by the 
incidence of CKD in a similar population with IGR compared to those with normoglycaemia. 
Next, the incidence of each CKD category (stages 1 – 2 /3 – 5) was determined separately in the 
IGR cohort. It continues by providing a brief introduction to the Health Improvement Network 
(THIN) Database followed by describing the criteria used to identify eligible patients, the 
outcome of interest, estimate baseline clinical measurements, identify covariates. The chapter 
ends by describing the appropriate method related to the analysis of the data.  
 
4.2 Study design 
This was a population based, matched retrospective, open cohort study using data from the 
THIN database. An open cohort design was used because it is dynamic, meaning patients aged 
18 to 40 years with IGR can enter or leave throughout the study period. Patients are continually 
added when they are diagnosed, replacing those who were lost to follow-up or died. A matched 
cohort design was chosen so that the comparison group (individuals with no glycaemic 
abnormality) is similar to the index group (individuals with IGR) with respect to age, gender, 




4.3 Data source 
Routinely collected electronic health records of patients registered with a practice contributing 
data to THIN were extracted and included in the analyses. THIN contains anonymised electronic 
patient records from over 600 general practices from across England, Wales, Scotland and 
Northern Ireland. As of September 2014 the database, holds a total of 13 million patients of 
whom 3.6 million are actively registered with a general practice equivalent to more than 85 
million person years of computerised data covering approximately 6% of the UK population 
(185) (http://www.epic-uk.org/our-data/statistics.shtml). The information recorded in THIN 
include demographic details, diagnoses, prescriptions, socio-economic data, free text comments 
and additional health records such as lifestyle habits (smoking and alcohol consumption). 
General practices contributing data to THIN are made up of practices using Vision software 
which codes clinical data using the 5-byte Read code clinical classification (131) and store drug 
prescriptions using their generic names which can be linked to the British National Formulary 
(133).  
4.4 Practice eligibility criteria 
Practices were eligible to contribute patients to the study cohort from one year after installation 
of the Vision software and have an Acceptable Mortality Rate (AMR) date (a marker for data 
quality in the THIN database). This ensured that practices were using their system adequately 
and important events were not missed (134). Practices continue to contribute patients to the 
study cohort until the date of the last data collection (maximum February 2015).  
4.5 Patient eligibility criteria 
Patients were eligible for inclusion in the study from the latest of the following four dates: 
Vision installation date, study start date (January 2000), patient registration date plus one year 
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(to ensure patients did not have the outcome of interest (CKD) prior to entry) and were aged 18 
years. Patients were followed up until the earliest of the following dates: aged 41 years, patient 
transferred out of the practice, patient died and study end date (February 2015), last data 
collection date. These dates were the patients start and end dates (their observation period).  
4.5.1 Exclusion criteria 
Patients who had no or inconsistent registration and re-registration dates and patients who were 
temporarily registered were excluded. Patients with an observation period of less than 90 days 
were also excluded from the study cohort.  
4.6 Exposure (IGR case definition)  
Patients with incident IGR within their observation period were eligible for inclusion as cases in 
the exposure cohort. The IGR index date was identified using the earliest of the following 
events:  
1. A Read coded diagnosis of IGR (IGT + IFG or Pre-diabetes) – Refer to Appendix 
11 
2. Reported measurements of: 
a. HbA1c in the range 42 – 47 mmol/mol (65, 186) 
b. Fasting blood glucose (FBG) in the range 6.1 – 6.9 mmol/L (65, 67) 
c. Oral Glucose Tolerance Test (OGTT) blood glucose in the range ≥7.8 
≤11.1 mmol/L (65, 67) 
4.6.1 Exclusion criteria 
a. Patients with an index date prior to their observation period 
b. Patients with diabetes (type1 or type 2) prior to the index date 
c. Patient observation period ended within 90 days of the index date 
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d. Patient diagnosed with diabetes (type 1 or type 2) within 30 days of 
the index date 
e. Patients with CKD prior to their index date 
4.7 Outcome (CKD case definition)  
Patients with incident CKD stage 1 – 5 were identified using the earliest of the following events:  
1. A Read coded diagnosis of CKD (1 – 2/ 3 – 5) – (Appendix 11) or 
2. A single estimated glomerular filtration rate (eGFR) of (≥60 
ml/min/1.73m2 [CKD stage 1 – 2 ]) with additional evidence of kidney 
disease which include the following: 
a. A single albumin creatinine ratio (ACR) of  (≥3mg/mmol) (9) 
b. A single protein creatinine ratio (PCR) of (50mg/mmol) (9) 
c. A single urinary albumin/protein loss of 0.5g/day (9) 
3. eGFR<60 ml/min/1.73m2 (CKD stage 3 – 5)   
4.8 Covariates 
Covariates (risk modifiers) were selected based on their biological plausibility and previously 
published epidemiological evidence (54, 58). These covariates were age hypertension, heart 
failure (HF), atrial fibrillation (AF), cardiovascular disease (CVD), and non-steroidal anti-
inflammatory drugs (NSAIDS). The latter was described as the date of the latest prescription 
prior to the index date. All the other covariates were recorded before the index date.  
 
4.9 Matching criteria 
Eligible IGR cases were matched on practice, gender and age (within 2 years) and IGR case 
index date. For each IGR case three unexposed controls (normoglycaemia) were selected. 
61 
 
Matched patients had to remain registered for at least one year prior to the index date of the IGR 
case and not have IGR or CKD on or before the index date.  
4.9.1 Exclusion 
1. Potential matches were excluded if: 
a. Their observation period ended within 90 days of the index date 
b. Diagnosed with diabetes (type 1/type 2) within 30 days of the 
index date 
4.10 Follow-up period 
1. IGR patients were followed up until the earliest of the following dates: 
a. Patient died 
b. Left practice 
c. Diagnosis of CKD 
d. Practice last data collection 
 
4.11 Extraction by Read code  
A Read code list was compiled to facilitate data extraction which was sufficiently accurate and 
valid for this study. This list was derived from the quality and outcomes framework (QOF) 
version (33.0) 2015 rulesets (http://www.hscic.gov.uk/qofbrv33). The Read code list was 
checked and approved by Professor Tom Marshall, Dr Paramjit Gill and Dr Ronan Ryan. A full 
list of Read codes for each study variable included in this study and a description of what each 





4.12 Missing data 
Several studies (187, 188) have shown that databases such as THIN are known to contain some 
missing data. However, excluding missing data (for e.g., only including complete case analysis) 
may result in unstable and inaccurate analysis (189). A challenge in THIN is that data are 
generally captured for clinical purposes and not for research which in some circumstances may 
result in data missing due to unobserved characteristics which are not likely to be missing at 
random (190). Furthermore, imputing missing values require the data to be missing at random 
(191). Additionally, some patients may consult infrequently and are likely to have missing data 
(for e.g., BMI, ethnicity) and are therefore less likely to be diagnosed with an illness. Therefore, 
no attempt was made to impute missing data. For categorical variable (e.g. ethnicity) and 
continuous variables (e.g. BMI) a separate ‘missing’ category was created for those with missing 
data.  
4.13 Ethics approval 
THIN database (data collection process) obtained ethical approval from the South East Multi-
centre Research Ethics Committee (reference number: 07/H1102/103). The protocol for this 
study was reviewed and approved in June 2014 (study reference: 14-038) by the THIN Scientific 
Review Committee (SCR) (Appendix 12). 
4.14 Statistical analysis 
4.14.1 Descriptive statistics 
All statistical analyses were conducted using Stata version 13.1 (Stata Corp, College Station 
Texas, USA). Appropriate descriptive statistics were used to summarise the covariates and 
matching characteristics for those exposed and unexposed to IGR. Categorical variables were 
investigated using (Chi-square [ ]) test and continuous variables were analysed using t-test. 
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Since, length of follow-up had a highly skewed distribution Mann-Whitney U test was used to 
compare groups. Statistical significance was set at 5% level (p – value = 0.05).  
4.14.2 Estimating IGR incidence 
The overall incidence rate of IGR amongst young adults aged 18 to 40 years was calculated by 
dividing the number of events (failure) that occurred by person years of follow-up (period of 
January 2000 to February 2015). Similarly, incidence rates by age group (18-25, 26-40), gender, 
ethnicity, deprivation quintile and calendar year (2000 - 2015) were also calculated. Incidence 
rates were expressed per 100,000 person-years of follow-up with 95% confidence interval (CI). 
Patients contributed person-years until the earliest of the following: developed diabetes, end date 
(died, left practice, practice last data collection date, earliest of age 40). STRATE command was 
used to examine incidence rates of IGR per 100,000 years of follow-up (192).  
4.14.3 Calculating period prevalence of diagnosed IGR with mid-year study population 
The period prevalence of diagnosed IGR amongst young adults aged 18 to 40 years was 
estimated over the study period (January 2000 to December 2014). Annual prevalence of 
diagnosed IGR was calculated by age group, gender and calendar year. The prevalence of IGR 
was estimated by including all new and pre-existing cases of IGR in each or any previous year as 
numerator divided by the mid-year study population in that year. The average population in the 
practice is calculated from the number of persons registered during the year. Patients with IGR 
were identified by Read code only because laboratory results recorded in their previous 
practice’s electronic records were not routinely transferred into the electronic record at their 
current (THIN) practice. Using a definition of IGR based on laboratory results would therefore 
mean we were more likely to identify cases diagnosed after registration with a THIN practice 
than before. We decided that it was preferable to adopt a definition based on Read codes alone as 
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it would avoid introducing an ascertainment bias. The cost of this decision is that our estimates 
of prevalence are likely to be lower than the true prevalence, but this was felt to be a more 
consistent way of representing prevalence over time. Period prevalence was expressed as a 
percentage with a corresponding 95% confidence interval (CI). Patients were excluded if they 
developed diabetes during the study period, aged (>40 years), died, left practice and practice last 
data collection date. A combination of STSPLIT and STRATE commands in STATA were used 
to calculate period prevalence of IGR by calendar year.  
4.14.4 Calculating incidence rate of CKD in IGR compared to those without IGR 
The incidence rate ratio of CKD in patients aged 18 to 40 years for the period January 2000 to 
February 2015 was estimated by dividing the incidence rate of CKD in patients with IGR to 
those with normoglycaemia. After patients developed IGR they were assumed to be exposed 
from this date onwards. There was no allowance for regression from IGR back to 
normoglycaemia. Incidence rate was expressed as 100,000 person-years of follow-up. Adjusted 
and unadjusted incidence rate ratio (IRR) of CKD was calculated with 95% CI and associated p 
– values matched on age, sex and practice. The STIR command was used to examine the 
unadjusted IRR of CKD. Poisson regression (Poisson command in STATA) (193) was used to 
adjust for patient level covariates (age, sex, ethnicity, level of deprivation, BMI categories, 
CVD, HF, AF, hypertension, NSAID). Patients were censored if they developed diabetes during 
follow-up, died, left practice, practice last data collection date or had a CKD diagnosis.    
4.14.5 Calculating incidence rate of CKD (stages 1 – 2 /3 – 5) separately in IGR  
The incidence rate of each CKD category (stages 1 – 2 /3 – 5) was calculated separately. Patients 
were classified as CKD stage (1 – 2/3 – 5) using the first recorded Read code or first recorded 
laboratory data. Incidence rates were expressed per 100,000 person-years of follow-up with 95% 
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(CI). STRATE command was used to examine the unadjusted incidence rate of CKD 1 – 2 and 
CKD 3 – 5 in IGR per 100,000 person-years of follow-up. Patients who were categorised as 
CKD stage (1 – 2) and later progressed to CKD stage (3 – 5) were censored at the date when 





CHAPTER FIVE: METHODS 
PREDICTORS OF CKD IN IGR 
 
5.1 Introduction 
The aim of this chapter was to determine future CKD risk in patients following a diagnosis of 
IGR. This was done using a Cox-proportional hazards model. The relationship between each 
baseline characteristic and CKD risk was assessed separately in a series of univariate analyses. 
This was followed by checking for a non-linear relationship between CKD risk and the 
continuous variables age and BMI by fitting fractional polynomials (194).  
 
Next, the probability of remaining free of CKD was estimated up to a maximum of 15 years 
following IGR diagnosis using Kaplan-Meier survivor function. The proportional hazards 
assumption for each variable was checked using Schoenfeld residuals and log-log survival plots. 
A multivariate Cox proportional hazards model containing all the predictor variables was then 
fitted. This chapter ends by exploring the goodness of fit of the final model, estimated by using 
the R-squared (R2) statistic for time-to-event models developed by Royston and colleagues 
(194).  
 
5.2 Method  
The study design, data source, patient and practice eligibility criteria, IGR case definition, 
outcome definition and prognostic variables included in this analysis have been previously 
discussed in chapter 4 (methods chapter: prevalence and incidence). Briefly, data from 10,561 
patients with incident IGR were included in this analysis. IGR cases were defined as patients 
without CKD at diagnosis of IGR and the outcome of interest was time to CKD diagnosis. IGR 
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patients were followed up until the earliest of the following events: 1) end of the study period, 
death or de-registration; 2) diagnosis of CKD; 3) diagnosis of diabetes (no longer IGR). 
Prognostic variables were chosen based on literature and clinical importance (54, 58).  
5.3 Model development 
5.3.1 Univariate analysis 
Each CKD risk predictor was tested separately by fitting Cox regression (195) using the stcox 
(196) command. A hazard ratio (HR) with 95% confidence interval (CI) and associated p-value 
were derived for each predictor. Predictors were tabulated for up to 15-years follow-up, with the 
aim of excluding predictors from the multivariate analysis where it was not possible to reliably 
estimate risk of CKD.   
 
5.4 Handling of continuous predictor: Checking for non-linear relationships between 
the continuous variable and the outcome 
Fractional polynomials (194) were used to check for a non-liner relationships between each of 
the continuous variables (BMI and age) and risk of CKD. The Stata command mfp stcox (197) 
was used to determine the best fitting functional form for each variable. 
 
5.5 CKD free survival following IGR diagnosis 
A Kaplan-Meier (K-M) survivor function (198) was used to determine probability of remaining 
CKD free from IGR diagnosis to a maximum of 15 years. The Kaplan-Meier function estimates 
probability of survival at specified time points in the presence of censored data. The sts list (199) 
command was used to retrieve a tabular version of the survival probabilities and 95% CIs. The 
results of the Kaplan-Meier survival estimates were reviewed to ensure that there were sufficient 
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number of patients included in the analysis, particularly in later years. A final decision on the 
length of follow-up was made using this information and clinical colleagues’ advice.  
5.6 Method for model checking – checking for proportional hazards assumption 
The Cox model makes the assumption that the effect of the predictor variables and time to event 
(risk of CKD) remains constant over time. This assumption was checked for each predictor and 
globally using the estat phtest detail (200) command. It produces Chi-square [ ] and a p-value 
for each predictor and globally. Proportionality was also checked visually using log-log graphs. 
The stphplot (200) command was used to draw log-log plots for the selected covariates. Hazards 
can be assumed proportional if the plotted line for each group remained roughly parallel with its 
neighbours over time (201).  
5.7 Multivariate analysis  
A multivariate Cox proportional hazards model was fitted containing predictors with reliable 
CKD risk estimates reported in the univariate analyses to determine risk of CKD in patients with 
IGR for up to 15-years follow-up. Risk of CKD was reported as hazard ratios (HR) along with 
95% confidence intervals (CI) and associated p-values.  
5.8 Model checking – proportion of variation in the final model 
To assess goodness of fit R-squared (R2) statistics was used. The command str2ph is based on 
Royston’s (202) modification of  Nagelkerke’s statistics for proportional hazards models (203). 
It estimates the proportion of variation in the data explained by the model. The R2 ranged from 0 




CHAPTER SIX: RESULTS 
INCIDENCE AND PREVALENCE 
6.1      Introduction 
This chapter presents the findings of the following analyses of the Health Improvement Network 
(THIN) database. The first part describes the incidence and period prevalence of impaired 
glucose regulation (IGR) in persons aged 18 to 40 years by age group, gender, ethnicity, area of 
deprivation and calendar year. After this the prevalence of IGR is compared to two published 
papers reporting prevalence of prediabetes and IGT/impaired fasting glucose (IFG) (Appendix 
13).  
The second part of the analysis consists of the unadjusted and adjusted incidence of chronic 
kidney disease (CKD) in persons aged 18 to 40 years with IGR compared to those with no 
glycaemic abnormality. The final part presents the results of the unadjusted incidence of CKD 1 
– 2 and 3 – 5 separately in the IGR cohort. The chapter concludes with a description of the 
baseline characteristics of the matched cohort (IGR compared to normoglycaemia in persons 
aged 18 to 40 years) and the number of CKD cases first recoded via Read code and first recorded 
via biomedical data in the IGR cohort.   
6.2   Incidence of IGR in persons aged 18 to 40 years 
6.2.1 Overall incidence of IGR  
The study population included in this analysis consists of approximately 3.5 million individuals 
aged 18 to 40 years contributing 14.9 million person-years (pyr) of follow-up for the period of 
(January 2000 to December 2014). The overall incidence rate (IR) of IGR was 72.2 cases per 
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100,000 pyr (95% CI, 70.9 to 73.6) of follow-up. The incidence rates per (100,000 pyr) by age 
group, gender, ethnicity, area of deprivation and calendar year are presented in Table 7. 
6.2.2 Incidence by age group and gender  
The incidence of IGR increased with age. For those aged 26 to 40 years the incidence rate was 
approximately 5 times higher (IR 93.8 [95% CI, 91.9 to 95.6]) per 100,000 pyr compared to 
individuals aged 18 to 25 years, the incidence rate was (22.1 [95% CI, 20.8 to 23.5]). The 
incidence rate was higher in females (79.0 [95% CI, 77.0 to 81.0]) per 100,000 pyr of follow-up 
as compared to males (65.8 [95% CI, 64.0 to 67.7]) per 100,000 person-years.  
6.2.3 Incidence by ethnicity 
The incidence of IGR in South Asians was approximately 5 times higher (IR 393.7 [95% CI, 
374.5 to 413.9]) and in Black approximately 3 times higher (IR 218.1 [95% CI, 197.9 to 240.4]) 
than the incidence in the White ethnic group (IR 76.5 [95% CI, 74.1 to 79.0]) per 100,000 pyr. 
The incidence rate for patients with missing information on ethnicity was 52.7 (95% CI, 51.3 to 
54.2) per 100,000 pyr.  
6.2.4 Incidence by deprivation quintile 
The incidence of IGR increases with increasing deprivation. The incidence rate was 
approximately 2.2 times higher (IR 105.5 [95% CI, 101.2 to 109.9]) in the most deprived areas 
(Townsend quintile 5) compared to the least deprived areas (IR 48.1 [95% CI, 45.8 to 50.6]).  
 
6.2.5 Incidence by calendar year 
Table 7, illustrates the annual incidence of IGR for the period (2000 – 2014). The incidence of 
IGR was approximately 8.4 times higher in 2014 (IR 137.3 [95% CI, 130.1 to 144.8]) than 2000 
(IR 16.4 [95% CI, 13.0 to 20.6]). This increasing trend appears to continue throughout the 15 
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year period. The highest peak recorded was in 2013, the incidence rate was more than 9 times 
higher (IR 157.1 [95% CI, 149.8 to 164.7]) than incidence in 2000.   
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Table 7: Incidence of IGR by age, sex, deprivation score, ethnicity and calendar year in THIN database from 
January 2000 to December 2014 





Person-years Incidence rate per 
100,000 person-years 
95% (CI) 
Total 10,776 3,456,259 14,915,070 72.2 (70.9, 73.6) 
Age group      
18-25 991 1,464,328 4,479,930 22.1 (20.8, 23.5) 
26-40 9785 2,579,647 10,435,140 93.8 (91.9, 95.6) 
Gender      
Male 5019 2,012,730 7,621,760 65.8 (64.0, 67.7) 
Female 5759 2,053,522 7,293,310 79.0 (77.0, 81.0) 
Ethnicity      
White 3727 1,396,260 4,874,090 76.5 (74.1, 79.0) 
Black 405 62,697 185,700 218.1 (197.9, 240.4) 
Asian 1535 125,643 389,870 393.7 (374.5, 413.9) 
Chinese 32 16,909 38,530 83.1 (58.7, 117.4) 
Mixed 63 24,352 67,370 93.2 (73.1, 119.7) 
Others 132 37,024 103,750 127.2 (107.3, 150.9) 
Unknown 4882 2,403,367 9,255,760 52.7 (51.3, 54.2) 
Townsend Quintile      
(Least deprived) 1 1540 811,852 3,202,050 48.1 (45.8, 50.6) 
2 1603 722,848 2,811,570 57.0 (54.3, 59.9) 
3 2216 834,840 3,092,000 71.7 (68.7, 74.7) 
4 2520 830,643 2,941,250 85.7 (82.4, 89.1) 
(Most deprived) 5 2283 617,112 2,164,970 105.5 (101.2, 109.9) 
Unknown 614 248,957 703,230 87.3 (80.7, 94.5) 
Incidence by calendar year      
2000 73 597,233 445,640 16.4 (13.0, 20.6) 
2001 105 741,360 626,240 16.8 (13.8, 20.3) 
2002 210 928,062 770,200 27.3 (23.8, 31.2) 
2003 338 1,012,844 898,260 37.6 (33.8, 41.9) 
2004 425 1,056,516 945,550 44.9 (40.9, 49.4) 
2005 538 1,141,176 1,012,820 53.1 (48.8, 57.8) 
2006 519 1,182,937 1,054,750 49.2 (45.2, 53.6) 
2007 635 1,222,252 1,080,410 58.8 (54.4, 63.5) 
2008 651 1,279,799 1,126,940 57.8 (53.5, 62.4) 
2009 849 1,310,172 1,163,760 73.0 (68.2, 78.0) 
2010 915 1,292,454 1,146,900 79.8 (74.8, 85.1) 
2011 1020 1,270,332 1,134,160 89.9 (84.6, 95.6) 
2012 1297 1,275,445 1,132,720 114.5 (108.4, 120.9) 
2013 1706 1,246,200 1,085,980 157.1 (149.8, 164.7) 
2014 1351 1,143,592 984,250 137.3 (130.1, 144.8) 
Abbreviations:  IGR, impaired glucose regulation; CI, confidence interval, PYR; person-years  
 
6.3   Read coded period prevalence of diagnosed IGR in persons aged 18 to 40 years based    
on mid-year population estimates 
 
A total of approximately 3.5 million individuals aged 18 to 40 years were included in this 
analysis. The annual prevalence of diagnosed IGR by calendar year, gender and age group for 
the period (January 2000 to December 2014), are presented in Tables (8 - 10).  
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6.3.1 Period prevalence of diagnosed IGR by calendar year based on mid-year study 
population for each year (2000 to 2014) 
The prevalence of diagnosed IGR increased 7 fold, from 0.030% (95% CI, 0.025% to 0.036%) in 
2000 to 0.207% (95% CI, 0.198% to 0.216%) in 2014 (Table 8). The annual prevalence 
consistently increased throughout the 15 year period (Figure 9). 
Table 8: Period prevalence of diagnosed IGR in persons aged 18 to 40 years by calendar year, 2000 to 2014 
based on mid-year population estimates 
Year Number of patients 
 with IGR 
Persons  
(Mid-year population)  
Prevalence (%) 95% (CI) 
2000 131 434,340 0.030 (0.025, 0.036) 
2001 175 626,262 0.028 (0.024, 0.032) 
2002 294 769,503 0.038 (0.034, 0.043) 
2003 476 907,332 0.052 (0.048, 0.057) 
2004 634 946,531 0.067 (0.062, 0.072) 
2005 926 1,022,355 0.091 (0.085, 0.097) 
2006 1149 1,050,507 0.109 (0.103, 0.116) 
2007 1333 1,082,085 0.123 (0.117, 0.130) 
2008 1519 1,127,671 0.135 (0.128. 0.142) 
2009 1706 1,171,734 0.146 (0.139, 0.153) 
2010 1865 1,144,575 0.163 (0.156, 0.171) 
2011 1968 1,136,167 0.173 (0.166, 0.181) 
2012 2079 1,134,967 0.183 (0.175, 0.191) 
2013 2152 1,099,471 0.196 (0.188, 0.204) 
2014 2052 993,259 0.207 (0.198, 0.216) 
Average annual 
prevalence 
  0.116 
 




Figure 9: Trend in the prevalence of diagnosed IGR in persons aged 18 to 40 years for the period  




6.3.2 Period prevalence of diagnosed IGR by age group based on mid-year study 
population for each year (2000 to 2014)  
The prevalence of diagnosed IGR in the age group 18 to 25 years was lower than in those aged 
26 to 40 years over the 15 year calendar period (January 2000 to December 2014) (Figure 10). 
Prevalence increased in both age groups from 0.040% (95% CI, 0.033% to 0.047%) in 2000 to 
0.339% (95% CI, 0.321% to 0.358%) in 2014 in those aged 26 to 40 years and from 0.006% 
(95% CI, 0.003% to 0.012%) in 2000 to 0.120% (95% CI, 0.112% to 0.129%) in 2014 in those 
aged 18 to 25 years. The annual prevalence of IGR by age group is shown in Table 9. Prevalence 
of IGR in this study was compared with Mainous and colleagues (76) and the NHS Diabetic 
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Aged (18 to 25 years) Aged (26 to 40 years)  
Ratio aged 
 (26-40:18-25) 












Prevalence (%) 95% (CI) 
 
 
2000 8 124,952 0.006 (0.003, 0.012) 123 309,388 0.040 (0.033, 0.047)  6.7 
2001 14 192,422 0.007 (0.004, 0.012) 161 433,840 0.037 (0.032, 0.043)  5.3 
2002 28 253,871 0.011 (0.008, 0.016) 266 515,632 0.052 (0.046, 0.053)  4.7 
2003 53 320,435 0.017 (0.013, 0.022) 423 586,897 0.072 (0.065, 0.079)  4.2 
2004 84 361,963 0.023 (0.019, 0.029) 550 584,568 0.094 (0.087, 0.103)  4.1 
2005 140 415,256 0.034 (0.029, 0.040) 786 607,099 0.129 (0.121, 0.139)  3.8 
2006 190 457,456 0.042 (0.036, 0.048) 959 593,051 0.162 (0.152, 0.172)  3.9 
2007 239 499,927 0.048 (0.042, 0.054) 1094 582,158 0.188 (0.177, 0.200)  3.9 
2008 294 546,131 0.054 (0.048, 0.060) 1225 581,540 0.211 (0.199, 0.223)  3.9 
2009 358 587,458 0.061 (0.055, 0.068) 1348 584,276 0.231 (0.219, 0.243)  3.8 
2010 440 597,126 0.074 (0.067, 0.080) 1425 547,449 0.260 (0.247, 0.274)  3.5 
2011 541 620,253 0.087 (0.080, 0.095) 1427 515,923 0.277 (0.263, 0.291)  3.2 
2012 618 642,231 0.096 (0.089, 0.104) 1461 492,736 0.297 (0.282, 0.312)  3.1 
2013 712 639,789 0.111 (0.103, 0.120) 1440 459,682 0.313 (0.297, 0.330)  2.8 




  0.053    0.180  
Average annual 
prevalence ratio 
aged (26-40:18-25)  
4.0 
Table 9: Prevalence of diagnosed IGR in persons aged 18 to 40 years by age group based on mid-year population estimates 
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Figure 10: Annual prevalence of diagnosed IGR by age group based on mid-year population estimates 
 
 
6.3.3 Period prevalence of diagnosed IGR by gender based on mid-year study 
population for each year (2000 to 2014)  
Figure 11 shows the trend in the prevalence of diagnosed IGR by gender for the study period 
(January 2000 to December 2014). Prevalence in females was consistently higher than males 
throughout the 15 year period. Prevalence increased from 0.014% (95% CI, 0.010% to 0.019%) 
in 2000 to 0.139% (95% CI, 0.129% to 0.150%) in 2014 in males and from 0.047% (95% CI, 
0.038% to 0.057%) in 2000 to 0.276% (95% CI, 0.261% to 0.291%) in 2014 in females. The 
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 Female Male  Ratio F:M 












Prevalence (%) 95% (CI) 
 
 
2000 100 212,602 0.047 (0.038, 0.057) 31 221,738 0.014 (0.010, 0.019)  3.4 
2001 134 305,873 0.044 (0.037, 0.052)  41 320,389 0.013 (0.009, 0.017)  3.4 
2002 219 374,854 0.058 (0.051, 0.067) 75 394,649 0.019 (0.015, 0.024)  3.1 
2003 346 441,593 0.078 (0.070, 0.087) 130 465,739 0.028 (0.024, 0.034)  2.8 
2004 446 460,024 0.097 (0.088, 0.106)  188 486,507 0.039 (0.034, 0.045)  2.5 
2005 642 497,235 0.129 (0.119, 0.139)  284 525,120 0.054 (0.048, 0.061)  2.4 
2006 789 510,950 0.154 (0.143, 0.165)  360 539,557 0.067 (0.060, 0.074)  2.3 
2007 898 526,358 0.171 (0.160, 0.182)  435 555,727 0.078 (0.071, 0.086)  2.2 
2008 977 550,137 0.178 (0.167, 0.189)  542 577,534 0.094 (0.086, 0.102)  1.9 
2009 1138 572,334 0.199 (0.187, 0.211) 568 599,400 0.095 (0.088, 0.104)  2.1 
2010 1230 559,698 0.220 (0.208,0.232)  635 584,877 0.109 (0.100, 0.117)  2.0 
2011 1291 557,500 0.232 (0.219, 0.245)  677 578,676 0.117 (0.109, 0.126)  2.0 
2012 1385 557,428 0.248 (0.235, 0.262) 694 577,539 0.120 (0.112, 0.130)  2.1 
2013 1421 542,829 0.262 (0.248, 0.276) 731 556,642 0.131 (0.121, 0.141)  2.0 









Table 10: Prevalence of diagnosed IGR in persons aged 18 to 40 years by gender based on mid-year population estimates 
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Figure 11: Annual prevalence of diagnosed IGR by gender based on mid-year population estimates 
 
 
6.4 Incidence rate of CKD in persons aged 18 to 40 years with IGR compared to those with 
normoglycaemia 
The study population included in this analysis contained approximately 41,000 individuals aged 
18 to 40 years for the period of (January 2000 to February 2015), matched on age, sex and 
general practice. The unadjusted incidence of CKD per 100,000 person-years (pyr) of follow-up 
in persons with IGR was 4 times higher [IRR 4.0, 95% CI, 3.2 to 5.1, p<0.001] compared to 
individuals with normoglycaemia. After adjustment for age, sex, ethnic group, deprivation 
quintile, BMI categories, cardiovascular disease, heart failure, atrial fibrillation, hypertension 
and NSAID, incidence of CKD was attenuated but still showed a significant association. The 
incidence was reduced to approximately 3 times higher [IRR 2.6, 95% CI, 2.0 to 3.4, p<0.001] in 
IGR than the normoglycaemia cohort. The unadjusted and adjusted incidence rates of CKD in 
patients with IGR compared to those with normoglycaemia are given in Table 11. The full model 


































Table 11: Incidence of CKD in IGR compared to normoglycaemia 
 Exposed Unexposed 95% CI P-Value 
CKD 182 126   
Total population at  risk 10,561 29,531   
Person-years of follow-up 24364.5 67351.1   
Unadjusted IRR* 4.0 (3.2, 5.1) <0.001 
Adjusted IRR** 2.6 (2.0, 3.4) <0.001 
* Matched on age, sex and practice 
**Adjusted for age, sex, ethnicity, level of deprivation, BMI category, cardiovascular disease, heart failure, atrial fibrillation,     
hypertension and NSAID.  
 
6.5 Incidence rate of CKD (stages 1 – 2 /3 – 5 ) in persons aged 18 to 40 years with IGR  
The study population included in this analysis consists of 10,561 individuals aged 18 to 40 years 
with IGR and without CKD at baseline for the period of (January 2000 to February 2015). The 
unadjusted incidence of CKD stage (3 – 5) per 100,000 person-years (pyr) of follow-up in 
persons with IGR was approximately 4 times higher (IR 106.4 [95% CI, 71.9 to 157.5]) than the 
incidence of CKD stage (1 – 2) (IR 27.9 [95% CI, 23.9 to 32.7]). The unadjusted incidence rates 
of CKD (1 – 2) and CKD (3 – 5) in the IGR cohort are given in Table 12. The number of 
outcomes for each CKD category (1 – 2 and 3 – 5) in the IGR cohort is provided in Table 12a.  
Table 12: Incidence of CKD stages (1 – 2/3 – 5) in the IGR cohort 
 Exposed 95% CI 
CKD 182  
Total population at risk 10,561  
Person-years of follow-up 24364.5  
Unadjusted IR per 100,000 pyr   
CKD stage (1 – 2) 27.9 (23.9, 32.7) 
CKD stage (3 – 5) 106.4 (71.9, 157.5) 
Abbreviations: CKD, chronic kidney disease; CI, confidence interval; PYR, person-years 
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Table 12a: Number of outcomes for each CKD category (1 – 2/3 – 5) in the IGR cohort 
CKD category 1-2 3-5 Total 
CKD outcome recorded 157 25 182 
Abbreviation: CKD, chronic kidney disease 
 
6.6 Characteristics of matched cohort study population 
The study population consists of 10,561 patients with impaired glucose regulation (IGR) cases 
and 29,531 controls matched on age, gender, IGR case index date and practice (without 
glycaemic abnormality). The median age at index date was 35 years [interquartile range (IQR) 
31-38 years] in both cases and controls. Fifty three percent of the cases and 53.5% of the 
controls were female. The median follow-up period for cases and controls was approximately 2 
years [IQR: 0.81-3.16] and [IQR: 0.79-3.14] respectively. Patients who progressed to diabetes 
during follow-up were censored. There were statistically significant differences in the proportion 
of cases and controls who were South Asians (14.0% cases, 6.4% controls; White 34.5% cases 
and 38.3% controls). Information on ethnicity was missing for 4,817 (45.6%) in cases and 
14,886 (50.5%) in control. Cases and controls were more likely to be living in areas of greater 
deprivation, 2,232 (21.1%) and 5,020 (17.0%) of cases and controls living in quintile 5 
respectively. Cases and controls (22.9% and 23.8%) respectively, were more likely to have body 
mass index (BMI) of (25 to 29.9 kg/m2) and less likely to be unknown, cases (9.5%) and controls 
(21.2%). A total of 190 (1.8%) of cardiovascular disease (CVD) were identified in cases and 274 
(0.9%) in controls at index date.  
Similarly, heart failure (HF) and atrial fibrillation (AF) were identified in 29 cases (0.3%), 21 
control (0.07%) and 17 cases (0.16%) and 21 controls (0.07%) at index date respectively. More 
than 10% (1,112) of cases were diagnosed with hypertension at index date with only 548 (1.9%) 
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in controls. Almost twice as many cases 200 (1.9%) were prescribed a non-steroidal anti-
inflammatory drug (NSAID) at baseline with 120 (0.4%) in controls. During follow-up 1262 
(11.9%) cases developed T2DM, only 124 (0.4%) were identified in controls. During follow-up, 
182 (1.7%) cases of CKD were observed in patients with IGR compared to 126 (0.4%) in the 
control group, patients who progressed to diabetes and subsequently developed CKD were 
censored. 429 (4.1%) of the 10,561 patients with IGR who progressed to diabetes during follow-
up developed CKD. The vast majority of cases (81%) and controls (80%) were identified from 
practices across England followed by Wales, 9.2% and 9.3% of cases and controls respectively. 
Descriptive characteristics of the study population are summarised in Table 13. 
6.6.1 Number of CKD cases recorded via Read code and laboratory data  
 
Table 13a provides information about the number of CKD cases first recoded via Read code and 
first recorded via laboratory data in the IGR cohort. Patients were either identified by a Read 
code diagnosis or laboratory measurements indicating CKD. These two measures were also used 
to categorise CKD type. Laboratory measurements indicating CKD followed the definitions of 
CKD shown in Table 1. However, due to data limitations, it is not clear whether the laboratory 
measurements refer to ACR, GFR, or a combination of these. Data were assigned and 
categorised as CKD type (1 – 2 or 3 – 5) by Dr Ronan Ryan following data extraction.  
Table 13a: Cases of CKD first recorded by Read code and first recorded by laboratory data in the IGR 
cohort 
CKD results Read code Laboratory data Total 
CKD cases recorded 26 156 182 





6.6.2 Number of IGR cases recorded via Read code and laboratory measurements 
Table 13b provides information about the number of cases of IGR recorded via Read code and 
laboratory measurements derived from fasting blood glucose, glycosylated haemoglobin and oral 
glucose tolerance test. 
Table 13b: Cases of IGR recorded by Readcode and laboratory measurements 
IGR case definition Readcode FBG HbA1c OGTT Total 
IGR cases recorded  2,245 3,483 4,778 55 10,561 
Abbreviations: IGR, impaired glucose tolerance; FBG, fasting blood glucose; HbA1c; glycosylated haemoglobin; OGTT; oral 
glucose tolerance test 
 
6.6.3 Number of IGR cases recorded via laboratory measurements by calendar year  
Table 13c provides information about the number of cases of IGR recorded via laboratory 
measurements by calendar year for the study period January 2000 to December 2014.  
Table 13c: Cases of IGR recorded via laboratory tests by calendar year (January 2000 to December 2014) 
















Abbreviation: IGR, impaired glucose regulation 
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Table 13: Characteristics of the matched cohort (IGR compared to normoglycaemia) † 
Abbreviations: CVD, cardiovascular disease; HF, heart failure; AF, atrial fibrillation; NSAIDS, non-steroidal anti-inflammatory 
drugs BMI, body mass index; IQR, interquartile range. Values are numbers (percentages) unless otherwise specified. P-values 








Age, median [IQR] 35 [31,38] 35 [31,38] 0.015†† 
Female, No. (%) 5,659 (53.6) 15,795 (53.5) 0.863† 
Years of follow-up, median [IQR] 1.68 [0.81, 
3.16] 
1.67 [0.79, 3.14] 0.684††† 
Ethnicity, No. (%) 
White 3,644 (34.5) 11,305 (38.3) <0.001† 
Black 392 (3.7) 784 (2.7)  
Asian 1,483 (14.0) 1,902 (6.4)  
Chinese 32 (0.3) 102 (0.4)  
Mixed 63 (0.6) 219 (0.7)  
Others 130 (1.2) 333 (1.1)  
Unknown 4,817 (45.6) 14,886 (50.5)  
Deprivation quintile, No. (%) 
(least deprived) 1 1,509 (14.3) 5,229 (17.7) <0.001† 
2 1,575 (14.9) 4,985 (16.9)  
3 2,177 (20.6) 6,149 (20.8)  
4 2,463 (23.3) 6,319 (21.4)  
(most deprived) 5 2,232 (21.1) 5,020 (17.0)  
Unknown 605 (5.7) 1,829 (6.2)  
CVD at index date, No. (%) 190 (1.8) 274 (0.9) <0.001† 
HF at index date, No. (%) 29 (0.30) 21 (0.07) <0.001† 
AF at index date, No. (%) 17 (0.16) 21 (0.07) 0.010† 
Hypertension at index date, No. (%) 1,112 (10.5) 548 (1.9) <0.001† 
Prescription of NSAID, No. (%) 200 (1.9) 120 (0.4) <0.001† 
BMI (kg/m2), No. (%) 
<20 332 (3.1) 2,191 (7.4) <0.001†† 
20-24.9 1,542 (14.6) 9,452 (32.0)  
25-29.9 2,420 (22.9) 7,028 (23.8)  
30-34.9 2,104 (19.9) 2,868 (9.7)  
35-39.9 1,585 (15.0) 1,071 (3.6)  
≥40 1,575 (15.0) 644 (2.2)  
Unknown 1,003 (9.5) 6,277 (21.2)  
BMI (kg/m2), median [IQR] 31 [26, 37.1] 24.9 [22.1, 28.7] <0.001†† 
T2DM during follow-up, No. (%) 1,262 (11.9) 124 (0.4) <0.001† 
CKD during follow-up, No. (%) 182 (1.7) 126 (0.4) <0.001† 
Country, No. (%)      
England 8,516 (80.6) 23,661 (80.0) 0.688† 
Northern Ireland 270 (2.6) 791 (2.7)  
Scotland 804 (7.6) 2,321 (7.9)  
Wales 971 (9.2) 2,758 (9.3)  
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CHAPTER SEVEN: RESULTS 
PREDICTORS OF CKD IN IGR 
7.1 Introduction 
This section describes the future CKD risk in patients following a diagnosis of IGR. The first 
part of the analysis examines the effect of the individual prognostic factors on the risk of CKD in 
a set of univariate analyses. Non-linear association between the continuous variables (age and 
BMI) and CKD were checked by fitting fractional polynomials (204). Survival probability 
(remaining free of CKD) was estimated and described using Kaplan-Meier survival estimates. A 
global test of the proportional hazards assumption (required for the Cox multivariable model) 
was undertaken for all covariates of interest, and additional log-log plots were used to check this 
assumption for specific covariates and to assess how best to enter BMI in the final model. A 
multivariable Cox regression was used to estimate the risk of CKD following a diagnosis of 
impaired glucose regulation (IGR). The goodness of fit of the final model was estimated by 
using the R-squared (R2) statistic for time-to-event models developed by Royston and Sauerbrei 
(205).  
7.2 Predictors of CKD in IGR - Study cohort characteristics 
The study population included in this analysis consists of 10,561 patients with IGR and without 
CKD at baseline, followed-up for a maximum of 15 years. The median age of patients with CKD 
following a diagnosis of IGR was 36 years [interquartile range (IQR): 32 – 38 years] with 52.8% 
being female. The median follow-up was 1.0 year [IQR: 0.2, 2.7]. Follow-up for CKD patients 
was shorter because they were censored on the date patients developed CKD. Of the 10,561 
patients with IGR, 182 (1.7%) developed CKD. During follow-up 41 (22.5%) patients with IGR 
who developed CKD progressed to type 2 diabetes (T2DM) (and were censored at this point). 
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The majority of patients with CKD following a diagnosis IGR were White (40.7%) followed by 
South Asian (15.4%). Information on ethnicity was missing for 39% of the IGR cohort who 
developed CKD. Missing data on ethnicity was categorised and a separate ‘Unknown’ category 
created. The most common body mass index (BMI) groups were 25 – 29.9 kgm2 (26.4%) and 30 
– 34.9 kg/m2 (26.4%) and 3.9% of the IGR cohort who developed CKD had missing BMI data. 
Baseline characteristics of the IGR cohort split by those who did and did not have CKD are 




Table 14: Demographic and clinical characteristics of the IGR cohort split by those who did and did not have CKD 
 CKD No CKD 
IGR (N=10,561) 
Age, median [IQR] 36 (32,38) 35 (31, 38) 
Female, No. (%) 96 (52.8) 5,563 (53.6) 
Years of follow-up, median [IQR] 1.0 (0.2, 2.7) 1.7 (0.8, 3.2) 
Ethnicity, No. (%)     
White 74 (40.7) 3,570 (34.4) 
Black 7 (3.9) 385 (3.7) 
South Asian 28 (15.4) 1,455 (14.0) 
Chinese 1 (0.6) 31 (0.3) 
Mixed 1 (0.6) 62 (0.6) 
Others 0 (0.0) 130 (1.3) 
Unknown 71 (39.0) 4,746 (45.7) 
Deprivation quintile, No. (%)     
(least deprived) 1 26 (14.3) 1,483 (14.3) 
2 26 (14.3) 1,549 (14.3) 
3 40 (22.0) 2,137 (20.6) 
4 39 (21.4) 2,424 (23.4) 
(most deprived) 5 38 (20.9) 2,194 (21.1) 
Unknown 13 (7.1) 562 (5.7) 
CVD at index date, No. (%) 3 (1.7) 187 (1.8) 
HF at index date, No. (%) 0 (0.0) 29 (0.3) 
AF at index date, No. (%) 1 (0.6) 16 (0.2) 
Hypertension at index date, No. (%) 46 (27.3) 1,066 (10.3) 
Prescription of NSAID, No. (%) 38 (20.9) 2,435 (23.5) 
BMI (kg/m2), No. (%)     
<20 1 (0.6) 331 (3.2) 
20-24.9 21 (11.5) 1,521 (14.7) 
25-29.9 48 (26.4) 2,272 (22.9) 
30-34.9 48 (26.4) 2,056 (19.8) 
35-39.9 27 (14.8) 1,558 (15.0) 
≥40 30 (16.5) 1,545 (14.9) 
Unknown 7 (3.9) 996 (9.6) 
BMI (kg/m2), median [IQR] 32 (26.7, 38.2) 31 (26, 37.1) 
T2DM during follow-up, No. (%) 41 (22.5) 1,221 (11.8) 
Country, No. (%)     
England 167 (91.8) 8,349 (80.4) 
Northern Ireland 0 (0.0) 270 (2.6) 
Scotland 6 (3.3) 778 (7.7) 
Wales 9 (5.0) 962 (9.3) 
Abbreviations: CVD, cardiovascular disease; HF, heart failure; AF, atrial fibrillation; NSAIDS, non-steroidal anti-inflammatory drugs; BMI, body mass index; IQR, 
interquartile range. Count of T2DM and CKD outcomes were for a maximum of 15 years following IGR diagnosis.  
 
 
7.3 Risk of CKD in patients with IGR for risk factors of interest (univariate analysis) 
The results of the univariate analyses are shown in Table 15. There was an increased risk of 
CKD with each additional year of age at IGR diagnosis (HR, 1.08; 95% CI, 1.04 to 1.12, 
p=<0.001). By comparison with the White ethnic group, patients with missing ethnicity were the 
only group showing a statistically significant difference in risk of CKD (HR, 0.68; 95% CI, 0.49 
87 
 
to 0.94, p=0.020). When compared with the most frequent BMI group (25 – 29.9), the only 
group to a statistically significant change in risk were patients with a BMI<20 (HR, 0.13; 95% 
CI, 0.02 to 0.97, p=0.046) and those with missing BMI (HR, 0.32; 95% CI, 0.14 to 0.71, 
p=0.005). Of the comorbidities only hypertension showed a statistically significant association 
(HR, 3.25; 95% CI, 2.32 to 4.54, p=<0.001). There was no statistically significant association 
between risk of CKD and gender, deprivation quintile, any known ethnic group, atrial fibrillation 
(AF), cardiovascular disease (CVD), heart failure (HF) or prescription of a non-steroidal anti-
inflammatory drug (NSAID).  
A pragmatic decision was made to combine groups with smaller numbers of IGR cases/outcomes 
for the final model to ensure that reliable estimates of risk would be obtained. Body mass index 
of <20 and 20 - 24.9 were combined to create a single category of <25 because of the relatively 
small numbers of cases in patients with BMI <20. The ethnic groups Chinese and Other were 




Table 15: Risk of CKD in IGR – Univariate analysis 









Age (per 1 year) 10,561 182 1.08 (1.04, 1.12) <0.001 
Gender Male (Reference) 4,902 86 1.00  
 Female 5,659 96 0.94 (0.70, 1.26) 0.692 
BMI (kgs/m2) <20 332 1 0.13 (0.02, 0.97) 0.046 
 20-24.9 1,542 21 0.67 (0.40, 1.12) 0.123 
 25-29.9 (Reference) 2,420 48 1.00  
 30-34.9 2,104 48 1.17 (0.79, 1.75) 0.433 
 35-39.9 1,585 27 0.86 (0.54, 1.38) 0.533 
 ≥40 1,575 30 0.96 (0.61, 1.52) 0.872 
 Missing 1,003 7 0.32 (0.14, 0.71) 0.005 
Townsend Quintile 1 (Reference) (least 
deprived) 
1,509 26 1.00  
 2 1,575 26 0.99 (0.58, 1.71) 0.973 
 3 2,177 40 1.10 (0.67, 1.80) 0.713 
 4 2,463 39 0.98 (0.60, 1.61) 0.936 
 5 (most deprived) 2,232 38 1.06 (0.64, 1.74) 0.829 
 Missing 605 13 1.36 (0.70, 2.64) 0.367 
Ethnicity White (Reference) 3,644 74 1.00  
 South Asian 1,483 28 1.06 (0.69, 1.64) 0.781 
 Black 392 7 1.01 (0.46, 2.19) 0.983 
 Chinese 32 1 1.98 (0.28, 14.25) 0.498 
 Mixed 63 1 0.90 (0.13, 6.47) 0.916 
 Other 130 0 N/A  
 Missing 4,817 71 0.68 (0.49, 0.94) 0.02 
CVD CVD 190 3 0.96 (0.31, 3.00) 0.942 
Heart Failure HF 29 0 N/A  
Atrial Fibrillation AF 17 1 3.55 (0.50, 25.31) 0.207 
Hypertension Hypertension 1,122 46 3.25 (2.32, 4.54) <0.001 
NSAID NSAID 2,473 38 0.94 (0.66, 1.34) 0.736 
Abbreviations: CKD, chronic kidney disease; IGR, impaired glucose regulation; HF, heart failure; CI, confidence interval 
 
7.4 Checking for non-linear relationships between the continuous variables and the 
outcome 
A non-linear association between the two continuous covariates (age and BMI) and risk of CKD 
was checked for using an automated method (mfp in STATA) (197) for fitting fractional 
polynomials developed by Royston and colleagues (194). A linear association was found to be 
the best fit for BMI and age. 
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7.5 CKD-free survival following a diagnosis of IGR 
 Table 16, describes the probability of remaining free of CKD up to 15 years following IGR 
diagnosis. A decision was made to present the 5 year survival probability (Table 17) of CKD 
following IGR diagnosis as fewer than 10% of the original cohort was still under observation 
after the fifth year. Rich and colleagues (198) point out that Kaplan-Meier (K-M) estimates are 
most accurate when most patients are still present in the study. Furthermore, K-M estimates can 
be misleading and should be interpreted with caution if only a subset of the population is 
included. During the first year, 7269 (69%) patients were still being followed-up, in the 
following year this was reduced to 4487 (43%), at five years 1098 (10%) patients remained and 
1 (0.009%) at 15 years. The risk of CKD by 2 years following IGR was 2% (0.98; 95% CI, 0.98 
to 0.99). At 5 years follow-up the risk of CKD was approximately 4% (0.96; 95% CI, 0.96 to 





Table 16: Fifteen years CKD risk estimates in patients with IGR – survival probability 
Following diagnosis 
of IGR (Year) 
Population at risk CKD events Survival probability 95% (CI) 
Total 10561     
1 7269 95 0.99 0.99 0.99 
2 4487 33 0.98 0.98 0.99 
3 2834 12 0.98 0.98 0.98 
4 1760 23 0.97 0.97 0.98 
5 1098 9 0.96 0.96 0.97 
6 664 7 0.96 0.95 0.96 
7 438 3 0.95 0.94 0.96 
8 270 0    
9 156 0    
10 77 0    
11 45 0    
12 20 0    
13 7 0    
14 2 0    
15 1 0    
Abbreviations: IGR, impaired glucose regulation; CKD, chronic kidney disease; CI, confidence interval 
 
Table 17: Five years CKD risk estimates in patients with IGR – survival probability 
Following diagnosis 
of IGR (Year) 
Population at risk CKD events Survival probability 95% (CI) 
Total 10561     
1 7269 95 0.99 0.99 0.99 
2 4487 33 0.98 0.98 0.99 
3 2834 12 0.98 0.98 0.98 
4 1760 23 0.97 0.97 0.98 
5 1098 9 0.96 0.96 0.97 
Abbreviations: IGR, impaired glucose regulation; CKD, chronic kidney disease; CI, confidence interval 
 
7.6 Testing proportional hazards assumptions – Five-year follow-up 
The proportional hazards assumption for each predictor along with the overall test for the risk of 
CKD (Table 18) was checked using the Schoenfeld residuals (estat phtest in STATA) (200). 
Proportionality was also checked by plotting the log-log survival curves for selected covariates ( 
 14 - 16). The overall test result indicates that the hazard proportional assumption was met (Chi-
square [ ] = 17.04, p= 0.650). However, the log-log plot for BMI did not show a consistent 
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relationship between increasing BMI and CKD risk, so BMI was entered into the analysis as a 
set of distinct BMI groups.  
Table 18: Proportional hazard assumption test for each predictor for the risk of CKD in IGR – Five year follow-up 
Predictors  Chi2 P-Value 
Age  0.00 0.995 
Gender    
Male  Reference   
Female  1.66 0.198 
BMI (kgs/m2)    
<25   0.47 0.494 
25-29.9 Reference   
30-34.9  0.82 0.365 
35-39.9  0.34 0.557 
≥40  0.95 0.330 
Missing  0.19 0.665 
Deprivation quintile    
Least deprived  Reference   
2  0.02 0.884 
3  0.24 0.621 
4  0.52 0.469 
Most deprived  4.00 0.046 
Missing  0.13 0.723 
Ethnicity    
White  Reference   
South Asian  0.54 0.463 
Black  4.71 0.030 
Chinese/Other  0.16 0.687 
Mixed  4.26 0.039 
Missing  1.21 0.272 
CVD  0.05 0.819 
HF  N/A  
AF  N/A  
Hypertension  0.68 0.408 
NSAID  0.02 0.901 
Overall test   17.04 0.650 
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HF, heart failure; AF, atrial fibrillation; Chi2, Chi-Square test 
Note: The covariates HF and AF do not have  and p-values reported because no failures were observed in the first 5 years.  
 
7.7 Risk of CKD in patients with IGR for risk factors of interest (multivariate analysis) 
The results of the Cox model are presented in Table 19. Heart failure and atrial fibrillation were 
removed from the analysis because no CKD outcomes were observed in the first 5 years. If they 




There was a 7% increased risk of CKD for each additional year of age at IGR diagnosis (HR, 
1.07; 95% CI, 1.03 to 1.11). Hypertension remained predictive of CKD in IGR (HR, 2.84; 95% 
CI, 1.99 to 4.05). There was no statistically significant association with BMI categories, 
ethnicity or gender. There was no statistically significant association between increasing 
deprivation or the two remaining predictors (CVD and NSAID) and CKD risk.  
Table 19: Cox proportional CKD risk estimates in IGR patients - Multivariate analysis (five-year follow-up) 









Age (per 1 year) 10,561 172 1.07 (1.03, 1.11) 0.001 
Gender Male (Reference) 4,902 80 1.00  
 Female 5,659 92 1.10 (0.80, 1.50) 0.551 
BMI (kg/m2) <25 1,874 21 0.67 (0.40, 1.13) 0.138 
 25-29.9 (Reference) 2,420 45 1.00  
 30-34.9 2,104 46 1.12 (0.74, 1.70) 0.590 
 35-39.9 1,585 25 0.81 (0.49, 1.33) 0.397 
 ≥40 1,575 28 0.91 (0.56, 1.49) 0.705 
 Missing 1,003 7 0.45 (0.20, 1.01) 0.054 
Townsend 
Quintile 
1 (Reference) 1,509 25 1.00  
 2 1,575 25 0.98 (0.56, 1.71) 0.951 
 3 2,177 36 1.04 (0.62, 1.73) 0.895 
 4 2,463 39 1.01 (0.61, 1.68) 0.973 
 5 2,232 35 1.03 (0.61, 1.73) 0.913 
 Missing 605 12 1.33 (0.66, 2.69) 0.423 
Ethnicity White (Reference) 3,644 70 1.00  
 South Asian 1,483 26 1.08 (0.68, 1.72) 0.748 
 Black 392 7 0.96 (0.43, 2.11) 0.910 
 Chinese/Other 162 1 0.35 (0.05, 2.52) 0.296 
 Mixed 63 1 0.92 (0.13, 6.61) 0.931 
 Missing 4,817 67 0.72 (0.51, 1.00) 0.052 
CVD CVD 190 3 0.80 (0.25, 2.52) 0.703 
Hypertension Hypertension 1,122 45 2.80 (1.96, 4.00) <0.001 
NSAID NSAID 2,473 35 0.81 (0.55, 1.18) 0.266 
 
7.8 Model checking: goodness of fit 
The proportion of variation explained by the model (R2) statistic was 0.24. This indicates that the 
final model accounted for 24% of the variation in the outcomes observed. 




Patients with hypertension were approximately 3 times more at risk of CKD and for each 
additional year of age at IGR diagnosis, CKD risk increased by 7%. The overall proportion of 
variation explained by the model was 24% (R2 0.24). The Kaplan-Meier (K-M) estimates 
suggest that 2% of IGR patients were diagnosed with CKD by 2 years increasing to 4% after 5 





CHAPTER EIGHT: DISCUSSION 
 
8.1 Introduction 
The primary focus of this thesis was to provide a robust estimate of the incidence of CKD stage 
1-5 in young adults aged 18 to 40 years with IGR compared to those with normoglycaemia, and 
to estimate the risk of CKD 1 – 2 and 3 – 5 separately in the IGR cohort. Additionally, a model 
presenting risk factors associated with future CKD outcome was devised to understand the 
course and factors associated with future CKD development in young adults with diagnosed 
IGR. A systematic review was conducted to distil available evidence exploring the incidence of 
CKD in young adults with IGR compared to those with normoglycaemia, and investigate 
whether any increased risk occurs only after they develop T2DM. An analysis of routinely 
recorded clinical data derived from a large UK primary care database investigated the incidence 
of CKD in young adults with IGR. This chapter summarises the key findings of these analyses 
and discusses their implications.  
8.2 Summary of key findings 
The first objective of this thesis was to systematically identify and summarise the best available 
evidence showing whether the risk of CKD is elevated in young adults with IGT/IFG compared 
to normoglycaemia or T2DM. The systematic review shows a paucity of studies exploring the 
incidence of CKD in young adults with IGT/IFG. The review showed that existing evidence does 
not allow quantification of CKD risk in young adults aged 18 to 40 years with IGT/IFG 
compared to normoglycaemia or T2DM. Pooled estimates of CKD risk and a meta-analysis were 
not possible because most studies did not report separate results in this age group (Chapter 3).  
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The second objective investigated the incidence of CKD in a retrospective matched cohort 
analysis using the THIN database and found that young adults with IGR were four times more at 
risk of developing CKD than individuals with normoglycaemia. After adjusting for confounders, 
the effect of CKD risk was attenuated but was still 2.6 times higher in individuals with IGR than 
those with normoglycaemia (Chapter 6). Additionally, the incidence of CKD stage (3 – 5) was 
approximately 4 times higher than the incidence of CKD stage (1 – 2) following a diagnosis of 
IGR (Chapter 6).    
The third research theme examined the incidence and prevalence of recorded IGR in young 
adults in the THIN database. The overall incidence of IGR found in this study was 72.2 cases per 
100,000 person-years of follow-up. Incidence was higher in the age group 26 to 40 years than 
those aged 18 to 25 years and was higher in females than males. Incidence was higher in patients 
living in the most deprived areas than those in the least deprived areas and higher in Black and 
South Asian than White ethnic groups. Incidence increased annually and was approximately nine 
times higher in 2014 than 2000 (Chapter 6). Additionally, the prevalence of diagnosed IGR 
increased consistently from 2000 to 2014. Prevalence was consistently higher in females than 
males and was higher in the age group 26 to 40 years than those aged 18 to 25 years and 
increased consistently in both age groups and both genders over the same period (Chapter 6).  
In the fourth and final research theme, future risk of CKD in patients with IGR was derived in a 
risk model. The aim of this model was to identify likely risk factors and determine their values in 
predicting incident CKD in young adults with IGR. Of all the modifiable risk factors included in 
the model only hypertension was significant. Patients with hypertension were approximately 
three times more at risk of CKD. Similarly, the effect of age was significant, there was a 7% 
increased risk of CKD for each additional year of age at IGR diagnosis. The Kaplan-Meier (K-
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M) estimates show a 2% increased risk of CKD by 2 years following IGR, which increased to 
4% after 5 years follow-up. The proportion of all the variation explained by the model was 24% 
(R2 0.24). Although the amount of variation in the outcome observed is moderate, the model 
found that age and hypertension were significant risk factors in predicting incident CKD 
(Chapter 7).  
8.3 Strengths and limitations 
The present study contributes novel findings by providing reliable estimates of the incidence of 
CKD in young adults with IGR compared to those with normoglycaemia by systematically 
reviewing available literature and by analysing data from large generalisable cohort of primary 
care patients.  
8.3.1 Systematic review 
Systematic reviews are increasingly recognised as the most robust and reproducible approach 
utilised to identify, critically appraise and synthesise all available evidences in order to provide 
an empirically reliable answer to a defined research question (206). However, systematic 
reviews are laborious and time consuming which relies on the identification of all the relevant 
articles. Although the search method was rigorous and systematic, retrieval of all the relevant 
articles could not be assured. This review was conducted according to the PRISMA (207) and 
MOOSE (151) guidelines. Furthermore, this review followed a pre-defined peer-reviewed 
protocol published in an Open Access scientific journal (152). From a review perspective, the 
strengths were that a comprehensive search strategy which was not restricted to the English 
language, geographical area or length of follow-up and a broad range of markers were used to 
identify patients with CKD. Additionally, two reviewers independently screened titles and 
abstracts, identified eligible studies and assessed quality of the included studies. Furthermore, 
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only observational studies with incident CKD were included, because of their large sample size, 
high rate of follow-up and frequency of CKD, which are more likely to be representative of the 
population at risk. The main limitations were because of the restrictive age range, quantification 
of CKD risk was not possible because only one study was found providing CKD risk estimates 
in persons aged 18 to 40 years with IGR. Furthermore, it was not possible to conduct a meta-
analysis because sufficient studies were not available, therefore a generalisable and precise 
estimates of CKD could not be presented. Additionally, results of this one study cannot be 
generalised because of the characteristics of the study population (Pima Indians).  
8.3.2 Analysis of the THIN data 
The strengths and weaknesses of utilising routinely collected electronic primary care data are 
discussed in (Chapter 2). In summary, the strengths include the large sample size of the database 
(THIN contains medical records of over 12 million patients) which is approximately 6% of the 
UK population (185). Generalisability was ensured by the fact that the dataset includes similar 
patients to those seen in primary care across the UK. This reflects the fact that data are collected 
in a non-interventional fashion during routine clinical practice. Internal validity (reducing the 
effect of confounders) was ensured by matching patient’s age, sex and general practice. 
Although the study was retrospective, data were collected prospectively, hence eliminating recall 
bias. Ascertainment of exposure and outcome of interest was carried out by both Read coded 
diagnosis and clinical measurements (e.g. HbA1c, ACR lab results). Furthermore, a single eGFR 
was used to identify patients with CKD in addition to patients with diagnosed CKD with a repeat 
serum creatinine as defined by NICE guidelines (9). This was undertaken because it is likely that 
patients suspected of being at high risk of CKD (e.g., hypertension, raised BMI) would have 
their serum creatinine recorded and eGFR calculated on one occasion and not necessarily have a 
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repeat serum creatinine test. Additionally, the completeness of lab results has significantly 
improved since it is now directly fed into GP databases through Path Link populating patient 
records. Therefore, improving ascertainment of IGR and CKD for this study and providing a 
reliable estimate of incident CKD in young adults with IGR. The main limitations relate to the 
identification of IGR, which depends on GPs doing blood tests. Therefore, the incidence and 
prevalence of IGR is an underestimate of the true incidence and prevalence and it is also biased 
as GPs are more likely to do blood tests for glucose in patients in whom they suspect diabetes, 
(e.g. high BMI, older age, some ethnic groups). This will exaggerate the association between 
IGR and these risk factors. Similarly, incidence and prevalence of recorded CKD also depends 
on GPs doing blood tests. This may also underestimate the frequency of CKD and may also be 
biased because GPs are more likely to do blood tests for CKD in patients in whom they suspect 
CKD. This includes those with diabetes, hypertension, certain ethnic groups and those with IGR. 
This may also increase the relationship between IGR and CKD. For this study both laboratory 
evidence of reduced eGFR and Read code were used to identify incident CKD patients with only 
Read coded CKD or only laboratory evidence of CKD would not be misclassified.  
There is a lack of data on some important confounding variables (e.g., ethnicity, BMI) pre 
Quality and Outcomes Framework (QOF) [prior to 2004]. Additionally, before lab-linkage 
practices lab results were entered manually and in some cases only abnormal results may have 
been entered into the GP system, this could underestimate the incidence of CKD. Furthermore, 
since 2006, general practitioners (GPs) in England have been incentivised to keep a register of 
patients with CKD stage 3-5 through QOF. This may have increased diagnosis entered in THIN 
in the later years (post 2006).  
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There is also potential for ascertainment bias which may arise when patients who have frequent 
laboratory tests may be more likely to have IGR diagnosed and also may be more likely to have 
CKD diagnosed. It can be seen that the prevalence of diagnosed IGR increased 7 fold, from 2000 
to 2014 (Table 8). If more laboratory tests were being undertaken we would expect that the 
number of patients diagnosed with IGR would also increase. This seems to have happened, with 
a 15 fold increase in diagnosed IGR from 2000 to 2014 (Table 8).  Additionally, the number of 
IGR cases detected from laboratory tests increases 20 fold over the study period (Table 13c). 
This is likely to be due to increased laboratory testing and increased recording of laboratory tests 
in electronic patient records. Increased laboratory testing and increased recording of laboratory 
tests could also lead to an increase in diagnosis of CKD. Moreover, before when GP was 
receiving lab results abnormal tests such as glucose on a pre-diabetic range may have been 
overlooked and not entered onto the database. Additionally, the median follow-up of this study 
was approximately two years. This may have been insufficient to allow for the development of 
CKD among those with IGR. Furthermore, the declining number of CKD diagnoses observed in 
the later years of the study may be attributed largely to IGR patients being censored (de-
registration, death and patients progressing to diabetes). Therefore, incidence of CKD cannot be 
reliably estimated in the later years of this study. Lastly, application of the predictors of CKD in 
IGR model developed as part of this thesis may not be appropriate because the relationship 
between predictors and CKD may change from the years the data was derived to develop this 
model (January 2000 to February 2015). This may be caused by changes in the recording of IGR 
and CKD or by changes in diagnosis or treatment strategies for CKD or IGR. Changes in the 




8.4 Demographic and clinical characteristics of the IGR cohort 
The characteristics of the study cohort and their clinical estimates at the point of IGR diagnosis 
are presented in Table 13 (Chapter 6). The median age of the study cohort was 35 years and 53% 
were female. Patients with IGR were more likely to be of White ethnicity followed by South 
Asians. Additionally, patients with IGR were more likely to be from areas of greater deprivation 
and were more likely to have a BMI of 25 to 29 kg/m2. Atrial fibrillation, heart failure and 
cardiovascular disease were found in 0.16%, 0.3% and 1.8% of the IGR population respectively. 
Furthermore, hypertension was found in more than 10% of the IGR cohort and 1.9% were on 
non-steroid anti-inflammatory drugs.   
8.5 Clinical significance of the findings presented in this thesis 
Diabetes is related to a wide range of macrovascular (coronary artery disease, peripheral 
vascular disease and stroke) and microvascular (retinopathy, neuropathy and nephropathy) 
complications (208). Kidney disease is frequently diagnosed during routine consultation and 
generally occurs in people with diabetes. The United Kingdom Prospective Diabetes Study 
(UKPDS trial) demonstrated a high incidence (29%) of renal impairment (eGFR<60 ml/min per 
1.73 m2 or a doubling of serum creatinine) after patients developed T2DM (209). Patients 
identified with IGR are also at increased risk of progressing to overt diabetes (210). Results of 
this study indicate that the trend in the prevalence and incidence of IGR is set to continue to 
increase. The trend shows a consistent increase in prevalence and incidence throughout the 
calendar period (2000-2014) in both males and females which are particularly alarming because 




Furthermore, there is also evidence suggesting that elevated blood glucose associated with IGR 
significantly increases the risk of kidney abnormalities resulting in CKD (5). The current study 
appears to confirm that elevated blood glucose associated with IGR increases the risk of CKD 
stage (3 – 5) by approximately 4 times than the risk of CKD stage (1 – 2). Furthermore, the 
current study also confirms result of the Framingham study. The unadjusted incidence of CKD in 
patients with IGR was approximately four times higher than patients with normoglycaemia. 
After adjustment for potential confounders, risks was slightly attenuated, the incidence was 
reduced to approximately three times higher. The annual incidence of CKD in patients with IGR 
may be low (e.g., 1 in 1000 person-years), if treatment was to halve the incidence from 1 to 0.5 
per 1000 person years it means that 2000 patients must be treated per year for one extra patient 
to benefit. This may not change the approach to care by healthcare professionals engaged in the 
management of these patients but should at least provide some perspective that raised blood 
glucose over a sustained period of time may cause microvascular complications and may warrant 
the need for patients with IGR to have their kidney function checked routinely.   
The results presented in Tables 15 and 19 of the CKD predictors in IGR model development 
(Chapter 7) shows that hypertension was the only comorbidity to show a statistically significant 
association in univariate analysis which remained predictive in multivariate analysis. Patients 
with hypertension at IGR diagnosis were approximately four times more at risk of CKD in the 
univariate analysis. Risk of CKD was slightly reduced to approximately three times in 
multivariate analysis. Hypertension has been shown to be a strong independent modifiable risk 
factor associated with an increased risk of kidney disease. This was demonstrated in a 
retrospective cohort study of 118,924 Taiwanese participants without diabetes and CKD at 
baseline. The study reported a 23% increased risk of CKD after adjustment in participants with 
102 
 
hypertension (6). Considering the results of the study and existing evidence, hypertension 
remains one of the most potent risk factor for CKD development but also easily treatable if 
adequately managed in high risk groups. Good control of hypertension remains one the most 
efficient way in managing CKD.  
8.6 Comparison with existing literature 
8.6.1 Systematic review 
To the best of our knowledge, no systematic review evaluated the risk of CKD in young adults 
aged 18 to 40 years with IGT/IFG compared to normoglycaemia or T2DM. According to a 
recently published systematic review, patients with prediabetes are at increased risk of 
developing CKD. Echouffo-Tcheugui and colleagues (184) examined nine cohort studies to 
estimate the incidence of CKD in adults aged (≥ 18 years old) with prediabetes, defined as 
(IGT/IFG). The pooled summary estimate in a random effect meta-analysis shows that the risk of 
CKD after adjustment for established CKD risk factors was 11% higher in individuals with 
prediabetes than those with normoglycaemia. Additionally, a systematic review examined the 
effect of metabolic syndrome and the risk of developing CKD, proteinuria or micro-albuminuria. 
This found that as an individual component of metabolic syndrome, the pooled summary 
estimate for impaired fasting glucose (IFG) shows a 16% increased risk of CKD (211). In 
contrast, several studies (166, 212) examined the effect of IGR and risk of CKD where IGR was 
included as a component of the metabolic syndrome. A prospective study conducted by Tozawa 
and colleagues (166) to examine the effect of metabolic syndrome on the incidence of CKD 
determined by (eGFR<60ml/min/1.73m2) in Japanese adults aged (≥19 years), found that 
individuals with IGR had a 22% increased risk of developing CKD after adjusting for age, sex, 
current cigarette smoking and alcohol drinking habits. Additionally, Kurella and colleagues 
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(212) reported an 11% increased risk of CKD in individuals with IFG. In contrast, Nelson and 
colleagues (167) in a population of 490 subjects (183 male, 307 female), reported a 
weak association between IGR and development of CKD (OR: 0.8, 95% CI; 0.4 to 1.5). 
Additionally, Nelson and colleagues (102) in a subsequent study followed 194 Pima 
Indians at intervals of 6 to 12 months for 4 years to analyse the changes in glomerular 
filtration rate that occur during progression of renal disease. Six groups were recruited 
with predefined characteristics: 31 had normal glucose tolerance; 29 with impaired 
glucose tolerance and 30 newly diagnosed diabetes. During the 4 year follow -up the 
glomerular filtration rate increased by 14% (p=0.008) in subjects with IGR. This was 
confirmed in another study; GFR was serially measured for 48 months in 26 Pima 
Indians with IGR and 27 with normal glucose tolerance. At baseline, the mean GFR was 
normal (<90ml/min/1.73m2). The baseline GFR increased by 20% in IGR compared to 
14% in NGT, showing an association with increased GFR and elevated glucose 
tolerance (163). These studies, however, did not report separate results in the age group 18 to 
40 years. 
8.6.2 Incidence of IGR in young adults 
Several studies have used large generalisable sample of UK general practices data. However, to 
the best of our knowledge, no previous study using the THIN database has explored the 
incidence of diagnosed IGR in young adults aged 18 to 40 years. A population based cohort 
study examining the incidence rate of diabetes and prediabetes in a South Asian cohort aged 
(≥20 years) from Chennai was carried out by Anjana and colleagues (213). The researchers used 
a sub-set of the Rural Epidemiology Study (CURES) cohort study. Prediabetes was defined as 
fasting plasma glucose of (5.6 to 6.9 mmol/L) or an oral glucose tolerance test of (7.8 to 11.0 
104 
 
mmol/L). After a median follow-up of 9.1 years, the incidence rate of prediabetes was 7.1 cases 
per 1000 person-years of follow-up. The incidence rate reported in this study is lower than those 
reported in the Biracial Cohort (POP-ABC) study, the incidence of prediabetes was 12.5 cases 
per 100 person-years of follow-up in adults aged (≥18 years) (214). Conversely, in a study using 
data from the General Practice Research Database (GPRD), the annual incidence rate of 
IGT/IFG, defined by a Read code suggesting IGT/IFG and reported measurements of blood and 
urine glucose, in adults aged (≥20 years) increased from 17 cases per 100,000 person-years in 
2000 to 31 per 100,000 person-years in 2004 (78). The incidence rate of IGR in 2004 presented 
in this study is higher (44.9 cases per 100,000 person-years) than the incidence rate reported by 
Gillett and colleagues in 2004 (31 cases per 100,000 person-years). The higher incidence rate 
observed in this study may be associated with a broader diagnostic criteria used to define IGR 
(Chapter 4 and Appendix 11). Incidence rates should be interpreted with caution because these 
studies were conducted in specific populations and separate results in the age group (18 to 40 
years) were not provided. Furthermore, incidence rates may be affected by population structure 
(e.g. population with a higher proportion of older people with IGR may have a higher incidence 
of CKD than a younger population with IGR).  
8.6.3 Prevalence of diagnosed IGR in young adults 
Prevalence estimates especially differ from other published work mainly because not all patients 
are tested for IGR. The prevalence in the present study is lower than the prevalence reported in a 
report published by the National Cardiovascular Intelligence Network (NCVIN) (77). The 
NCVIN analysis used a combined dataset (2003 to 2013) from the Health Survey for England 
(HSE) to determine the prevalence of non-diabetic hyperglycaemia also known as pre-diabetes 
or impaired glucose regulation in adults aged (≥16 years). Non-diabetic hyperglycaemia was 
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defined as an HbA1c value between 6.0 – 6.4% (42 – 47 mmol/mol) excluding those diagnosed 
with diabetes. The prevalence was 2.6% in the 16 to 39 years age group. In contrast, Mainous 
and colleagues (76) estimated prevalence of pre-diabetes in adults aged (≥16 years) using data 
from HSE for the years 2003, 2006, 2009 and 2011. Pre-diabetes was determined by the ADA 
(68) definition, a glycated haemoglobin (HbA1c) value of 5.7 – 6.4% (39 – 47 mmol/mol). They 
reported a pre-diabetes prevalence of 11.6% in 2003 rising to 35.3% in 2011. Prevalence of pre-
diabetes in the age group 16 to 30 years was 5% in 2011. Prevalence of pre-diabetes reported by 
Mainous and colleagues was higher than the prevalence reported in the present study. The 
difference in prevalence may be explained by the definitions used to determine IGR. Mainous 
and colleagues used a lower HbA1c 5.7 – 6.4% (39 – 47 mmol/mol) range, whereas this study 
used the NICE (65) recommended HbA1c cut-off value of 6.0 – 6.4% (42 – 47 mmol/mol). 
Additionally, data from Project STAND (Sedentary Time and Diabetes), a randomised 
controlled trial of obese young adults aged 18 to 40 years recruited within Leicestershire and 
South East Midlands, the prevalence of impaired glucose metabolism was 18.1% (75). In the 
Australian Diabetes, Obesity and lifestyle study (AusDiab), a cross-sectional survey across six 
states and the Northern Territory, the prevalence of IGR was 16.4% in adults aged (≥25 years) 
(215). Furthermore, the sole use of HbA1c as diagnostic criteria for IGR may mean that some 
patients with diabetes are included and therefore overestimate frequency of IGR. Incorrectly 
classifying patients with diabetes as IGR may increase the association with risk of CKD. 
However, incorrectly classifying those with normal glucose regulation as IGR may dilute the 
association between IGR and risk of CKD in this population. On the other hand, the STAND 
project used both an oral glucose tolerance test (OGTT) and HbA1c (6.0 – 6.4%) measurements 
to ascertain impaired glucose metabolism. Additionally, the AusDiab survey used only an OGTT 
to determine IGT/IFG. For the purpose of this thesis a broader diagnostic criteria (Chapter 4) 
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was used to determine IGR. Furthermore, the present study population was larger 
(approximately 3.5 million) compared to NCVIN (54,644), Mainous and colleagues (20,139) 
STAND (193) and AusDiab (11,247).    
8.6.4 Incidence of CKD in young adults with IGR compared to those with 
normoglycaemia 
To the best of our knowledge, this study was the first population based study utilising data from 
a large cohort of general practices and their patients from across the UK, and contemporary data, 
to investigate the incidence of CKD in young adults aged 18 to 40 years with IGR compared to 
those with normoglycaemia. Several studies have been conducted internationally exploring 
whether IGR as an individual component of a cluster of metabolic abnormalities is associated 
with an increased risk of CKD development determined by an (eGFR<60ml/min/1.73m2) or an 
albumin creatinine ratio (ACR) (6, 166, 170). Similarly, Watanabe and colleagues (7) in the 
Niigata Preventive Medicine Study, examining the risk of CKD in individual components of 
metabolic syndrome, found the incidence of IGR was approximately twice as high in subjects 
with IGR as those with normoglycaemia. Meigs and colleagues (162) in the Framingham 
Offspring study provided separate results for males and females, the odds of CKD 
development was 6% and 7% higher in males and females respectively with IGR 
compared to normoglycaemia. These studies, however, did not report separate results in 
persons aged 18 to 40 years with IGR and risk of CKD, but rather results were 
presented for the population as a whole. Therefore, quantification of CKD risk was not 
possible in the age group 18 to 40 years. Nevertheless, the results presented in this thesis appear 
to be consistent with previous studies showing an elevated risk of CKD in adults with IGR 
compared to those with normoglycaemia. 
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8.6.5 Incidence of CKD by each category (stages 1 – 2/3 – 5) in the IGR cohort 
To the best of our knowledge this is the first population based study examining the burden of 
CKD by each category (stages 1 – 2/3 – 5) in young adults aged 18 to 40 years with IGR. In a 
community based 10 – year follow-up study, using data from an annual health check in Japan, 
Yamagata and colleagues (216) examined the risk factors associated with incident CKD in adults 
aged ≥40 years without evidence of CKD stage (1 – 2/3 – 5) at baseline. During the follow-up 
period, the hazard of developing CKD stage (1 – 2) in individuals with IGR increased by 21% in 
men (HR: 1.21; CI, 1.08 to 1.35) and 19% in women (HR: 1.19; CI, 1.05 to 1.35). In contrast, 
there was not a statistically significant association between CKD stage (3 – 5) in both males and 
females with IGR, the hazard were (HR: 0.86; CI, 0.79 to 0.93) and (HR: 0.80; CI, 0.76 to 0.85) 
respectively. This study, however did not report separate results in the age group 18 to 40 years. 
The follow-up period for this study was 10 years compared a shorter length of follow-up for 
individual patients in the current study (median 2 years approximately). In their study, Yamagata 
and colleagues included 113, 764 individuals aged (≥40 years) and 33% were male compared to 
a study population of over 40,000 individuals aged 18 to 40 years and 46.4% male in the current 
study. 
8.6.6 Predicting future CKD outcome in young adults with IGR 
Electronic patient records of patients registered with a general practice and contributing to the 
THIN database was used to develop a prediction model to quantify the effect of risk factors in 
determining incident CKD in young adults aged 18 to 40 years with diagnosed IGR. The K-M 
model was used to describe the risk of CKD over time following IGR diagnosis. The present 
prediction model used a broad range of diagnostic criteria (Read code and clinical 
measurements) to identify cases, outcomes and risk factors. In a recently published prediction 
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model, the incidence of CKD in patients with type 2 diabetes and free from CKD at baseline 
were determined using data derived from the Ongoing Telmisartan Alone and Ramipril Global 
Endpoint (ONTARGET) clinical trials (217). Two prediction models were developed (laboratory 
and clinical models). The clinical model was compared to the present study because this model 
contained comparable risk factors. This study used only urinary albumin creatinine ratio and 
eGFR (<15 ml/min per 1.73 m2) to ascertain outcome compared to a range of clinical 
measurements used in the present study to define the outcome of interest. Risk factors included 
in this study differs from the present study. Some important predictors in this study (i.e. BMI and 
ethnicity) had limited detailed group which could have markedly different risks. The overall 
performance of the model (R2=10.73%) reported in this study is lower compared to the present 
study (24%). It should be noted that this study included individuals aged (≥55 years), therefore 
like for like comparison cannot be made. Furthermore, predictors of CKD risk in the present 
study are likely to differ from the above study. The reason for this disparity may be attributed to 
the inclusion of adults aged 18 to 40 years in the present study compared to an older age group in 
the ONTARGET study. Furthermore, Riphagen and colleagues (218) developed a 10 year risk 
prediction model to determine the risk of microalbuminuria and increase in serum creatinine in 
patients with T2DM using data from the Zwolle Outpatient Diabetes Project Integrating 
Available Care (ZODIAC) study. Some risk factors included in this study are similar to those 
included in the current study. However, the statistical significance of each risk factor was not 
tested in univariate analyses before inclusion in the final model. The Cox model shows a 52% 
increased risk of microalbuminuria and a 45% increased risk of renal function loss determined 
by a 50% increase in baseline serum creatinine for each 10 additional years of age at T2DM 
diagnosis. In the current study, there was a 7% increased risk of CKD for each additional year of 
age at IGR diagnosis. In this study males showed a 63% increased risk of microalbuminuria 
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compared to females. However, there was no statistically significant association between gender 
and an increase in serum creatinine. BMI was presented as a continuous variable, there was a 7% 
increased risk of renal function loss for every unit increase in BMI. For each unit increase in 
systolic blood pressure the risk of microalbuminuria and renal function loss was 16% and 12% 
respectively. Hypertension in the current study showed a statistically significant association in 
the univariate analysis and remained predictive of CKD in IGR (HR, 2.84) in the multivariate 
analysis. Macrovascular diseases were tested as a single group, both risks of microalbuminuria 
(HR: 1.52) and renal function loss (HR: 1.22) were significant. There was no statistically 
significant association between risk of CKD and atrial fibrillation, cardiovascular disease, heart 
failure or prescription of a non-steroidal anti-inflammatory drug in the current study. The study 
contained data for 1,143 patients with a mean age 68(+/-12) and 42.8% were male compared to a 
study population of 10,561 patients with IGR and 46.4% male in the current study.    
8.6.7 Ascertainment of exposure and outcome compared to other studies 
Other studies have investigated the risk of CKD in people with impaired glucose regulation (5, 
169). However, the method used to ascertain exposure and outcome of interest vary widely 
between studies. The current study used a wide range of clinical measurements obtained from 
laboratory results and Read coded diagnosis to identify exposure/ outcome of interest and 
relevant covariates compared to other studies (Chapter 4). In a prospective study, Fox and 
colleagues (5), investigated the effect of worsening glucose in non-diabetic patients and risk of 
CKD, used only a 2 hour oral glucose tolerance (OGTT) test to identify patients with IGR, 
kidney function on the other hand was estimated by an (eGFR<60 ml/min per 1.73 m2), from 
serum creatinine results and calculated using the modification of diet in renal disease (MDRD) 
equation. Additionally, Kurella and colleagues (212) using data from a longitudinal prospective 
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study of cardiovascular disease risk in non-diabetic adults (Atherosclerosis Risk In Communities 
[ARIC] study) examined the effect of metabolic syndrome and risk of CKD development. 
Metabolic traits were defined by the National Cholesterol Education Program (NCEP) 
guidelines. Patients with impaired fasting glucose were identified by fasting glucose 
(≥110mg/dL) alone and the outcome of interest, CKD was defined by an (eGFR<60 ml/min per 
1.73 m2) using serum creatinine and calculated by the MDRD equation.  
8.7 Future research 
A diagnosis of IGR in young adults aged 18 to 40 years may be an incidental discovery when 
screening for comorbidities in primary care. This study has shown that young adults with IGR 
are at increased risk of developing CKD. There are a number of areas that could be investigated 
in future research: 
 A randomised controlled study to investigate whether hypertension treatment can 
prevent the development of kidney disease among those with IGR aged 18 to 40 
years  
 Qualitative research with GPs might help understand biases in ascertainment and 
recording of IGR and CKD by understanding what risk factors might cause GPs 
to do blood tests for IGR or CKD in young adults.  
 A clinical trial investigating whether glucose lowering drugs versus glycaemic 
control prevent the  development of CKD following IGR diagnosis 
 




 Further research to determine whether lifestyle interventions strategy could 
potentially prevent or delay progression of IGR in young adults aged 18 to 40 
years.  
 
 A cohort study to validate the sole use of HbA1c (6.0 – 6.4%) against a 
combination of HbA1c and OGTT as a method to reliably diagnose IGR in young 
adults aged 18 to 40 years.  
 A cohort study using the THIN database to identify which IGR patients following 
introduction of the NHS Diabetes Prevention Programme are at highest risk of 
developing CKD and focus preventative treatment at those at highest risk.  
8.8 Clinical implication  
8.8.1 Practice 
This thesis provides reliable estimates of the incidence of CKD in young adults aged 18 to 40 
years with IGR compared to those with normoglycaemia. The unadjusted incidence of CKD was 
four times higher in IGR patients than individuals with normoglycaemia. After adjustment for 
potential confounders risk was reduced to approximately three times. These results provide a 
twofold opportunity to monitor individuals with IGR in primary care by assessing for worsening 
glycaemic status and monitor kidney function at least annually. Those individuals with IGR and 
hypertension should be monitored more closely for CKD development. Furthermore, risk of 
developing CKD stage (3 – 5) was higher than risk of CKD stage (1 – 2) in the IGR cohort, 
providing further opportunity for individuals with IGR to consider lifestyle modification and 
have regular follow-up check of their kidney function to detect CKD at an early stage. Among 
the comorbidities it is worth noting that a proportion of individuals with IGR at baseline already 
had cardiovascular related complication (1.8%) and hypertension (10.5%). These findings 
112 
 
reinforce the need to consider appropriate preventative treatment (for e.g., anti-hypertensive and 
cholesterol lowering treatments) along with lifestyle advice following IGR diagnosis. 
8.8.2 Policy 
The current NICE guidelines on the early identification and management of CKD in adults 
recommend that patients at risk of developing CKD (e.g. diabetes/hypertension) are offered 
screening test at least annually to detect further decline in kidney function (9). This study shows 
that risk of CKD is approximately four times higher in patients with IGR than those with 
normoglycaemia. Risk of CKD is already elevated even before patient progresses to T2DM. This 
may suggest that targeted routine screening could potentially be beneficial at IGR diagnosis and 
initiation of early CKD treatment may slow the decline of kidney function and reduce the risk of 
kidney failure (9). Furthermore, NICE recommend that patients on prolong treatment with an 
NSAID should have their kidney function checked at least annually to monitor further decline in 
GFR (9). In this study 1.9% (200), patients with IGR at baseline were prescribed an NSAID. 
This provides further opportunity to monitor and screen these patients at an early stage, 
especially in patients with other risk factors for CKD progression.  
8.9 Conclusion 
The National Institute for Health and Care Excellence (NICE) recently published guidelines on 
early identification and management of people diagnosed with CKD. This was driven by Kidney 
Disease Improving Global Outcomes (KDIGO) current CKD classification and data from 
recently published prognostic studies. Furthermore, NICE recommend that people with IGR are 
monitored to prevent future risk of diabetes. This thesis provides evidence of an increased risk of 
CKD amongst young adults with IGR. Analyses revealed that patients with IGR are at higher 
risk of developing CKD stage (3 – 5) than CKD stage (1 – 2). Additionally, among the 
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modifiable risk factors, hypertension was consistently linked to higher incidence of CKD. These 
results are in agreement with NICE guidelines, that patients at high risk should be tested for 
CKD. The result of this thesis shows the sizeable adverse effect of IGR on the development of 
CKD, and if left undetected may cause serious long term health issues and should be addressed 
at an early stage to reduce the future burden of CKD in patients with IGR. Estimates of the 
present study may provide a snapshot of young adults aged 18 to 40 years diagnosed with IGR in 
the UK between the January 2000 and February 2015 and may serve as a baseline comparison 
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12.0 Appendix 3 : Electronic search for Medline for CKD outcomes 
Count Searches Results 
1 exp Renal Insufficiency Chronic/ 84840 
2 chronic kidney disease.mp. 18247 
3 chronic kidney disease$.mp. 18745 
4 exp Kidney Failure, Chronic/ 78448 
5 chronic kidney failure.mp. 975 
6 chronic kidney failure$.mp. 976 
7 chronic renal failure.mp. 20307 
8 chronic renal failure$.mp. 20319 
9 end stage kidney disease.mp. 997 
10 end stage kidney disease$.mp. 1005 
11 esrd.mp. 9767 
12 esrd$.mp. 9769 
13 chronic kidney insufficiency.mp. 195 
14 chronic kidney insufficiency$.mp. 195 
15 end stage renal disease.mp. 19454 
16 end stage renal disease$.mp. 19625 
17 end stage renal failure.mp. 4888 
18 end stage renal failure$.mp. 4891 
19 kidney failure.mp. 81179 
20 kidney failure$.mp. 81828 
21 renal insufficiency/ 10919 
22 renal failure.mp. 71184 
23 renal failure$.mp. 71271 
24 kidney insufficiency.mp. 577 
25 kidney insufficiency$.mp. 577 
26 exp renal dialysis/ 93204 
27 renal dialysis.mp. 74276 
28 renal dialysis$.mp. 74276 
29 extracorporeal dialysis.mp. 161 
30 extracorporeal dialysis$.mp. 162 
31 hemodialysis.mp. 47033 
32 hemodialysis$.mp. 47039 
33 haemodialysis.mp. 11565 
34 haemodialysis$.mp. 11576 
35 exp peritoneal dialysis/ 22761 
36 peritoneal dialysis.mp. 26208 
37 peritoneal dialysis$.mp. 26210 
38 renal disease.mp. 39428 
39 renal disease$.mp. 43692 
40 exp kidney diseases/ 414228 
41 kidney disease.mp. 30990 
42 kidney disease$.mp. 103750 
43 nephropathy.mp. 37719 
149 
 
Count Searches Results 
44 nephropathy$.mp. 37721 
45 exp diabetic nephropathies/ 19707 
46 diabetic nephropathy.mp. 11909 
47 diabetic nephropathy$.mp. 11909 
48 exp kidney transplantation/ 79900 
49 kidney transplantation.mp. 81478 
50 kidney transplantation$.mp. 81539 
51 renal transplant.mp. 18888 
52 renal transplant$.mp. 36596 
53 exp dialysis/ 22124 
54 dialysis.mp. 132315 
55 dialysis$.mp. 132329 
56 exp renal insufficiency/ 127094 
57 renal insufficiency.mp. 33560 
58 renal insufficiency$.mp. 33571 
59 EGFR.mp. 27296 
60 EGFR$.mp. 27669 
61 exp glomerular filtration rate/ 33096 
62 glomerular filtration rate.mp. 42765 
63 glomerular filtration rate$.mp. 43111 
64 exp creatinine/ 46991 
65 creatinine.mp. 95418 
66 creatinine$.mp. 95673 
67 serum creatinine.mp. 26670 
68 serum creatinine$.mp. 26781 
69 serum creatinine clearance.mp. 53 
70 serum creatinine clearance$.mp. 58 
71 exp albuminuria/ 12045 
72 albuminuria$.mp. 14614 
73 exp proteinuria/ 32445 
74 proteinuria.mp. 36905 
75 proteinuria$.mp. 36921 
76 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 
or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 
57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 
or 71 or 72 or 73 or 74 or 75 
683333 
77 exp diabetes mellitus, type 2/ 87630 
78 diabetes mellitus type 2.mp. 87782 
79 type 2 diabetes.mp. 60366 
80 type 2 diabetes$.mp. 60434 
81 niddm.mp. 6673 
82 niddm$.mp. 6704 
83 exp diabetes insipidus/ 7011 
150 
 
Count Searches Results 
84 diabetes insipidus.mp. 8589 
85 diabetes insipidus$.mp. 8589 
86 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 113193 
87 exp glucose intolerance/ 6360 
88 impaired glucose tolerance.mp. 8065 
89 impaired glucose tolerance$.mp. 8066 
90 glucose intolerance.mp. 11300 
91 glucose intolerance$.mp. 11302 
92 exp prediabetic state/ 3852 
93 prediabetes.mp. 1633 
94 prediabetic state.mp. 4004 
95 prediabetic state$.mp. 4053 
96 exp blood glucose/ 130285 
97 blood glucose.mp. 147811 
98 blood glucose$.mp. 147841 
99 glucose metabolism.mp. 23463 
100 glucose metabolism$.mp. 23713 
101 exp glucose tolerance test/ 29397 
102 glucose tolerance test.mp. 33799 
103 glucose tolerance test$.mp. 34976 
104 OGTT.mp. 5382 
105 OGTT$.mp. 5481 
106 exp Hyperglycemia/ 26636 
107 hyperglycemia.mp. 37642 
108 hyperglycemia$.mp. 37682 
109 hyperglycaemia.mp. 6827 
110 hyperglycaemia$.mp. 6840 
111 impaired fasting glucose.mp. 2336 
112 impaired fasting glucose$.mp. 2336 
113 postprandial hyperglycemia.mp. 911 
114 postprandial hyperglycaemia.mp. 283 
115 exp hemoglobin a, glycosylated/ 23254 
116 hemoglobin a, glycosylated.mp. 23255 
117 hemoglobin a, glycosylated$.mp. 23255 
118 Haemoglobin a, glycosylated.mp. 1 
119 HbA1c.mp. 13678 
120 HbA1c$.mp. 13741 
121 glycemic abnormality.mp. 7 
122 Glycaemic abnormality.mp. 0 
123 Fasting plasma glucose.mp. 7250 
124 Fasting plasma glucose$.mp. 7259 
125 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 
100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 
111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 
122 or 123 or 124 
223393 
126 76 and 86 and 125 4367 
151 
 
Count Searches Results 
127 exp cohort studies/ 1387399 
128 cohort$.tw. 263907 
129 controlled clinical trial.pt. 88411 
130 epidemiologic methods/ 29569 
131 exp case-control studies/ 688110 
132 (case$ and control$).tw. 311313 
133 127 or 128 or 129 or 130 or 131 or 132 1909067 
























































148 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 














13.0 Appendix 4: Sensitive search of Medline for CKD outcomes 
Count Searches Results 
1 exp Renal Insufficiency Chronic/ 98188 
2 chronic kidney disease.mp. 29057 
3 chronic kidney disease$.mp. 29695 
4 exp Kidney Failure, Chronic/ 85933 
5 chronic kidney failure.mp. 1102 
6 chronic kidney failure$.mp. 1103 
7 chronic renal failure.mp. 21495 
8 chronic renal failure$.mp. 21510 
9 end stage kidney disease.mp. 1526 
10 end stage kidney disease$.mp. 1536 
11 esrd.mp. 11723 
12 esrd$.mp. 11727 
13 chronic kidney insufficiency.mp. 197 
14 chronic kidney insufficiency$.mp. 197 
15 end stage renal disease.mp. 23179 
16 end stage renal disease$.mp. 23319 
17 end stage renal failure.mp. 5301 
18 end stage renal failure$.mp. 5304 
19 kidney failure.mp. 89943 
20 kidney failure$.mp. 89958 
21 renal insufficiency/ 14052 
22 renal failure.mp. 77621 
23 renal failure$.mp. 77723 
24 kidney insufficiency.mp. 609 
25 kidney insufficiency$.mp. 609 
26 exp renal dialysis/ 103600 
27 renal dialysis.mp. 83217 
28 renal dialysis$.mp. 83217 
29 extracorporeal dialysis.mp. 173 
30 extracorporeal dialysis$.mp. 174 
31 hemodialysis.mp. 52361 
32 hemodialysis$.mp. 52366 
33 haemodialysis.mp. 12671 
34 haemodialysis$.mp. 12682 
35 exp peritoneal dialysis/ 24546 
36 peritoneal dialysis.mp. 28321 
37 peritoneal dialysis$.mp. 28326 
38 renal disease.mp. 45665 
39 renal disease$.mp. 50430 
40 exp kidney diseases/ 463998 
41 kidney disease.mp. 44884 
42 kidney disease$.mp. 125612 
43 nephropathy.mp. 43133 
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Count Searches Results 
44 nephropathy$.mp. 43138 
45 exp diabetic nephropathies/ 22277 
46 diabetic nephropathy.mp. 13892 
47 diabetic nephropathy$.mp. 13893 
48 exp kidney transplantation/ 86693 
49 kidney transplantation.mp. 88628 
50 kidney transplantation$.mp. 88690 
51 renal transplant.mp. 20699 
52 renal transplant$.mp. 39656 
53 exp dialysis/ 22949 
54 dialysis.mp. 144958 
55 dialysis$.mp. 144967 
56 exp renal insufficiency/ 147955 
57 renal insufficiency.mp. 43607 
58 renal insufficiency$.mp. 43608 
59 EGFR.mp. 37069 
60 EGFR$.mp. 37583 
61 exp glomerular filtration rate/ 37849 
62 glomerular filtration rate.mp. 49606 
63 glomerular filtration rate$.mp. 50041 
64 exp creatinine/ 51891 
65 creatinine.mp. 108189 
66 creatinine$.mp. 108453 
67 serum creatinine.mp. 31076 
68 serum creatinine$.mp. 31197 
69 serum creatinine clearance.mp. 59 
70 serum creatinine clearance$.mp. 64 
71 exp albuminuria/ 13604 
72 albuminuria$.mp. 16772 
73 exp proteinuria/ 36295 
74 proteinuria.mp. 41047 
75 proteinuria$.mp. 41065 
76 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 
or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 
57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 
or 71 or 72 or 73 or 74 or 75 
765478 
77 exp glucose intolerance/ 7404 
78 impaired glucose tolerance.mp. 9148 
79 impaired glucose tolerance$.mp. 9149 
80 glucose intolerance.mp. 12943 
81 glucose intolerance$.mp. 12945 
82 exp prediabetic state/ 5110 
83 prediabetes.mp. 2524 
84 prediabetic state.mp. 5243 
154 
 
Count Searches Results 
85 prediabetic state$.mp. 5279 
86 exp blood glucose/ 147244 
87 blood glucose.mp. 168289 
88 blood glucose$.mp. 168320 
89 glucose metabolism.mp. 27693 
90 glucose metabolism$.mp. 27738 
91 exp glucose tolerance test/ 32128 
92 glucose tolerance test.mp. 37296 
93 glucose tolerance test$.mp. 38628 
94 OGTT.mp. 6360 
95 OGTT$.mp. 6480 
96 exp Hyperglycemia/ 31346 
97 hyperglycemia.mp. 44272 
98 hyperglycemia$.mp. 44321 
99 hyperglycaemia.mp. 7873 
100 hyperglycaemia$.mp. 7888 
101 impaired fasting glucose.mp. 2874 
102 impaired fasting glucose$.mp. 2875 
103 postprandial hyperglycemia.mp. 1080 
104 postprandial hyperglycaemia.mp. 318 
105 exp hemoglobin a, glycosylated/ 28871 
106 hemoglobin a, glycosylated.mp. 28873 
107 hemoglobin a, glycosylated$.mp. 28873 
108 Haemoglobin a, glycosylated.mp. 1 
109 HbA1c.mp. 19317 
110 HbA1c$.mp. 19411 
111 glycemic abnormality.mp. 9 
112 Glycaemic abnormality.mp. 2 
113 Fasting plasma glucose.mp. 8981 
114 Fasting plasma glucose$.mp. 8992 
115 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 
or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 
103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 
114 
257303 
116 exp cohort studies/ 1652390 
117 cohort$.tw. 348084 
118 controlled clinical trial.pt. 93340 
119 epidemiologic methods/ 30928 
120 exp case-control studies/ 850703 
121 (case$ and control$).tw. 363820 
122 cohort studies/ 208646 
123 longitudinal studies/ 107497 
124 follow-up studies/ 577197 
125 prospective studies/ 449579 
126 retrospective studies/ 634617 
127 cohort.ti,ab. 315613 
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Count Searches Results 
128 longitudinal.ti,ab. 160875 
129 prospective.ti,ab. 407292 
130 retrospective.ti,ab. 331108 
131 Case-Control Studies/ 232869 
132 Control Groups/ 1585 
133 Matched-Pair Analysis/ 4559 
134 retrospective studies/ 634617 
135 ((case* adj5 control*) or (case adj3 comparison*) or control group*).ti,ab. 448137 
136 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 
127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135  
2686063 
137 76 and 115 and 136 6187 
138 limit 137 to humans 5737 
139 limit 138 to yr="1946 - 2015" 5487 























14.0 Appendix 5: Review eligibility criteria checklist 
 
  
Study design Cohort studies 
Case-control studies 




Other (please specify) 
Participants Studies where some participants are aged (18 to 40 years) 
With IGR  
With pre-diabetes (can refer to either IGT or Impaired Fasting Glucose (IFG). 
With metabolic syndrome (where IGR is part of metabolic syndrome) 
Free from CKD at baseline 
Comparator Participant with normoglycaemia 
Participants with diabetes 
Outcome Chronic kidney disease [eGFR stages: 3A, 3B, 4 and 5] 
Albuminuria 
Proteinuria ≥1 
ACR (albumin creatinine ratio ≥30mg/mmol 
PCR (protein creatinine ratio ≥50mg/mmol 
SCr (serum creatinine) data 
CrCl (creatinine clearance) data 
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15.0 Appendix 6: Data extraction form 
Abbreviation 
IGR Impaired Glucose Regulation 
CKD Chronic Kidney Disease 
T2DM Type 2 Diabetes 
SCr Serum Creatinine 
CrCl Creatinine Clearance 
ESRD End Stage Renal Disease 
ACR Albumin Creatinine Ratio 
PCR Protein Creatinine Ratio 
EX Excluded 
NR Not Reported 
eGFR Estimated Glomerular Filtration Rate 
 
Eligibility criteria for title and abstract screening phase 
Study design Assessment Comment 
Is it: 
[1] A cohort study (Prospective or Retrospective) 





Population   
[1] Were patients diagnosed with IGR? 
[2] Were patients followed up for T2DM 
 





Are patients aged (18-40) years 
 














Study design Assessment Comment 





ESRD (stage 5) 
ACR - >30mg/mmol 




Follow up   
Were the patients followed up and adequate measures 
taken 
 
NB: Please answer Yes if adequate measure were taken 























Reasons for exclusion of study from review (please circle where appropriate) 
Methods Not a cohort/case-control study 
Patients No IGR/no T2DM follow up/T2DM or Type 1 
diabetes diagnosis /CKD /wrong age group 
Outcomes No relevant outcomes assessed 
No data for relevant subgroup extractable 
Follow up period No follow up  




Specific inclusion criteria (please include if answer is Yes to all questions below) 
Eligibility criteria 
Satisfaction of eligibility criteria Yes 
No 
Unclear 
Effect sizes  
Is there sufficient reporting of statistics or data 






Organisational aspect  Exclude  Include 
Reviewer/date: Checked by: 
Author/Year     
Journal/Source     
Country of origin     
Publication type Full text/Abstract/Book chapter/progress report/ 
Other – please specify 
Fate Decision pending/Check references/Use for discussion/EX without 
listing/EX with listing 
Other – please specify 




General study characteristics (please circle where appropriate) 
Location of study  
Study aims Reported/NR 
Dates of recruitment From _______ to ________ 
Median (range): # 
Mean:# 
Length of follow up of CKD outcome + length 
of follow up of study 
From _______ to ________ 
Median (range): # 
Mean:# 
Outcomes assessed Did the study report any of the following outcome: 





End Stage Renal Disease (stage 5) 
Albumin creatinine ratio - >30mg/mmol 
Protein creatinine ratio - >45mg/mmol 
Serum creatinine measures 
Creatinine clearance measures 
Other (please specify): 
Outcome definition  
Relationship between outcome and relevant 
factor 




If No, is it due to 
Low powered or inconclusive study/A true negative 
study 
Power calculation Yes/No/Not reported 
 
Calculated sample size: # 




Please state where reported 










Baseline characteristics of patients (please circle where appropriate) 
 Exposure Control Notes: any relationship 
with outcomes? 
Yes/No/NR  
If Yes please state if 
statistically significant and 
RR/OR values 
Overall comment: Significant/In significant 
Number of patients    
Age range (if reported) 
Mean 
   
Ethnicity 
No% 








No of patients screened for IGR    
No of patients recruited    
No of patients allocated    
No of patients evaluated    
No of dropouts    
Reasons for dropouts    
    
Number of protocol violations    
  
Definition of IGR 
 
 














   
Status of patient at recruitment 
 














If Yes please state 
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Observational study characteristics (please circle where appropriate) 
Sample size  
Number of excluded patients  
Recruitment method  
Type of observational study Cohort studies (retrospective/prospective) 
Case-control studies/nested case-control 
Are group comparable? Yes/No 
 
If No, please specify 
Any confounders? Yes/No 
 
If No, please specify 
Analysis  
Drop outs stated Yes/No 
 
If Yes: # in each group 
 
Outcome details 
The following table have to be copied for every relevant outcome assessed (please fill out fields only where 
applicable) 
Outcomes assessed (please state where relevant) 
Definition of each outcome  
Time of assessment of each outcome (post IGR)  
Timing of assessment  
Length of follow up for each outcome  
Method of measurement  
















Methodological quality summary for observational studies 
 
 
Reviewer/Date: Checked by: 
 
 
Contents (please refer 
to tables below for 
guidance 
Yes Partly No Unsure Comments 
Study participation      
Study attrition      
Measurement of 
prognostic factors 




     
Measurement of 
outcomes 
     
Analysis approach      










16.0 Appendix 7: Quality assessment form adapted from Ottawa-Newcastle scale (NOS) for assessing 
non-randomised studies 
  Yes/No/Unclear 
Selection of participants 
[1] Was the inclusion/exclusion clearly described? 
(for example, age, diagnosis status, IGT/IFG) 
 
 [2] Was inclusion/exclusion assessed using valid and 
reliable measures? (For example, if there are important 
inclusion/exclusion criteria that are not directly related to 
exposure and outcome and for which the accuracy of 
measurement may need scrutiny, e.g. age, diagnosis).  
 
[3] Was recruitment strategy clearly described? 
 
[4] Did the investigators ensure that the 
exposed/unexposed group were comparable (for example, 











Adequate description of 
study population 
[1] Was study population well characterised? 
 Age 
 Sex 
 Ethnicity  
 Suitable definition of IGT/IFG 
 
 
Validated method for 
ascertaining exposure 
[1] Was the method used to ascertain exposure clearly 
defined?  
[2] Was a valid and reliable measure used to ascertain 
exposure?  





Fasting Plasma Glucose 6.1 – 6.9 mmol/L 
Oral Glucose Tolerance Test (2h 
value) 
7.8 – 11.0 mmol/L 












[1]Was valid and reliable measures used to ascertain 







ACR - >30mg/mmol 
PCR - >45mg/mmol 
SCr measures 
CrCl measures 














Adequate follow up period 
[1] Was follow up long enough for the outcome to occur? 
 
[2] Was the follow up period the same across all groups? 
[3] Were differences in follow-up adjusted for using 
statistical techniques, e.g., survival analysis?  
 
Completeness of follow-up 
(Attrition) 
[1] Were drop-out rates and reasons for drop-out similar 
across exposed and unexposed? 
[2] Were numbers of dropouts/withdrawals documented at 





  Yes/No/Unclear 
Analysis controls for 
confounding 
[1] Does the study identify and control for important 
confounding variables and effect modifiers?  
 
Sample size calculated 
[1] Is the sample size adequate? 
 
[2] Did the study describe how the sample size was 
calculated? 
 Did the investigators conduct a power analysis to 
determine the adequacy of study group sizes for the 
outcome of interest?  
 Was the sample size large enough to detect 
differences in event or a significant OR/RR between 





[1] Was the kind of analysis done appropriate for the kind 
of outcome data? For example, 
 Dichotomous – logistic regression, survival analysis 
 Categorical – mixed model for categorical outcomes 
 Continuous – Mixed model, ANCOVA 
 Mean change (+/-SE) 
[2] Was loss to follow up accounted for in the analysis 








Overall appraisal: Include  Exclude Seek further info 
 










































17.0 Appendix 8: Sensitivity search PRISMA flow diagram 
Additional records identified through 
other sources (n=12) 
 















Records identified through database search: 
(n=14585) 
CINAHL = 3628 
EMBASE = 7268 
MEDLINE = 3011 
PubMed = 678 
 
Full text articles excluded (n=88) 
Reasons: 
Cross sectional studies = 45 
Aged (>40 years) = 2 
Case-review = 1 
Conference abstract = 2 
Exposure only diabetics = 7 
No IGT/IFG patients included = 13 
No renal outcome = 4 
Review paper = 6 
Outcomes is diabetes = 2 
No separate analysis for IGT/IFG = 4 
Incidence of diabetes not CKD = 1 
RCT = 1 
 
 
Full text articles assessed 
































Reason: No separate data reported for 




18.0 Appendix 9: Characteristics of studies reporting IGT/IFG compared to normoglycaemia and development of CKD 
Author/Year 
(Reference) 
Country Study type 
Mean age (+/- SD) 
or range (years) or 
percentages 
















aged (18 to 60 years) 4 years 
Community  based 
population 
ACR 29/60 IGT Mean (+/-SE) change in GFR N/A 





aged (28 to 62 years) 7 years 
Framingham 
Offspring study 
eGFR<60ml/min/1.73m2 704/3,102 IGT/IFG 
Unadjusted OR: 1.65(1.16 to 2.36) 
 
Adjusted OR: 0.98(0.67 to 1.45) 
Age, sex, baseline 
GFR, SBP, 
hypertension treatment, 
smoking, BMI, total & 
HDL cholesterol, MI, 
congestive heart failure 





Aged (≥34 years) 24 years 
Framingham 
Offspring study 
ACR 2,501/5,330 IGT/IFG 
Adjusted OR: 
Men – 1.06(1.03 to 1.09) 
Women – 1.07 (1.04 to 1.10) 











Aged (18 to 60 years) 4 years 
Community  based 
population 
ACR 27/80 IGT Mean (+/-SE) change in GFR N/A 





Aged (≥15 years) 6 years 
Community  based 
population 
ACR 217/2,945 IGT Adjusted OR: 1.5(1.0 to 2.2) Age, sex, BP 
Yokoyama et 




Aged 61 (+/-12) 
Median 3 
years 
Outpatient clinic eGFR<60ml/min/1.73m2 194/1,117 IGT/IFG Unadjusted OR: 1.31(0.91 to 1.87) No adjustment 





Aged (19 to 84 years) 5 years 
Community based 
population 
GFR<60ml/min/1.73m2 884/7,255 IGT/IFG 
Unadjusted RR: 1.28(0.94 to 1.75) 
Adjusted RR: 1.22(0.89 to 1.07) 
Age, sex, current 
cigarette smoking, 
alcohol drinking habit 











ACR 412/902 IGT Unadjusted OR: 0.8(0.4 to 1.5) No adjustment 





Aged 48 (+/-12) 3 years 
Community based 
population 
CrCL 1,010/5,617 IFG Unadjusted OR: 1.02(0.99 to 1.04) No adjustment 
Kitiyakara et 











eGFR<60ml/min/1.73m2 227/2,294 IGT/IFG 
Unadjusted OR based on IDF 
definition – 1.59(0.99 to 
2.54)Unadjusted OR based on 
NCEP definition – 2.44(1.29 to 
4.60)Adjusted OR based on IDF 
definition – 1.38(0.85 to 
2.22)Adjusted OR based on NCEP 
definition – 1.97(1.03 to 3.78) 
Age, sex and smoking 
status 





Aged (20 to 74 years) 3.7 (+/-2.4) 
Population 
database 
eGFR<60ml/min/1.73m2 17,039/135,963 IGT/IFG 
Unadjusted HR: 1.26(1.22 to 
1.32)Adjusted HR: 0.97(0.93 to 
1.01) 
Age, sex, check-up 
centres and current 
smoking 









Population survey eGFR<60ml/min/1.73m2 637/4,885 IGT/IFG 
Unadjusted HR: 2.47(1.83 to 3.32) 
Adjusted HR: 1.33(1.03 to 1.89) 
Age, sex, BMI, serum 
level, total cholesterol, 
BP, triglyceride, HDL 

















HR: 0.67(0.41 to1.10) -SCr 
HR: 0.60(0.42 to 0.86) - 
eGFR<60ml/min/1.73m2 
HR: 0.67(0.42 to 1.09) - 
eGFR<30ml/min/1.73m2 
HR: 0.88(0.49 to 1.60) - 
eGFR<15ml/min/1.73m 
No adjustments 





Country Study type 
Mean age (+/- SD) 
or range (years) or 
percentages 












al (2010)  
Japan Prospective 
cohort 






1,082/15,971 IGT Adjusted HR: 1.94(1.06 to 3.54) - 
eGFR<60ml/min/1.73m2 
 
Sex and age 










787/10,685 IGT/IFG Adjusted HR: 1.04(0.60 to 1.79) 
Age, baseline GFR, 
glutamyltranspeptide, 
uric acid, triglyceride, 
HDL cholesterol, BP, 
obesity 





Aged (35 to 59 years) 10 years Hospital setting 




Adjusted RR: 1.7(1.4 to 1.9) – 
MenAdjusted RR: 1.5(1.0 to 2.2) - 
Women 
BMI, total cholesterol, 
SBP 





Aged (≥20 years) 10 years 
Community based 
population 






Aged (50 – 74 years) 8 years ESTHER study eGFR<60ml/min/1.73m2 258/3,538 IGT/IFG 
Unadjusted RR: 1.33(1.03 to 1.73) 
Adjusted RR: 1.06(0.71 to 1.32) 
BMI, BP, cholesterol, 
antihypertensive drug, 
statins, smoking, 
history of CVD 





Aged (30-64 years) 6 years DESIR study 




Adjusted OR: 1.87(1.25 to 2.81) – 
Men 
Adjusted OR: 1.40(0.80 to 2.46) - 
Women 
Age, ACE inhibitors, 
smoking, fibrinogen 
level 





Aged (45-74 years) 9 years Strong heart study 
ACR: ≥30mg/g 
eGFR<60ml/min/1.73m2 
896/2,380 IFG/IGT Adjusted HR: 1.3(1.1 to 1.6) 
age, sex, study centre, 
education, and smoking 

















Aged (≥40 years) 5 years 
Community based 
population 













Aged (18-30 years) 25 years CARDIA study eGFR<60ml.min/1.73m2 2,174/5,115 IGT/IFG 
Unadjusted RR: 1.59(1.04 to 2.43) 
Adjusted RR: 1.11(0.71 to 1.72) 












19.0 Appendix 10: Characteristics of studies reporting IGT/IFG compared to T2DM and development of CKD 
Author/Year 
(Reference) 
Country Study type 
Mean age (+/- SD) or 
range (years) or 
percentages 














Aged (5 to 19 years) 25.2 years Community based 
population 
ACR 2,534/5,200 IGT Incidence (cases/1000 PY) 
0.13% (IGT) 
2.4% (T2DM) 
Age and sex 








74,440/152,969 IGT/IFG Adjusted OR: 3.01(1.74 to 
5.52) 




5 OR, odds ratio; IRR, incidence rate ratio; HR hazard ratio; GFR, glomerular filtration rate; ACR, albumin creatinine ratio; SCr, serum creatinine; CrCl, creatinine clearance; SBP, systolic blood pressure; SBP, systolic 
blood pressure; BMI, body mass index; MI, myocardial infarction; HDL, high density lipoprotein; BP, blood pressure; DBP, diastolic blood pressure; SD, standard deviation; SE, standard error 
 
 




20.0 Appendix 11: Read code description  
Read codes used to identify cases of IGR 
 
Read code Description 
44V2.00 Glucose tolerance test impaired 
C11y200 Impaired glucose tolerance 
C11y300 Impaired fasting glycaemia 
C11y400 Impaired glucose regulation 
C11y500 Pre-diabetes 
6AC..00 Review of impaired glucose tolerance 
9NS0400 Referral for impaired glucose tolerance management offered 
R102.00 [D]Glucose tolerance test abnormal 
R102.11 [D]Prediabetes 
R102.12 [D]Impaired glucose tolerance test 
R10D000 [D]Impaired fasting glycaemia 
R10D011 [D]Impaired fasting glucose 
R10E.00 [D]Impaired glucose tolerance 
C313500 Glucose intolerance 
Abbreviation: [D], diagnosis 
Read code used to identify cases of T2DM 
Note: This list include codes which do not specifically specify diabetes type 
Read Code Description 
C10..00 Diabetes mellitus 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10C.00 Diabetes mellitus autosomal dominant 
C10D.00 Diabetes mellitus autosomal dominant type 2 
C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
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Read Code Description 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FK11 Hyperosmolar non-ketotic state in type II diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FN11 Type II diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10FQ11 Type II diabetes mellitus with exudative maculopathy 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10FR11 Type II diabetes mellitus with gastroparesis 
C10FS00 Maternally inherited diabetes mellitus 
C10G.00 Secondary pancreatic diabetes mellitus 
C10G000 Secondary pancreatic diabetes mellitus without complication 
C10H.00 Diabetes mellitus induced by non-steroid drugs 
C10H000 Diabetes Mellitus induced by non-steroid drugs without complication 
C10M.00 Lipoatrophic diabetes mellitus 
C10M000 Lipoatrophic diabetes mellitus without complication 
C10N.00 Secondary diabetes mellitus 
C10N000 Secondary diabetes mellitus without complication 
C10N100 Cystic fibrosis related diabetes mellitus 
C10P.00 Diabetes mellitus in remission 
C10P100 Type II diabetes mellitus in remission 
C10P111 Type 2 diabetes mellitus in remission 
PKyP.00 Diabetes insipidus,diabetes mellitus,optic atrophy and deafness 
 
Read code used to identify cases of CKD 
 
Read code Description 
1Z12.00 Chronic kidney disease stage 3 
1Z13.00 Chronic kidney disease stage 4 
1Z14.00 Chronic kidney disease stage 5 
1Z15.00 Chronic kidney disease stage 3A 
1Z16.00 Chronic kidney disease stage 3B 
1Z1B.00 Chronic kidney disease stage 3 with proteinuria 
1Z1B.11 CKD stage 3 with proteinuria 
1Z1C.00 Chronic kidney disease stage 3 without proteinuria 
1Z1C.11 CKD stage 3 without proteinuria 
1Z1D.00 Chronic kidney disease stage 3A with proteinuria 
1Z1D.11 CKD stage 3A with proteinuria 
1Z1E.00 Chronic kidney disease stage 3A without proteinuria 
1Z1E.11 CKD stage 3A without proteinuria 
1Z1F.00 Chronic kidney disease stage 3B with proteinuria 
1Z1F.11 CKD stage 3B with proteinuria 
1Z1G.00 Chronic kidney disease stage 3B without proteinuria 
1Z1G.11 CKD stage 3B without proteinuria 
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Read code Description 
1Z1H.00 Chronic kidney disease stage 4 with proteinuria 
1Z1H.11 CKD stage 4 with proteinuria 
1Z1J.00 Chronic kidney disease stage 4 without proteinuria 
1Z1J.11 CKD stage 4 without proteinuria 
1Z1K.00 Chronic kidney disease stage 5 with proteinuria 
1Z1K.11 CKD stage 5 with proteinuria 
1Z1L.00 Chronic kidney disease stage 5 without proteinuria 
1Z1L.11 CKD stage 5 without proteinuria 
1Z1N. CKD with GFR category G1 & albuminuria category A2 
1Z1P. CKD with GFR category G1 & albuminuria category A3 
1Z1R. CKD with GFR category G2 & albuminuria category A2 
1Z1S. CKD with GFR category G2 & albuminuria category A3 
1Z1T. CKD with GFR category G3a & albuminuria category A1 
1Z1V. CKD with GFR category G3a & albuminuria category A2 
1Z1W. CKD with GFR category G3a & albuminuria category A3 
1Z1X. CKD with GFR category G3b & albuminuria category A1 
1Z1Y. CKD with GFR category G3b & albuminuria category A2 
1Z1Z. CKD with GFR category G3b & albuminuria category A3 
1Z1a. CKD with GFR category G4 & albuminuria category A1 
1Z1b. CKD with GFR category G4 & albuminuria category A2 
1Z1c. CKD with GFR category G4 & albuminuria category A3 
1Z1d. CKD with GFR category G5 & albuminuria category A1 
1Z1e. CKD with GFR category G5 & albuminuria category A2 
1Z1f. CKD with GFR category G5 & albuminuria category A3 
K053 CKD (Stage 3) 
K054 CKD (Stage 4) 
K055 CKD (Stage 5) 
1Z10.00 Chronic kidney disease stage 1 
1Z11.00 Chronic kidney disease stage 2 
1Z17.11 CKD stage 1 with proteinuria 
1Z18.00 Chronic kidney disease stage 1 without proteinuria 
1Z18.11 CKD stage 1 without proteinuria 
1Z19.00 Chronic kidney disease stage 2 with proteinuria 
1Z19.11 CKD stage 2 with proteinuria 
1Z1A.00 Chronic kidney disease stage 2 without proteinuria 
1Z1A.11 CKD stage 2 without proteinuria 
K051.00 Chronic kidney disease stage 1 
K052.00 Chronic kidney disease stage 2 
1Z1M. CKD with GFR category G1 & albuminuria category A1 
46TC.00 Urine albumin: creatinine ratio 
44lD.00 Urine protein: creatinine ratio 
44J7.00 Albumin: creatinine ratio 
Read codes used to identify cases of atrial fibrillation 
Read code Description 
G573.00 Atrial fibrillation and flutter 
G573000 Atrial fibrillation 
G573200 Paroxysmal atrial fibrillation 
G573300 Non-rheumatic atrial fibrillation 
G573400 Permanent atrial fibrillation 
G573500 Persistent atrial fibrillation 
G573z00 Atrial fibrillation and flutter NOS 




Read codes used to identify cases with hypertension 
Read code Description 
G2...00 Hypertensive disease 
G20..00 Essential hypertension 
G20..11 High blood pressure 
G20..12 Primary hypertension 
G200.00 Malignant essential hypertension 
G201.00 Benign essential hypertension 
G202.00 Systolic hypertension 
G203.00 Diastolic hypertension 
G20z.00 Essential hypertension NOS 
G20z.11 Hypertension NOS 
G21..00 Hypertensive heart disease 
G210.00 Malignant hypertensive heart disease 
G210000 Malignant hypertensive heart disease without CCF 
G210100 Malignant hypertensive heart disease with CCF 
G210z00 Malignant hypertensive heart disease NOS 
G211.00 Benign hypertensive heart disease 
G211000 Benign hypertensive heart disease without CCF 
G211100 Benign hypertensive heart disease with CCF 
G211z00 Benign hypertensive heart disease NOS 
G21z.00 Hypertensive heart disease NOS 
G21z000 Hypertensive heart disease NOS without CCF 
G21z011 Cardiomegaly - hypertensive 
G21z100 Hypertensive heart disease NOS with CCF 
G21zz00 Hypertensive heart disease NOS 
G22..00 Hypertensive renal disease 
G22..11 Nephrosclerosis 
G220.00 Malignant hypertensive renal disease 
G221.00 Benign hypertensive renal disease 
G222.00 Hypertensive renal disease with renal failure 
G22z.00 Hypertensive renal disease NOS 
G2 2z.11 Renal hypertension 
G23..00 Hypertensive heart and renal disease 
G230.00 Malignant hypertensive heart and renal disease 
G231.00 Benign hypertensive heart and renal disease 
G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
G233.00 Hypertensive heart and renal disease with renal failure 
G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G23z.00 Hypertensive heart and renal disease NOS 
G24..00 Secondary hypertension 
G240.00 Secondary malignant hypertension 
G240z00 Secondary malignant hypertension NOS 
G241.00 Secondary benign hypertension 
G241z00 Secondary benign hypertension NOS 
G244.00 Hypertension secondary to endocrine disorders 
G24z.00 Secondary hypertension NOS 
G24z000 Secondary renovascular hypertension NOS 
G24zz00 Secondary hypertension NOS 
G25..00 Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
G25..11 Stage 1 hypertension 
G250.00 Stage 1 hyperten (NICE 2011) without evidence end organ damage 
G251.00 Stage 1 hyperten (NICE 2011) with evidence end organ damage 
G26..00 Severe hypertension (Nat Inst for Health Clinical Excl 2011) 
G26..11 Severe hypertension 
G28..00 Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
G2y..00 Other specified hypertensive disease 
G2z..00 Hypertensive disease NOS 
Gyu2. [X]Hypertensive diseases 
Gyu20. [X]Other secondary hypertension 
Abbreviations: NOS, not otherwise specified; CCF, congestive cardiac failure 
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Read codes used to identify cases of cardiovascular disease 
Note: This list includes CHD, PAD, stroke and TIA combined to create a single CVD group.  
Read code Description 
CHD codes  
G3...00 Ischaemic heart disease 
G3...11 Arteriosclerotic heart disease 
G3...12 Atherosclerotic heart disease 
G3...13 IHD - Ischaemic heart disease 
G30..00 Acute myocardial infarction 
G30..11 Attack - heart 
G30..12 Coronary thrombosis 
G30..13 Cardiac rupture following myocardial infarction (MI) 
G30..14 Heart attack 
G30..15 MI - acute myocardial infarction 
G30..16 Thrombosis - coronary 
G30..17 Silent myocardial infarction 
G300.00 Acute anterolateral infarction 
G301.00 Other specified anterior myocardial infarction 
G301000 Acute anteroapical infarction 
G301100 Acute anteroseptal infarction 
G301z00 Anterior myocardial infarction NOS 
G302.00 Acute inferolateral infarction 
G303.00 Acute inferoposterior infarction 
G304.00 Posterior myocardial infarction NOS 
G305.00 Lateral myocardial infarction NOS 
G306.00 True posterior myocardial infarction 
G307.00 Acute subendocardial infarction 
G307000 Acute non-Q wave infarction 
G307100 Acute non-ST segment elevation myocardial infarction 
G308.00 Inferior myocardial infarction NOS 
G309.00 Acute Q-wave infarct 
G30B.00 Acute posterolateral myocardial infarction 
G30X.00 Acute transmural myocardial infarction of unspecif site 
G30X000 Acute ST segment elevation myocardial infarction 
G30y.00 Other acute myocardial infarction 
G30y000 Acute atrial infarction 
G30y100 Acute papillary muscle infarction 
G30y200 Acute septal infarction 
G30yz00 Other acute myocardial infarction NOS 
G30z.00 Acute myocardial infarction NOS 
G31..00 Other acute and subacute ischaemic heart disease 
G310.11 Dressler's syndrome 
G311.00 Preinfarction syndrome 
G311.11 Crescendo angina 
G311.12 Impending infarction 
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G311.13 Unstable angina 
G311.14 Angina at rest 
G311000 Myocardial infarction aborted 
G311011 MI - myocardial infarction aborted 
G311100 Unstable angina 
G311200 Angina at rest 
G311300 Refractory angina 
G311400 Worsening angina 
G311500 Acute coronary syndrome 
G311z00 Preinfarction syndrome NOS 
G312.00 Coronary thrombosis not resulting in myocardial infarction 
G31y.00 Other acute and subacute ischaemic heart disease 
G31y000 Acute coronary insufficiency 
G31y100 Microinfarction of heart 
G31y200 Subendocardial ischaemia 
G31y300 Transient myocardial ischaemia 
G31yz00 Other acute and subacute ischaemic heart disease NOS 
G32..00 Old myocardial infarction 
G32..11 Healed myocardial infarction 
G32..12 Personal history of myocardial infarction 
G33..00 Angina pectoris 
G330.00 Angina decubitus 
G330000 Nocturnal angina 
G330z00 Angina decubitus NOS 
medcode description 
G33z.00 Angina pectoris NOS 
G33z000 Status anginosus 
G33z100 Stenocardia 
G33z200 Syncope anginosa 
G33z300 Angina on effort 
G33z400 Ischaemic chest pain 
G33z500 Post infarct angina 
G33z600 New onset angina 
G33z700 Stable angina 
G33zz00 Angina pectoris NOS 
G34..00 Other chronic ischaemic heart disease 
G340.00 Coronary atherosclerosis 
G340.11 Triple vessel disease of the heart 
G340.12 Coronary artery disease 
G340000 Single coronary vessel disease 
G340100 Double coronary vessel disease 
medcode description 
G342.00 Atherosclerotic cardiovascular disease 
G343.00 Ischaemic cardiomyopathy 
G344.00 Silent myocardial ischaemia 
176  
 
Read code Description 
G34y.00 Other specified chronic ischaemic heart disease 
G34y000 Chronic coronary insufficiency 
G34y100 Chronic myocardial ischaemia 
G34yz00 Other specified chronic ischaemic heart disease NOS 
G34z.00 Other chronic ischaemic heart disease NOS 
G34z000 Asymptomatic coronary heart disease 
G35..00 Subsequent myocardial infarction 
G350.00 Subsequent myocardial infarction of anterior wall 
G351.00 Subsequent myocardial infarction of inferior wall 
G353.00 Subsequent myocardial infarction of other sites 
G35X.00 Subsequent myocardial infarction of unspecified site 
G38..00 Postoperative myocardial infarction 
G380.00 Postoperative transmural myocardial infarction anterior wall 
G381.00 Postoperative transmural myocardial infarction inferior wall 
G382.00 Postoperative transmural myocardial infarction other sites 
G383.00 Postoperative transmural myocardial infarction unspec site 
G384.00 Postoperative subendocardial myocardial infarction 
G38z.00 Postoperative myocardial infarction, unspecified 
G39..00 Coronary microvascular disease 
G3y..00 Other specified ischaemic heart disease 
G3z..00 Ischaemic heart disease NOS 
Gyu3.00 [X]Ischaemic heart diseases 
Gyu3000 [X]Other forms of angina pectoris 
Gyu3200 [X]Other forms of acute ischaemic heart disease 
Gyu3300 [X]Other forms of chronic ischaemic heart disease 
Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
Gyu3500 [X]Subsequent myocardial infarction of other sites 
Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
PAD codes  
G73..00 Other peripheral vascular disease 
G73..11 Peripheral ischaemic vascular disease 
G73..12 Ischaemia of legs 
G73..13 Peripheral ischaemia 
G730.00 Raynaud's syndrome 
G730000 Raynaud's disease 
G730100 Raynaud's phenomenon 
G730111 Vibratory white finger 
G730z00 Raynaud's syndrome NOS 
G731.00 Thromboangiitis obliterans 
G731000 Buerger's disease 
G731100 Presenile gangrene 
G731z00 Thromboangiitis obliterans NOS 
G732.00 Peripheral gangrene 
G732000 Gangrene of toe 
G732100 Gangrene of foot 
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G732200 Gangrene of finger 
G732300 Gangrene of thumb 
G732400 Gangrene of hand 
G733.00 Ischaemic foot 
G734.00 Peripheral arterial disease 
G735.00 HAVS - Hand-arm vibration syndrome 
G735.11 Vibration white finger 
G73y.00 Other specified peripheral vascular disease 
G73y000 Diabetic peripheral angiopathy 
G73y100 Peripheral angiopathic disease EC NOS 
G73y200 Acrocyanosis 
G73y400 Acroparaesthesia - Schultze's type 
G73y411 Schultze's simple acroparaesthesia 
G73y500 Acroparaesthesia - Nothnagel's type 
G73y511 Nothnagel's vasomotor acroparaesthesia 




G73yz00 Other specified peripheral vascular disease NOS 
G73z.00 Peripheral vascular disease NOS 
G73z000 Intermittent claudication 
G73z011 Claudication 
G73z012 Vascular claudication 
G73zz00 Peripheral vascular disease NOS 
Gyu7400 [X]Other specified peripheral vascular diseases 
G734.00 Peripheral arterial disease 
G73y.00 Other specified peripheral vascular disease 
Stroke/TIA codes  
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G618.00 Intracerebral haemorrhage, multiple localized 
G619.00 Lobar cerebral haemorrhage 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G63y.00 Other precerebral artery occlusion 
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G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
G63y100 Cerebral infarction due to embolism of precerebral arteries 
G64..00 Cerebral arterial occlusion 
G64..11 CVA - cerebral artery occlusion 
G64..12 Infarction - cerebral 
G64..13 Stroke due to cerebral arterial occlusion 
G640.00 Cerebral thrombosis 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G641.00 Cerebral embolism 
G641.11 Cerebral embolus 
G641000 Cerebral infarction due to embolism of cerebral arteries 
G64z.00 Cerebral infarction NOS 
G64z.11 Brainstem infarction NOS 
G64z.12 Cerebellar infarction 
G64z000 Brainstem infarction 
G64z100 Wallenberg syndrome 
G64z111 Lateral medullary syndrome 
G64z200 Left sided cerebral infarction 
G64z300 Right sided cerebral infarction 
G64z400 Infarction of basal ganglia 
G66..00 Stroke and cerebrovascular accident unspecified 
G66..11 CVA unspecified 
G66..12 Stroke unspecified 
G66..13 CVA - Cerebrovascular accident unspecified 
G660.00 Middle cerebral artery syndrome 
G661.00 Anterior cerebral artery syndrome 
G662.00 Posterior cerebral artery syndrome 
G663.00 Brain stem stroke syndrome 
G664.00 Cerebellar stroke syndrome 
G665.00 Pure motor lacunar syndrome 
G666.00 Pure sensory lacunar syndrome 
G667.00 Left sided CVA 
G668.00 Right sided CVA 
G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
Gy62.00 Rupture of dialysis arteriovenous shunt 
Gyu..00 [X]Additional circulatory system disease classificatn terms 
Gyu0.00 [X]Acute rheumatic fever 
Gyu0000 [X]Other acute rheumatic heart disease 
Gyu1.00 [X] Chronic rheumatic heart disease 
Gyu1000 [X]Other mitral valve diseases 
Gyu1100 [X]Other rheumatic aortic valve diseases 
Gyu1200 [X]Other tricuspid valve diseases 
Gyu1300 [X]Other multiple valve diseases 
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Gyu1400 [X]Other specified rheumatic heart diseases 
Gyu1500 [X]Multiple valve disease, unspecified 
Gyu2.00 [X]Hypertensive diseases 
Gyu2000 [X]Other secondary hypertension 
Gyu2100 [X]Hypertension secondary to other renal disorders 
Gyu3.00 [X]Ischaemic heart diseases 
Gyu3000 [X]Other forms of angina pectoris 
Gyu3100 [X]Other current complications following acute myocardial infarct 
Gyu3200 [X]Other forms of acute ischaemic heart disease 
Gyu3300 [X]Other forms of chronic ischaemic heart disease 
Gyu3400 [X]Acute transmural myocardial infarction of unspecified site 
Gyu3500 [X]Subsequent myocardial infarction of other sites 
Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
Gyu4.00 [X]Pulmonary heart disease & diseases of pulmonary circulation 
Gyu4000 [X]Other specified pulmonary heart diseases 
Gyu4100 [X]Other diseases of pulmonary vessels 
Gyu5.00 [X]Other forms of heart disease 
Gyu5000 [X]Other forms of acute pericarditis 
Gyu5100 [X]Other specified diseases of pericardium 
Gyu5200 [X]Pericarditis in bacterial diseases classified elsewhere 
Gyu5300 [X]Pericarditis in other infectious+parasitic diseases CE 
Gyu5400 [X]Pericarditis in other diseases classified elsewhere 
Gyu5500 [X]Other nonrheumatic mitral valve disorders 
Gyu5600 [X]Other aortic valve disorders 
Gyu5700 [X]Other nonrheumatic tricuspid valve disorders 
Gyu5800 [X]Other pulmonary valve disorders 
Gyu5900 [X]Mitral valve disorders in diseases classified elsewhere 
Gyu5A00 [X]Aortic valve disorders in diseases classified elsewhere 
Gyu5a00 [X]Other specified cardiac arrhythmias 
Gyu5b00 [X]Other ill-defined heart diseases 
Gyu5B00 [X]Tricuspid valve disorders/diseases CE 
Gyu5c00 [X]Other heart disorders in bacterial diseases CE 
Gyu5C00 [X]Pulmonary valve disorders in diseases CE 
Gyu5D00 [X]Multiple valve disorders/diseases CE 
Gyu5d00 [X]Oth heart disorders/oth infectious+parasitic diseases CE 
Gyu5e00 [X]Other heart disorders in other diseases CE 
Gyu5E00 [X]Endocarditis,valve unspecified,in diseases CE 
Gyu5f00 [X]Nonrheumatic tricuspid valve disorder, unspecified 
Gyu5F00 [X]Other acute myocarditis 
Gyu5G00 [X]Acute myocarditis, unspecified 
Gyu5g00 [X]Cardiovascular disease, unspecified 
Gyu5H00 [X]Myocarditis in bacterial diseases classified elsewhere 
Gyu5J00 [X]Myocarditis in viral diseases classified elsewhere 
Gyu5K00 [X]Myocarditis in other infectious+parasitic diseases CE 
Gyu5L00 [X]Myocarditis in other diseases classified elsewhere 
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Gyu5M00 [X]Other hypertrophic cardiomyopathy 
Gyu5N00 [X]Other restrictive cardiomyopathy 
Gyu5P00 [X]Other cardiomyopathies 
Gyu5Q00 [X]Cardiomyopathy in infectious+parasitic diseases CE 
Gyu5R00 [X]Cardiomyopathy in metabolic diseases CE 
Gyu5S00 [X]Cardiomyopathy in nutritional diseases CE 
Gyu5T00 [X]Cardiomyopathy in other diseases classified elsewhere 
Gyu5U00 [X]Other and unspecified atrioventricular block 
Gyu5V00 [X]Other and unspecified fascicular block 
Gyu5W00 [X]Other and unspecified right bundle-branch block 
Gyu5X00 [X]Other specified heart block 
Gyu5Y00 [X]Other specified conduction disorders 
Gyu5Z00 [X]Other and unspecified premature depolarization 
Gyu6.00 [X]Cerebrovascular diseases 
Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
Gyu6100 [X]Other subarachnoid haemorrhage 
Gyu6200 [X]Other intracerebral haemorrhage 
Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
Gyu6400 [X]Other cerebral infarction 
Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
G65..00 Transient cerebral ischaemia 
G65..11 Drop attack 
G65..12 Transient ischaemic attack 
G65..13 Vertebro-basilar insufficiency 
G650.00 Basilar artery syndrome 
G650.11 Insufficiency - basilar artery 
G651.00 Vertebral artery syndrome 
G651000 Vertebro-basilar artery syndrome 
G652.00 Subclavian steal syndrome 
G653.00 Carotid artery syndrome hemispheric 
G654.00 Multiple and bilateral precerebral artery syndromes 
G656.00 Vertebrobasilar insufficiency 
G657.00 Carotid territory transient ischaemic attack 
G65y.00 Other transient cerebral ischaemia 
G65z.00 Transient cerebral ischaemia NOS 
G65z000 Impending cerebral ischaemia 
G65z100 Intermittent cerebral ischaemia 
G65zz00 Transient cerebral ischaemia NOS 
ZV12D00 [V]Personal history of transient ischaemic attack 
Fyu5500 [X]Other transnt cerebral ischaemic attacks+related syndroms 
Abbreviations: CHD, coronary heart disease; NOS, not otherwise specified; [X], Cross referenced to specific ICD-10 codes; PAD, 




Read codes used to identify cases of heart failure 
Read code Description 
G58..00 Heart failure 
G58..11 Cardiac failure 
G580.00 Congestive heart failure 
G580.11 Congestive cardiac failure 
G580.12 Right heart failure 
G580.13 Right ventricular failure 
G580.14 Biventricular failure 
G580000 Acute congestive heart failure 
G580100 Chronic congestive heart failure 
G580200 Decompensated cardiac failure 
G580300 Compensated cardiac failure 
G580400 Congestive heart failure due to valvular disease 
G581.00 Left ventricular failure 
G581.11 Asthma - cardiac 
G581.12 Pulmonary oedema - acute 
G581.13 Impaired left ventricular function 
G581000 Acute left ventricular failure 
G582.00 Acute heart failure 
G583.00 Heart failure with normal ejection fraction 
G583.11 HFNEF - heart failure with normal ejection fraction 
G583.12 Heart failure with preserved ejection fraction 
G584.00 Right ventricular failure 
G58z.00 Heart failure NOS 
G58z.11 Weak heart 
G58z.12 Cardiac failure NOS 
G1yz100 Rheumatic left ventricular failure 
662f.00 New York Heart Association classification - class I 
662F.00 Hypertension treatment. started 
662G.00 Hypertensive treatment changed 
662g.00 New York Heart Association classification - class II 
662H.00 Hypertension treatment stopped 
662h.00 New York Heart Association classification - class III 
662i.00 New York Heart Association classification - class IV 
585f.00 Echocardiogram shows left ventricular systolic dysfunction 
G5yy900 Left ventricular systolic dysfunction 
G5yyD00 Left ventricular cardiac dysfunction 




Drug codes used to identify prescription of non-steroidal anti-inflammatory drugs 
Drug code Generic name 
52437979 Naproxen 250mg tablets 
52438979 Mefenamic acid 500mg tablets 
53244979 Ibuprofen lysine 400mg oral powder sachets 
53245979 Ibuprofen lysine 400mg oral powder sachets 
54501979 Ibuprofen 200mg capsules 
59408979 Indometacin 25mg capsules 
60599979 Etoricoxib 30mg tablets 
68279979 Naproxen 75mg/5ml oral suspension 
68284979 Naproxen 100mg/5ml oral suspension 
70267978 Ibuprofen 200mg tablets 
79388978 Misoprostol 400microgram tablets 
79449979 Naproxen 500mg/5ml oral suspension 
79451979 Naproxen 250mg/5ml oral suspension 
79837979 Indometacin 25mg/5ml oral solution 
81659998 Ibuprofen 200mg effervescent tablets 
81664998 Ibuprofen 10% gel 
81960998 Ketoprofen 200mg modified-release capsules 
82031998 Celecoxib 400mg capsules 
82272998 Ibuprofen 5% spray 
82307998 Tenoxicam 20mg tablets 
82366998 Ibuprofen lysine 200mg tablets 
82686998 Ibuprofen 5% gel 
82872978 Meloxicam 7.5mg orodispersible tablets sugar free 
82874978 Meloxicam 15mg orodispersible tablets sugar free 
82923998 Ketoprofen 150mg modified-release capsules 
82924998 Ketoprofen 200mg modified-release capsules 
82925998 Ketoprofen 100mg modified-release capsules 
82926998 Ketoprofen 100mg suppositories 
82927998 Ketoprofen 100mg capsules 
82928998 Ketoprofen 50mg capsules 
83070998 Naproxen 200mg/5ml oral suspension 
83154998 Ibuprofen 400mg capsules 
83155998 Ibuprofen 200mg capsules 
83433998 Ibuprofen 400mg tablets 
83434998 Aspirin 500mg effervescent tablets sugar free 
83445998 Piroxicam 20mg orodispersible tablets sugar free 
83471998 Ibuprofen 800mg modified-release tablets 
83494998 Ibuprofen sodium dihydrate 200mg tablets 
83497998 Ibuprofen sodium dihydrate 200mg tablets 
83500998 Ibuprofen 200mg tablets 
83608998 Etodolac 600mg modified-release tablets 
83611998 Flurbiprofen 200mg modified release capsules 
83984998 Naproxen 250mg gastro-resistant tablets 
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84019998 Ibuprofen 5% gel 
84058998 Ibuprofen 5% cream 
84104998 Ibuprofen 200mg/5ml oral suspension 
84128998 Etoricoxib 30mg tablets 
84129998 Etoricoxib 30mg tablets 
84153998 Ibuprofen 400mg tablets 
84155998 Ibuprofen 200mg tablets 
84160998 Ibuprofen 200mg tablets 
84174998 Ibuprofen 5% gel 
84433998 Ibuprofen 200mg capsules 
84434998 Ibuprofen lysine 400mg tablets 
84435998 Ibuprofen 400mg capsules 
84437998 Ibuprofen lysine 200mg tablets 
84490998 Ibuprofen 200mg tablets 
84553998 Ibuprofen 200mg capsules 
84554998 Ibuprofen 200mg tablets 
84555998 Ibuprofen 200mg tablets 
84973998 Indometacin oral solution 
85154998 Diclofenac sodium 25mg gastro-resistant tablets 
85272998 Naproxen oral solution 
85428998 Etodolac 600mg modified-release tablets 
85741998 Ibuprofen 400mg capsules 
85783998 Ibuprofen 400mg capsules 
85891979 Ibuprofen lysine 200mg tablets 
85953998 Phenylbutazone 100mg tablets 
86170998 Ibuprofen lysine 400mg tablets 
86171998 Ibuprofen 400mg tablets 
86329998 Ibuprofen 10mg/2ml solution for infusion ampoules 
86594998 Ibuprofen lysine 200mg tablets 
86624998 Dexibuprofen 400mg tablets 
86628998 Dexibuprofen 300mg tablets 
86629998 Dexibuprofen 400mg tablets 
86635998 Dexibuprofen 300mg tablets 
86940998 Ibuprofen 5% gel 
86953998 Ibuprofen 200mg tablets 
87070998 Ibuprofen 300mg modified-release capsules 
87413998 Ketoprofen 50mg capsules 
87936998 Aspirin 500mg granules sachets sugar free 
88047997 Ketoprofen 200mg modified-release capsules 
88047998 Ketoprofen 100mg modified-release capsules 
88138998 Naproxen 500mg gastro-resistant tablets 
88139998 Naproxen 250mg gastro-resistant tablets 
88143998 Ibuprofen 5% gel 
88145996 Ibuprofen 400mg tablets 
88145998 Ibuprofen 5% gel 
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88174998 Ibuprofen 200mg capsules 
88204998 Ibuprofen 5% mousse 
88205998 Ibuprofen 5% foam 
88228998 Ibuprofen lysine 200mg tablets 
88233998 Ibuprofen 200mg tablets 
88284998 Ibuprofen 400mg tablets 
88442998 Mefenamic acid 250mg capsules 
88455998 Indometacin 75mg modified-release capsules 
88527997 Ibuprofen 200mg capsules 
88527998 Ibuprofen 200mg tablets 
88817998 Tolfenamic acid 200mg tablets 
88943998 Ketoprofen 200mg modified release capsules 
88970998 Etoricoxib 60mg tablets 
88977998 Etoricoxib 120mg tablets 
89014998 Ibuprofen 200mg modified-release capsules 
89117998 Ibuprofen 200mg tablets 
89137997 Ketoprofen 200mg modified release capsules 
89139998 Ibuprofen 5% gel 
89217998 Aspirin 300mg gastro-resistant tablets 
89398979 Etoricoxib 90mg tablets 
89404979 Etoricoxib 60mg tablets 
89472997 Ibuprofen 5% gel 
89479998 Tolfenamic acid 200mg capsules 
89484997 Tolfenamic acid 200mg tablets 
89484998 Tolfenamic acid 200mg capsule 
89499998 Ibuprofen 10% gel 
89572998 Etodolac 300mg capsules 
89580998 Ibuprofen 200mg tablets 
89593997 Ibuprofen 400mg tablets 
89621998 Ibuprofen 200mg orodispersible tablets sugar free 
89691997 Ibuprofen 400mg tablets 
89691998 Ibuprofen 200mg tablets 
89760998 Ibuprofen 300mg modified-release capsules 
89801998 Flurbiprofen 8.75mg lozenges 
89890998 Ibuprofen lysine 200mg tablets 
89898998 Codeine 8mg with aspirin 500mg soluble tablets 
89909998 Ketoprofen 200mg modified release capsules 
89966998 Ketoprofen 2.5% gel 
89993998 Ibuprofen 5% gel 
90116998 Ibuprofen 200mg tablets 
90125998 Ibuprofen 200mg tablets 
90278998 Aspirin 500mg effervescent tablets sugar free 
90351997 Meloxicam 15mg tablets 
90351998 Meloxicam 7.5mg tablets 
90361997 Meloxicam 15mg tablets 
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90361998 Meloxicam 7.5mg tablets 
90368997 Celecoxib 200mg capsules 
90368998 Celecoxib 100mg capsules 
90377997 Aspirin 500mg effervescent tablets sugar free 
90377998 Aspirin 300mg effervescent tablets sugar free 
90635998 Aceclofenac 100mg tablets 
90636998 Aceclofenac 100mg tablets 
90709998 Flurbiprofen 8.75mg lozenges 
90846998 Ketoprofen 200mg modified-release capsules 
90869998 Ibuprofen 400mg tablets 
90954998 Flurbiprofen 8.75mg lozenges 
91081996 Ibuprofen 200mg tablets 
91081997 Ibuprofen 200mg capsules 
91081998 Ibuprofen 400mg granules 
91105998 Indometacin 25mg modified-release capsules 
91109997 Mefenamic acid 500mg tablets 
91109998 Mefenamic acid 250mg capsules 
91120998 Ibuprofen 200mg tablets 
91155998 Ibuprofen 10% gel 
91315998 Ketoprofen 2.5% gel 
91421998 Dexketoprofen 25mg tablets 
91438979 Ibuprofen 10% gel 
91442979 Piroxicam 0.5% gel 
91443979 Piroxicam 0.5% gel 
91446979 Piroxicam 0.5% gel 
91447979 Piroxicam 0.5% gel 
91451979 Piroxicam 0.5% gel 
91463997 Piroxicam 20mg capsules 
91463998 Piroxicam 10mg capsules 
91466979 Ketoprofen 2.5% gel 
91475979 Ibuprofen 5% gel 
91479979 Celecoxib 100mg capsules 
91486979 Celecoxib 200mg capsules 
91502998 Indometacin 75mg modified release capsules 
91517998 Piroxicam 0.5% gel 
91523998 Ibuprofen 10% gel 
91581997 Celecoxib 200mg capsules 
91581998 Celecoxib 100mg capsules 
91682979 Tenoxicam 20mg tablets 
91713979 Piroxicam 20mg orodispersible tablets sugar free 
91751979 Naproxen 250mg tablets 
91752979 Naproxen 250mg tablets 
91757979 Naproxen 250mg tablets 
91763979 Mefenamic acid 500mg tablets 
91770979 Mefenamic acid 250mg capsules 
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91774979 Ketoprofen 200mg modified-release capsules 
91774998 Indometacin 75mg modified release capsules 
91777998 Ibuprofen 10% gel 
91778979 Ketoprofen 200mg modified-release capsules 
91782979 Ketoprofen 100mg modified-release capsules 
91815997 Mefenamic acid 500mg tablets 
91815998 Mefenamic acid 250mg capsules 
91841998 Aspirin 300mg orodispersible tablets sugar free 
91843979 Ibuprofen 400mg tablets 
91850979 Ibuprofen 400mg tablets 
91851979 Ibuprofen 400mg tablets 
91854979 Ibuprofen 400mg tablets 
91856979 Ibuprofen 200mg tablets 
91863979 Ibuprofen 200mg tablets 
91864979 Ibuprofen 200mg tablets 
91877998 Ketoprofen 200mg modified release capsules 
91920997 Mefenamic acid 500mg tablets 
91920998 Mefenamic acid 250mg capsules 
91965979 Aspirin 300mg tablets 
91988998 Etoricoxib 90mg tablets 
91989998 Etoricoxib 60mg tablets 
91990998 Etoricoxib 120mg tablets 
91991998 Etoricoxib 90mg tablets 
92092990 Ketoprofen 2.5% gel 
92112998 Ketoprofen 200mg modified-release capsules 
92113998 Indometacin 75mg modified release capsules 
92158998 Tiaprofenic acid 300mg tablets 
92169998 Ibuprofen 200mg capsules 
92189998 Piroxicam betadex 20mg tablets 
92290998 Ibuprofen 200mg orodispersible tablets sugar free 
92550990 Mefenamic acid 500mg tablets 
92551990 Mefenamic acid 250mg capsules 
92671998 Aspirin 500mg modified-release tablets 
92706998 Aspirin 300mg gastro-resistant tablets 
92738990 Naproxen 500mg gastro-resistant tablets 
92778998 Aspirin 300mg orodispersible tablets sugar free 
92801998 Piroxicam 10mg capsules 
92851998 Tenoxicam 20mg injection plus diluent 
92863998 Etodolac 600mg modified-release tablets 
92864998 Etodolac 600mg modified-release tablets 
92950996 Naproxen 500mg gastro-resistant tablets 
92950997 Naproxen 250mg tablets 
92950998 Naproxen 500mg tablets 
92953997 Ketoprofen 100mg capsules 
92954997 Indometacin 75mg modified release capsules 
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92954998 Indometacin 25mg capsules 
92958998 Indometacin 1mg injection (powder for reconstitution) 
92965998 Ibuprofen 400mg tablets 
93029998 Naproxen 500mg modified release tablets 
93089997 Ketoprofen 200mg modified-release capsules 
93089998 Ketoprofen 100mg modified-release capsules 
93099997 Aspirin 300mg modified release tablets 
93135996 Naproxen 500mg modified-release tablets 
93135997 Naproxen 375mg modified-release tablet 
93135998 Naproxen 500mg granules 
93152998 Ketoprofen 100mg/2ml injection 
93169996 Naproxen 375mg gastro-resistant tablets 
93169997 Naproxen 500mg gastro-resistant tablets 
93169998 Naproxen 250mg gastro-resistant tablets 
93170997 Naproxen 500mg gastro-resistant tablets 
93170998 Naproxen 250mg gastro-resistant tablets 
93218998 Ibuprofen 200mg tablets 
93235990 Ibuprofen 10% gel 
93247998 Acemetacin 60mg capsules 
93261998 Nabumetone 500mg dispersible tablets sugar free 
93267998 Naproxen 375mg tablets 
93272996 Ibuprofen lysine 400mg tablets 
93272997 Ibuprofen 200mg tablets 
93272998 Ibuprofen 200mg tablets 
93351990 Indometacin 25mg capsules 
93368998 Aspirin 300mg dispersible tablets 
93579990 Meloxicam 15mg tablets 
93580990 Meloxicam 7.5mg tablets 
93625998 Ibuprofen 5% cream 
93626996 Ibuprofen 5% spray 
93626997 Ibuprofen 5% gel 
93626998 Ibuprofen 5% cream 
93688992 Aspirin s/r 500 mg tab 
93698990 Meloxicam 7.5mg tablets 
93726990 Meloxicam 7.5mg tablets 
93731992 Aspirin disp 500 mg tab 
93756990 Ibuprofen 400mg tablets 
93866998 Ibuprofen 200mg tablets 
94020992 Aspirin soluble 600 mg tab 
94073992 Aspirin 600 mg sup 
94152998 Ibuprofen 10% gel 
94165992 Fenoprofen 300mg tablets 
94213998 Aspirin 600mg tablets 
94214997 Aspirin 300mg gastro-resistant tablets 
94214998 Aspirin 324mg gastro-resistant tablets 
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94215996 Aspirin 300mg orodispersible tablets sugar free 
94215997 Aspirin 300mg orodispersible tablets sugar free 
94216997 Aspirin 300mg modified-release tablets 
94216998 Aspirin 324mg modified-release tablets 
94240992 Ibuprofen 200mg tablets 
94254998 Aspirin 300mg gastro-resistant tablets 
94257998 Piroxicam 0.5% gel 
94258997 Piroxicam 0.5% gel 
94258998 Piroxicam 0.5% gel 
94262998 Aspirin 500mg with papaveretum 7.71mg dispersible tablets 
94352998 Ketoprofen 100mg/2ml solution for injection ampoules 
94437990 Piroxicam 0.5% gel 
94459990 Ibuprofen 400mg tablets 
94489996 Ketoprofen 150mg modified-release capsules 
94489997 Ketoprofen 200mg modified-release capsules 
94489998 Ketoprofen 100mg modified-release capsules 
94513997 Aspirin 300mg effervescent tablets 
94514996 Tenoxicam 20mg effervescent tablets 
94514997 Tenoxicam 20mg/sachet granules 
94514998 Tenoxicam 20mg tablets 
94515996 Tenoxicam 20mg effervescent tablets 
94515998 Tenoxicam 20mg tablets 
94589997 Aspirin 300mg effervescent tablets 
94589998 Aspirin 100mg effervescent tablets 
94607996 Ketorolac 10mg/1ml solution for injection ampoules 
94607997 Ketorolac 10mg tablets 
94607998 Ketorolac 30mg/1ml solution for injection ampoules 
94608996 Ketorolac trometamol 10mg/1ml injection 
94608997 Ketorolac trometamol 10mg tablets 
94608998 Ketorolac 30mg/1ml solution for injection ampoules 
94626990 Ibuprofen 400mg tablets 
94631998 Misoprostol 200microgram tablets 
94632998 Misoprostol 200microgram vaginal tablets 
94651992 Ibuprofen 400mg tablets 
94667992 Aspirin m/f 324 mg tab 
94668992 Aspirin 325 mg cap 
94671992 Aspirin 500 mg sup 
94674992 Aspirin disp 600 mg tab 
94678990 Ibuprofen 400mg tablets 
94678992 Aspirin soluble 400 mg tab 
94679992 Aspirin soluble 500 mg tab 
94709997 Aspirin 300mg effervescent tablets sugar free 
94709998 Aspirin 500mg effervescent tablets sugar free 
94743992 Brufen sup 
94759998 Aspirin 500mg with cyclizine 25mg effervescent tablets 
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94784998 Flurbiprofen 200mg modified-release capsules 
94798998 Flurbiprofen 200mg modified release capsules 
94805997 Ibuprofen 600mg effervescent granules sachets 
94805998 Ibuprofen 800mg modified-release tablets 
94809997 Piroxicam 20mg dispersible tablets 
94809998 Piroxicam 10mg dispersible tablets 
94832996 Indometacin 25mg modified release tablets 
94832997 Indometacin 50mg modified release tablets 
94832998 Indometacin 75mg modified release tablets 
94874998 Ibuprofen 800mg tablets 
94875998 Ibuprofen 800mg tablets 
94887998 Ibuprofen 200mg orodispersible tablets sugar free 
94907997 Nabumetone 500mg/5ml oral suspension sugar free 
94907998 Nabumetone 500mg tablets 
94914997 Nabumetone 500mg/5ml suspension 
94914998 Nabumetone 500mg tablets 
94916998 Ibuprofen 5% foam 
94928998 Tiaprofenic acid 300mg modified release capsules 
95006998 Ketoprofen 2.5% gel 
95013998 Ketoprofen 2.5% gel 
95014992 Fenoprofen 300mg tablets 
95061998 Dexketoprofen 25mg tablets 
95075998 Indometacin 25mg modified-release tablets 
95093996 Naproxen 500mg gastro-resistant tablets 
95093997 Naproxen 375mg gastro-resistant tablets 
95093998 Naproxen 250mg gastro-resistant tablets 
95143992 Ibuprofen 200mg capsules 
95167996 Tiaprofenic acid 300mg sachets 
95167997 Tiaprofenic acid 300mg tablets 
95167998 Tiaprofenic acid 200mg tablets 
95172990 Ibuprofen 10% gel 
95191990 Piroxicam 0.5% gel 
95212992 Aspirin 500mg modified release tablets 
95227997 Sulindac 200mg tablets 
95227998 Sulindac 100mg tablets 
95340990 Ibuprofen 200mg tablets 
95347990 Ibuprofen 400mg tablets 
95348990 Ibuprofen 200mg tablets 
95351990 Aspirin 300mg dispersible tablets 
95496990 Piroxicam 0.5% gel 
95496998 Piroxicam 10mg capsules 
95497998 Piroxicam 20mg suppositories 
95498996 Piroxicam 20mg orodispersible tablets sugar free 
95498997 Piroxicam 20mg capsules 
95498998 Piroxicam 10mg capsules 
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95539997 Phenylbutazone 200mg tablets 
95539998 Phenylbutazone 100mg tablets 
95540998 Phenylbutazone 100mg gastro-resistant tablets 
95541997 Phenylbutazone 200mg tablets 
95541998 Phenylbutazone 100mg tablets 
95611990 Ketoprofen 2.5% gel 
95753998 Naproxen sodium 275mg tablets 
95754997 Naproxen 125mg/5ml oral suspension 
95754998 Naproxen 500mg suppositories 
95909996 Mefenamic acid 50mg/5ml oral suspension 
95909997 Mefenamic acid 500mg tablets 
95909998 Mefenamic acid 250mg dispersible tablet 
95911992 Aspirin 300mg dispersible tablets 
95992990 Ibuprofen 5% gel 
96035996 Ketoprofen 100mg suppositories 
96035997 Ketoprofen 100mg capsules 
96035998 Ketoprofen 50mg capsules 
96310989 Ibuprofen 400mg tablets 
96310990 Ibuprofen 200mg tablets 
96369990 Ibuprofen 200mg tablets 
96405996 Ibuprofen 600mg tablets 
96405997 Ibuprofen 400mg tablets 
96405998 Ibuprofen 200mg tablets 
96407989 Indometacin 50mg capsules 
96407990 Indometacin 25mg capsules 
96414990 Aspirin 300mg dispersible tablets 
96418989 Ibuprofen 400mg tablets 
96451997 Naproxen 500mg tablets 
96451998 Naproxen 250mg tablets 
96452997 Naproxen 500mg tablets 
96452998 Naproxen 250mg tablets 
96495996 Flurbiprofen 100mg suppositories 
96495997 Flurbiprofen 100mg tablets 
96495998 Flurbiprofen 50mg tablets 
96555996 Fenoprofen 600mg tablets 
96555997 Fenoprofen 300mg tablets 
96555998 Fenoprofen 200mg tablet 
96566989 Aspirin 300mg dispersible tablets 
96566990 Aspirin 300mg tablets 
96569992 Aspirin sr 300 mg tab 
96583990 Ibuprofen 5% gel 
96625988 Naproxen 500mg gastro-resistant tablets 
96841990 Piroxicam 20mg dispersible tablets 
96842989 Piroxicam 20mg capsules 
96851990 Mefenamic acid 250mg capsules 
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96879990 Naproxen 250mg gastro-resistant tablets 
96921998 Nabumetone 500mg dispersible tablets 
96939989 Ibuprofen 400mg tablets 
96939990 Ibuprofen 200mg tablets 
96961989 Mefenamic acid 500mg tablets 
96961990 Mefenamic acid 250mg capsules 
97056996 Ibuprofen 600mg tablets 
97056997 Ibuprofen 400mg tablets 
97056998 Ibuprofen 200mg tablets 
97088992 Aspirin 324mg gastro-resistant tablets 
97100989 Naproxen 500mg gastro-resistant tablets 
97100990 Naproxen 250mg gastro-resistant tablets 
97104988 Ibuprofen 600mg tablets 
97104989 Ibuprofen 400mg tablets 
97104990 Ibuprofen 200mg tablets 
97106997 Ibuprofen 400mg tablets 
97107997 Ibuprofen 400mg tablets 
97111990 Mefenamic acid 250mg capsules 
97114990 Indometacin 75mg modified-release capsules 
97180989 Naproxen 500mg gastro-resistant tablets 
97180990 Naproxen 250mg gastro-resistant tablets 
97181990 Aspirin 300mg gastro-resistant tablets 
97305992 Dihydrocodeine tartrate/aspirin 300 mg tab 
97356998 Indometacin 75mg modified-release capsules 
97357996 Indometacin 100mg suppositories 
97358997 Ibuprofen 400mg tablets 
97358998 Ibuprofen 200mg tablets 
97537989 Aspirin 300mg gastro-resistant tablets 
97550988 Naproxen 250mg gastro-resistant tablets 
97551989 Ibuprofen 400mg tablets 
97551990 Ibuprofen 200mg tablets 
97564998 Naproxen sodium 275mg tablets 
97565998 Naproxen 500mg tablets 
97566996 Naproxen 500mg suppositories 
97566997 Naproxen 125mg/5ml suspension 
97566998 Naproxen 250mg tablets 
97593996 Ibuprofen 600mg tablets 
97594997 Ibuprofen 400mg tablets 
97594998 Ibuprofen 200mg tablets 
97641992 Ketorolac 30mg/1ml solution for injection ampoules 
97657997 Naproxen 500mg tablets 
97657998 Naproxen 250mg tablets 
97658997 Naproxen 500mg modified release tablets 
97658998 Naproxen 375mg modified release tablets 
97668998 Piroxicam 20mg/1ml injection 
192  
 
Drug code Generic name 
97674989 Ibuprofen 400mg tablets 
97674990 Ibuprofen 200mg tablets 
97678997 Ibuprofen 400mg tablets 
97700990 Naproxen 500mg gastro-resistant tablets 
97712997 Naproxen 500mg tablets 
97712998 Naproxen 250mg tablets 
97746990 Ketoprofen 200mg modified-release capsules 
97748998 Piroxicam 20mg/1ml solution for injection ampoules 
97902990 Piroxicam 20mg dispersible tablets 
97906996 Ibuprofen 600mg tablets 
97906997 Ibuprofen 400mg tablets 
97906998 Ibuprofen 200mg tablets 
97918989 Aspirin 300mg dispersible tablets 
98040988 Ketoprofen 100mg capsules 
98041990 Indometacin 50mg capsules 
98127989 Mefenamic acid 500mg tablets 
98127990 Mefenamic acid 250mg capsules 
98134989 Flurbiprofen 50mg tablets 
98137998 Ibuprofen 10% gel 
98142989 Aspirin 300mg dispersible tablets 
98150990 Ibuprofen 600mg tablets 
98151990 Ibuprofen 600mg tablets 
98166996 Piroxicam 20mg orodispersible tablets sugar free 
98166997 Piroxicam 20mg dispersible tablets 
98166998 Piroxicam 10mg dispersible tablets 
98280998 Aspirin & metoclopramide 450mg+5mg effervescent tablets 
98399998 Indometacin 75mg modified-release capsules 
98419997 Aspirin 300mg dispersible tablets 
98419998 Aspirin 300mg tablets 
98426989 Piroxicam 20mg capsules 
98426990 Piroxicam 10mg capsules 
98429998 Ibuprofen & codeine phosphate 300mg+20mg modified release tab 
98495989 Mefenamic acid 500mg tablets 
98495990 Mefenamic acid 250mg capsules 
98513990 Aspirin 300mg tablets 
98515998 Ibuprofen 600mg tablets 
98516998 Ibuprofen 400mg tablets 
98528990 Ibuprofen 600mg tablets 
98529988 Ibuprofen 600mg tablets 
98529989 Ibuprofen 400mg tablets 
98529990 Ibuprofen 200mg tablets 
98530988 Ibuprofen 600mg tablets 
98530989 Ibuprofen 400mg tablets 
98530990 Ibuprofen 200mg tablets 
98555989 Ibuprofen 400mg tablets 
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98555990 Ibuprofen 200mg tablets 
98578998 Ibuprofen 300mg modified-release capsules 
98592988 Aspirin 300mg dispersible tablets 
98600989 Ketoprofen 200mg modified-release capsules 
98621989 Ketoprofen 200mg modified-release capsules 
98654998 Mefenamic acid 50mg/5ml paediatric suspension 
98671988 Indometacin 50mg capsules 
98671989 Indometacin 25mg capsules 
98671990 Indometacin 75mg modified-release capsules 
98672989 Indometacin 25mg capsules 
98672990 Indometacin 50mg capsules 
98673988 Ibuprofen 200mg tablets 
98673989 Ibuprofen 400mg tablets 
98673990 Ibuprofen 600mg tablets 
98674988 Naproxen 250mg gastro-resistant tablets 
98674989 Naproxen 500mg gastro-resistant tablets 
98674990 Naproxen 250mg tablets 
98693998 Acemetacin 60mg capsules 
98758998 Ketoprofen 200mg modified release capsules 
98764998 Ibuprofen 200mg modified-release capsules 
98779998 Ketoprofen 100mg suppositories 
98907998 Naproxen 500mg/sachet granules 
99334997 Aspirin 600mg gastro-resistant tablets 
99334998 Aspirin 300mg gastro-resistant tablets 
99442989 Piroxicam 20mg capsules 
99442990 Piroxicam 10mg capsules 
99444989 Piroxicam 20mg capsules 
99444990 Piroxicam 10mg capsules 
99445989 Piroxicam 20mg capsules 
99445990 Piroxicam 10mg capsules 
99466996 Ibuprofen 400mg tablets 
99466997 Ibuprofen 200mg tablets 
99482998 Piroxicam betadex 20mg tablets 
99516998 Tiaprofenic acid 300mg modified-release capsules 
99517989 Mefenamic acid 500mg tablets 
99517990 Mefenamic acid 250mg capsules 
99519989 Mefenamic acid 500mg tablets 
99519990 Mefenamic acid 250mg capsules 
99520989 Mefenamic acid 500mg tablets 
99520990 Mefenamic acid 250mg capsules 
99535996 Indometacin 25mg/5ml sugar free suspension 
99535997 Indometacin 50mg capsules 
99535998 Indometacin 25mg capsules 
99539996 Indometacin 100mg suppositories 
99539997 Indometacin 50mg capsules 
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99539998 Indometacin 25mg capsules 
99550989 Indometacin 50mg capsules 
99550990 Indometacin 25mg capsules 
99551990 Indometacin 25mg capsules 
99552988 Indometacin 100mg suppositories 
99552989 Indometacin 50mg capsules 
99552990 Indometacin 25mg capsules 
99553989 Indometacin 75mg modified-release capsules 
99553990 Indometacin 25mg capsules 
99557988 Ibuprofen 600mg tablets 
99557989 Ibuprofen 400mg tablets 
99557990 Ibuprofen 200mg tablets 
99558988 Ibuprofen 400mg tablets 
99558989 Ibuprofen 600mg tablets 
99558990 Ibuprofen 200mg tablets 
99621996 Flurbiprofen 100mg suppositories 
99621997 Flurbiprofen 100mg tablets 
99621998 Flurbiprofen 50mg tablets 
99652997 Fenoprofen 600mg tablets 
99652998 Fenoprofen 300mg tablets 
99653996 Piroxicam 20mg suppositories 
99653997 Piroxicam 20mg capsules 
99653998 Piroxicam 10mg capsules 
99728988 Naproxen 500mg gastro-resistant tablets 
99728989 Naproxen 500mg gastro-resistant tablets 
99728990 Naproxen 250mg tablets 
99730989 Naproxen 500mg gastro-resistant tablets 
99730990 Naproxen 250mg tablets 
99731989 Naproxen 500mg gastro-resistant tablets 
99731990 Naproxen 250mg tablets 
99807988 Aspirin 300mg tablets 
99807989 Aspirin 300mg dispersible tablets 
99808988 Aspirin 300mg tablets 
99808989 Aspirin 300mg dispersible tablets 
99810989 Aspirin 300mg dispersible tablets 
99823997 Sulindac 200mg tablets 
99823998 Sulindac 100mg tablets 
99824998 Aspirin 300mg tablets 
99868998 Ibuprofen 200mg tablets 






Read code used to detect glycaemic abnormality 
Note: Fructosamine is an alternative test of assessing glucose abnormality in patients where 
HbA1c cannot be reliably measured 
Read code Description 
Sickle cell 
D1060 Sickle cell anaemia of unspecific type 
D1061 Sickle cell anaemia with no crisis 
D1062 Sickle cell anaemia with crisis 
D1063 Sickle cell anaemia with haemoglobin C disease 
D1064 Sickle cell anaemia with haemoglobin D disease 
D1065 Sickle cell anaemia with haemoglobin E disease 
D106z Sickle cell anaemia NOS 
Test result code 
42D4 Sickle cell present 
Thalassaemia 
D1040 Thalassaemia major NEC 
D1041 Thalassaemia minor NEC 
D1042 Thalassaemia with haemoglobin S disease 
D1043 Alpha Thalassaemia 
D1046 Beta intermediate Thalassaemia 
D1047 Beta major Thalassaemia 
D1048 Beta minor Thalassaemia 
D104z Thalassaemia NOS 
Lab test code 
44TD.00 Fructosamine 













21.0 Appendix 12: THIN Scientific Review Committee approval 
SRC Feedback 
 
Researcher Name: Dr Feroz Jadhakhan  
Organisation: University of Birmingham 
SRC Reference Number: 14-038 
Date: 13th June 2014 
Study title: Cumulative incidence of Chronic Kidney Disease (CKD) in young adults (aged 18 to 40 
years) with Impaired Glucose Tolerance (IGT) 
Committee opinion: Approved  
______________________________________________________________ 
 
The following feedback has been supplied by the SRC. 
 





We are pleased to inform that you can proceed with the study as this is now approved. CSD Medical 
Research will let the relevant Ethics committee know this study has been approved by the SRC. 
 
Once the study has been completed and published, it is important for you to inform CSD Medical 
Research in order for us to advise the SRC and your reference number to be closed. 
 
References to all published studies are added to our website enabling other researchers to become 
aware of your work. Copies of publication(s), where available, will be appreciated. 
 
































22.0 Appendix 13: Comparison of prevalence of prediabetes/non-diabetic hyperglycaemia  
 Authors Database Age Prevalence of non-diabetic hyperglycaemia 
NHS-DPP (2015) (77) HSE 16 to 39 2.6% in (2009 - 2013) 
    
   Prevalence of pre-diabetes 
Mainous et al (2014) (76) HSE ≥16 years 35.3% in (2011) 
Abbreviations: IGR, impaired glucose regulation; IFG, impaired fasting glucose; GPRD, general practice research database; 
HSE, health survey for England 
 
23.0 Appendix14: Adjusted incidence rate of CKD in IGR compared to normoglycaemia 
Predictors IRR 95% (CI) P-Value 
IGR vs normoglycaemia 2.6 (2.0, 3.4) <0.001 
Female 1.1 (0.9, 1.4) 0.425 
Age 1.1 (1.0, 1.1) <0.001 
Ethnicity 
White Reference 1.0   
Asian 1.2 (0.8, 1.7) 0.389 
Black 1.0 (0.6, 1.9) 0.955 
Chinese 1.2 (0.2, 8.7) 0.845 
Mixed 0.5 (0.1, 3.3) 0.439 
Other 1.0 (0.4, 2.8) 0.970 
Missing 0.7 (0.5, 0.8) 0.001 
BMI (kgs/m2) 
<20 Reference 1.0   
20-24.9 1.9 (0.9, 4.5) 0.127 
25-29.9 2.5 (1.1, 5.8) 0.029 
30-34.9 3.2 (1.4, 7.5) 0.006 
35-39.9 2.6 (1.1, 6.2) 0.037 
≥40 3.2 (1.3, 7.6) 0.010 
Missing 1.4 (0.6, 3.5) 0.452 
Deprivation quintile    
Least deprived Reference 1.0   
2 0.8 (0.5, 1.3) 0.394 
3 1.1 (0.8, 1.6) 0.571 
4 0.9 (0.6, 1.4) 0.756 
Most deprived 1.3 (0.9, 1.9) 0.123 
Missing 1.4 (0.8, 2.3) 0.256 
CVD 0.9 (0.4, 2.3) 0.905 
HF 0.8 (0.1, 6.2) 0.872 
AF 2.9 (0.4, 21.0) 0.285 
Hypertension 3.1 (2.3, 4.2) <0.001 
NSAID 1.1 (0.9, 1.5) 0.404 




















BMI categories: Appendix 15 shows the risk of CKD over time in patients with IGR 
and various BMI categories. The group remained roughly parallel over time, but the risk 
of CKD did not increase in a consistent manner for each BMI group. The proportional 
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 Hypertension: Appendix 16 shows the risk of CKD over time among IGR patients who 
had hypertension to those who did not have hypertension at baseline. The log-log survival 
curve was parallel meeting the proportional hazard assumption therefore baseline 
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Sex: Appendix 17 shows the probability of CKD risk over time for males and 
females. The survival probability remained parallel during follow-up, suggesting 
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Appendix 17: Log-log plot – Gender 
 
